













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 






INVESTIGATING NEW GENETIC SUSCEPTIBILITY 
LOCI IN OSTEOARTHRITIS 
 









A thesis submitted for the degree of Doctor of Philosophy 





Investigating New Genetic Susceptibility Loci in 
Osteoarthritis 
Simon Benedict Roberts 
University of Edinburgh 
ABSTRACT 
Primary osteoarthritis (OA) is a late-onset, degenerative condition of synovial joints, 
and is the major cause of pain and disability in older persons. OA represents a 
significant disease burden and focus of research, especially as no disease-modifying 
therapies exist to manage the condition. The genetic influence to OA is complex and 
polygenic. The arcOGEN study, the most powerful genome-wide association study yet 
to investigate OA in humans, identified the 9q33.1 locus to be significantly associated 
with hip OA in females. TRIM32 lies within the 9q33.1 susceptibility locus and may 
have strong biological relevance to OA; it encodes a protein with E3 ubiquitin ligase 
activity. 
Sanger sequencing of TRIM32 in the youngest 500 female patients with hip OA 
from the arcOGEN study was performed to identify rare variants in TRIM32 that are 
associated with OA of the hip in females. Polymorphisms were identified in the 
proximal promoter, and 3’untranslated regions (3’UTR) of TRIM32 that are 
disproportionately represented in female patients with hip OA, compared to the control 
population. 
In vitro studies identified expression of TRIM32 in human femoral head 
cartilage; reduced expression of TRIM32 was also demonstrated in femoral head 
primary articular chondrocytes from patients with hip OA compared to control patients. 
Trim32 knockout resulted in increased aggrecanolysis in murine femoral head explants. 
Murine chondrocytes deficient in Trim32 also exhibited increased expression of markers 
of a mature chondrocyte phenotype in response to anabolic cytokine stimulation, and 
increased expression of markers of a hypertrophic chondrocyte phenotype upon 
catabolic cytokine stimulation. 
 
 iii 
In vivo studies of joint degeneration in Trim32 knockout mice demonstrated 
increased cartilage degradation and tibial epiphyseal bone changes after surgically 
induced knee joint instability, compared to wild-type mice. Increased cartilage 
degradation and medial knee subchondral bone changes were also identified upon 
ageing of Trim32 knockout mice. 
These results further implicate TRIM32 in the genetic predisposition to OA, and 
indicate a role for TRIM32 in the joint degeneration evident in OA. These results 
support the further study of TRIM32 in the pathophysiology of OA and development of 
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LAY SUMMARY 
Primary osteoarthritis (OA) is a degenerative condition affecting joints and is a leading 
cause of pain and disability in elderly persons. As the proportion of older persons in the 
population increases, OA represents an increasing disease burden and its management 
has significant economic implications. No therapies exist to prevent progression of OA, 
which is therefore a focus of research. OA has an established hereditary component, 
though the exact genetic mechanisms predisposing to the disease are incompletely 
understood. The most powerful population-wide genome study investigating OA in 
humans identified variation within a region on chromosome 9 as associated with the 
development of OA. TRIM32 is a gene at this region that may have strong biological 
relevance to OA. 
In this study, genetic fine mapping of TRIM32 was performed in female patients 
with early-onset primary hip OA to identify variants that may predispose to the disease. 
Variants were identified in the region proximal to the gene and in the non-coding region 
immediately downstream of TRIM32 that were present at a disproportionate frequency 
in patients with OA, thereby further implicating TRIM32 in the genetic predisposition to 
OA. 
The expression of TRIM32 protein was reduced in chondrocytes, the 
predominant cell type of joint cartilage, from patients with hip OA compared to samples 
from patients without OA. Hip joint cartilage from mice deficient in Trim32 
demonstrated increased cartilage degradation. Joint chondrocytes from mice deficient in 




The role of Trim32 was also investigated in models of OA in mice lacking 
Trim32. Mice deficient in Trim32 developed increased cartilage degradation and 
adjacent bone changes typical of OA following surgically induced knee joint instability 
and upon ageing, compared to normal wild-type mice. 
These results indicate a role for TRIM32 in the joint degeneration evident in OA, 
and support the further study of TRIM32 in the pathophysiology of OA and the 
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1.1 Osteoarthritis (OA) 
1.1.1 Definition 
Osteoarthritis (Online Mendelian Inheritance in Man (OMIM (1)) ♯165720) is defined 
by the Osteoarthritis Research Society International (OARSI) (2) as: 
‘… a progressive disease of synovial joints that represents failed repair of joint 
damage that results from stresses that may be initiated by an abnormality in any 
of the synovial joint tissues, including articular cartilage, subchondral bone, 
ligaments, menisci (when present), periarticular muscles, peripheral nerves, or 
synovium. This ultimately results in the breakdown of cartilage and bone, 
leading to symptoms of pain, stiffness, and functional disability.’ 
 
1.1.2 Epidemiology: burden of disease 
Primary osteoarthritis (OA) is a late-onset, degenerative condition that affects 70% of 
persons over 60 years of age (3). Secondary OA can develop following infection, 
trauma, deformity, congenital abnormalities, local or systemic medical conditions, or 
previous surgery affecting a joint. Primary OA is the most prevalent form of OA 
globally, and is the major cause of pain and disability in older persons (3). It is reported 
to affect 8.75 million persons in the United Kingdom (UK), and costs the UK economy 
1% of gross national product (GNP) per year. Although OA may affect any synovial 
joint, this research has investigated OA affecting the hip and knee joint, which are two 
of the most clinically relevant sites affected by OA. Hip and knee OA affect 8% and 
18% of persons in the UK aged over 45 years, respectively (4). With the population 
aging, the prevalence of OA is increasing in both developed and developing countries 
(5). This increasing burden has led to OA being adopted as a major research focus, 
especially as no disease-modifying therapies exist to manage the condition (6). Current 
medical management comprises analgesic medication until the development of severe 
disease, characterised by unremitting pain and disability, necessitates joint replacement 
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surgery. Indeed, 93% of total hip replacements (THR), and 98% of total knee 
replacements (TKR) in the UK are performed to manage OA (4). 
 
1.1.3 Clinical features 
OA may be primary in nature, in which no cause is identified, or develop secondary to a 
traumatic injury, or an infective, inflammatory, metabolic, congenital, developmental or 
neurological condition (7-9). OA usually develops and progresses gradually over several 
years. The diagnosis of OA depends upon both clinical and radiological evidence of 
disease (10). Radiological features of OA do not directly correlate with clinical 
symptoms, and approximately 50% of patients with radiological features of disease 
experience no symptoms. The principal symptoms comprise joint pain, stiffness, 
deformity, and a consequent reduced functional capacity and quality of life (11, 12).  
Current treatment modalities to treat OA include analgesic medications, low-impact 
exercise, weight reduction, acupuncture, chondroitin sulphate, glucosamine, and joint 
surgery (13-17). Risk factors for developing OA include both environmental and genetic 
factors, and differ depending on the joint affected (10). Identified risk factors include 
increasing age, female gender, vitamin-D deficiency, obesity, joint injury, and excessive 
mechanical loading of joints (18). 
 
1.2 Pathology of OA 
1.2.1 Structure of synovial joints 
Synovial joints, also known as diarthrodial joints, are comprised of congruent layers of 
articular cartilage, supported by subchondral bone, encompassed by synovium that 
produces synovial fluid (Figure 1.1). Joints are stabilised by supporting muscles 
surrounding the joint, ligaments in the joint capsule, and also by menisci within the knee 
joint and labrum within the hip joint (19). OA develops as a consequence of 
dysregulation of the normal balance of synthesis and degradation of joint tissues (7), 
resulting in the failure of articular cartilage (20). 
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Figure 1.1 - Schematic diagram of the structure of synovial joints 
 
Synovial tissue develops from mesenchymal stem cells (MSCs) and is composed 
of two distinct layers: an outer layer of dense connective tissue termed the stratum 
fibrosum, and an inner layer called the synovial membrane (7, 21). This membrane 
contains in its luminal surface a unique cellular lining. The synovial intimal cells, 
referred to as synoviocytes, produce synovial fluid, resorb constituents of the synovial 
cavity, and enact the exchange of components between the blood and synovial fluid 
(22). Two principal types of synoviocytes have been identified: type A and type B cells 
(22). A further synovial intimal cell type displaying properties of both type A and B 
cells has also been reported (23). Type A cells are derived from blood mononuclear 
cells, protect the joint from bacterial infection, and possess phagocytic and antigen-
presenting characteristics. Type B cells are characterised by an abundance of rough 
endoplasmic reticulum and dendritic processes that form a structured network in the 
luminal surface of the synovial membrane. Type B cells produce the specialised joint 
matrix constituents including hyaluronan, lubricin, collagens and fibronectin for the 
intimal interstitium and synovial fluid (24, 25). The synovial matrix provides both a 
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permeable membrane through which exchange of molecules may occur, and sufficient 
resistance to outflow of the constituents of synovial fluid (26). 
Synovial fluid is an ultra-filtrate of blood plasma with high viscosity. In 
diathrodial joints, the role of synovial fluid is as a biological lubricant and a medium 
through which nutrients and regulatory cytokines may pass to the articular chondrocytes 
and subchondral bone (27). The low-friction and low-wear properties of synovial joints 
are imparted largely by the presence of proteoglycan 4 (PRG4), hyaluronan, (HA), and 
surface-active phospholipids (SAPL) in the synovial fluid (28-30).  
 
1.2.2 Structure of articular cartilage 
Articular cartilage comprises chondrocytes within a hydrated extracellular matrix 
(ECM) composed mainly of type II collagen (Col II) and proteoglycans. Chondrocytes 
are the only cell type present in articular cartilage and are responsible for the generation 
and homeostasis of the cartilaginous extracellular environment (31). Articular cartilage 
is normally aneural and avascular, and the hydrated matrix provides articular cartilage 
with tensile and compressive strength to maintain the biomechanical function of 
diarthrodial joints (32, 33).  
 
1.2.2.1 Chondrocytes 
In mature articular cartilage, chondrocytes are embedded within lacunae, a glycocalyx-
filled fibrillar pericellular capsule surrounded by ECM. The organisation and structure 
of chondrocytes varies depending on their progression through the zonal architecture of 
articular cartilage (34). Mature chondrocytes have small nuclei with dispersed 
chromatin, and granular cytoplasm with a prominent rough endoplasmic reticulum. 
These features reflect the activity of chondrocytes in the synthesis of the ECM, which is 
entirely dependent on the viability of the chondrocytes, and both anabolic and catabolic 
factors required for cartilage homeostasis (35). 
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1.2.2.2 Chondrogenesis 
Chondrogenesis, the process by which cartilage is developed, occurs in utero. The 
generation of cartilage is initiated by the differentiation of stellate-shaped mesenchymal 
stem cells (MSCs) into rounded precursor cells termed chondroblasts (36). Sequential 
mitotic divisions produce aggregations of chondroblasts that start to produce ground 
substance and fibrous ECM, thereby enclosing each chondroblast within cartilage 
matrix. Individual chondroblasts subsequently undergo further mitotic divisions to form 
small clusters of mature chondrocytes separated by ECM (37). Proliferating 
chondrocytes are organised in parallel columns, and characteristically express type II, 
IX and XI collagen (Col II, Col IX, and Col XI) and proteoglycans, especially aggrecan 
(ACAN). Chondrocytes become hypertrophic as they differentiate and express high 
levels of alkaline phosphatase and type X collagen (Col X). 
SRY (Sex Determining Region Y)-Box 9 (SOX9) is a critical transcription factor 
involved in chondrogenesis. It is expressed at the mesenchymal osteoprogenitor stage 
and transactivates genes specific for chondrocyte proliferation, including COL2A1 that 
encodes Col II (38, 39). SOX5 and SOX6 interact with SOX9 to activate enhancers 
specific to chondrocytes. Hypertrophic maturation of chondrocytes also requires the 
transcription factors runt-related transcription factor 2 (RUNX2) and RUNX3 that 
transactivate IHH (Indian hedgehog homolog), COL10A1 (encoding Col X), and 
MMP13 (Matrix metallopeptidase 13) genes (40-42). 
Fibroblast growth factors (FGFs) are also fundamental to chondrogenesis by 
activating signalling through FGF receptors (FGFRs). In particular, FGFR3 is expressed 
early during chondrogenesis by mesenchymal cells and also by proliferating 
chondrocytes (43). Mature hypertrophic chondrocytes preferentially express FGFR1 
(44). The onset of hypertrophic proliferation of chondrocytes is regulated by both a local 
negative feedback mechanism between IHH and parathyroid hormone-related protein 
(PTHrP), and by IHH-independent activation of Wnt and bone morphogenic protein 
(BMP) signalling (45, 46). Other important regulators of chondrogenesis include 
transforming growth factor beta (TGFβ), insulin-like growth factors (IGFs), C-type 
natriuretic peptide (CNP), and thyroid hormone (47). 
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As chondrocytes mature, cell-matrix interactions have an increasingly significant 
influence upon chondrogenesis. Association with the ECM is mediated by integrins and 
cell surface transmembrane receptors. Chondrocytes express many integrin subunits, 
though β1 integrin is particularly important for integrin-mediated signalling via the 
ECM (48). Sulfation of proteoglycans by sulphate-modifying factor 1 (SUMF1) also 
modulates chondrocyte proliferation and differentiation by regulating FGF signalling 
(49). Vinculin is also important for signalling between chondrocytes and the ECM 
through integrins by regulating IGF1-induced upregulation of COL2A1 and ACAN (50). 
 
1.2.2.3 Extracellular matrix 
The ECM constitutes approximately 98% of the volume of articular cartilage in adults; 
the remaining 2% is occupied by chondrocytes. The ECM consists of a hydrated 
collagen fibre network enmeshed with proteoglycans and other non-collagenous 
proteins. 
 
1.2.2.4 Collagen network 
Collagen fibrils form an extensive network throughout the ECM, varying in size from 20 
nm in the superficial zone of articular cartilage to 120 nm in the deep zone, and 90% of 
which comprise Col II (51). Type VI collagen (Col VI) is concentrated in pericellular 
regions, and forms a highly branched network that binds both decorin and hyaluronan 
(52). Col IX is contained within the fibrils, is also present at pericellular locations, and 
represents 2% of total collagen (53). Col X is expressed predominantly by hypertrophic 
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1.2.2.5 Proteoglycans 
The other main structural component of articular cartilage is the proteoglycan ACAN. 
Proteoglycans confer compressive stiffness upon the articular cartilage through 
hydration of chondroitin sulphate and keratan sulphate chains. ACAN binds to HA that 
is associated with collagen fibrils; the interaction between ACAN and HA is stabilised 
by link protein. HA also binds to chondrocytes through the CD44 (CD; cluster of 
differentiation) cell surface receptor (54). In addition to ACAN, other less abundant 
proteoglycans that contribute to the structural integrity of ECM include biglycan, 
chondroadherin, fibromodulin, lumican, and versican (55). 
 
1.2.2.6 Other matrix molecules 
Cartilage oligomeric matrix protein (COMP) is a non-collagenous glycoprotein and a 
member of the thrombospondin family that binds collagen molecules, particularly Col 
IX. It may have a significant role in collagen fibril assembly in which five collagen 
molecules interact to form a microfibril (56). Fibrillin-1 is a protein present in 
pericellular regions where it is arranged into banded fibrils. Perlecan is a heparan 
sulphate-containing proteoglycan cell surface molecule that binds Col VI and is 
essential for ECM integrity (57). Vitamin K-dependent carboxylation/gamma-
carboxyglutamic (GLA) protein prevents calcification of the ECM; in its absence 
calcification of cartilage develops (58). Matrilin-1 is a developmental cartilage matrix 
protein that is absent from healthy mature cartilage in adults; its presence in articular 
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1.2.2.7 Architecture of articular cartilage  
The structure of articular cartilage is directly related to its function (Figure 1.2). At the 
superficial layer, adjacent to the synovial fluid of the joint, the chondrocytes and 
collagen fibrils are elongated and arranged parallel to the articular surface. In this 
superficial zone, chondrocytes produce superficial zone protein, also known as lubricin. 
Lubricin is fundamental to the low-friction articulation with diarthrodial joints. The 
collagen fibrils in the superficial zone are closely organised in parallel to the overlying 
joint surface. The ECM at this level predominantly comprises the cartilage fibrillar 
network (60). The proportional presence of ACAN is at its lowest in this level, whereas 
the proteoglycans decorin and biglycan are most abundant here. The tensile strength of 
cartilage is also greatest in the superficial zone, which is exposed most to tensile, shear 
and compressive forces during articulation (61). 
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Figure 1.2 – Structure of human articular cartilage; the zones, regions, and relationship to the 
subchondral bone are shown. Adapted from Poole et al (59).  
 
Beneath the superficial zone is the mid zone of articular cartilage. The midzone 
displays typical characteristics of articular cartilage, with spherical chondrocytes of low 
density, an ECM abundant with ACAN, and enmeshed collagen fibrils of large 
diameter. The midzone is situated immediately above the deep zone of articular 
cartilage, in which ACAN is present at its highest concentration, but chondrocyte 
density and collagen content are at their lowest (60). The deepest layer of articular 
cartilage is the calcified cartilage, an intermediate zone between the more superficial 
uncalcified cartilage and the supportive subchondral bone. Hypertrophic chondrocytes 
predominate in the calcified cartilage, producing Col X and calcifying the ECM to 
provide a structural interface with subchondral bone that resists vascular invasion in 
healthy mature articular cartilage. 
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The features of the ECM surrounding, and between, chondrocytes also varies 
across and within the zones of articular cartilage. Chondrocytes are immediately 
surrounded by a 2 µm diameter pericellular region, which contains predominantly Col II 
fibrils at a low density, and relatively high concentrations of Col VI, decorin, and 
ACAN (62, 63). The region surrounding the pericellular region is termed the territorial 
region, and is present in all zones of articular cartilage. In the deep zones only, an 
interterritorial region is also evident; this is the region of the ECM most distant from 
chondrocytes. Breakdown products of ACAN and other proteoglycans following 
incomplete proteolysis are concentrated in the interterritorial region (64).  
 
1.2.2.8 Cartilage homeostasis 
Chondrocytes are responsible for the balanced synthesis and degradation of the ECM of 
articular cartilage. In healthy articular cartilage, this is a strictly regulated process 
influenced by anabolic and catabolic cytokines, growth factors, and physiological 
mechanical stimulation. 
The catabolic cytokines interleukin-1 (IL1), tumour necrosis factor alpha 
(TNFα), IL17, and IL18 result in increased synthesis of matrix metalloproteinases 
(MMPs), a decrease in MMP enzyme inhibitors, and reduced ECM production.  
Anabolic cytokines, including insulin growth factor 1 (IGF1), TGFβ1, -2, and -3, FGF2, 
-4, and -8, and BMPs stimulate ECM synthesis (65). Articular chondrocytes synthesise 
and store BMPs in both their active and inactive forms; BMP7 is particularly important 
for both ECM synthesis and chondrogenesis in healthy cartilage (66). The balanced 
production of anabolic and catabolic cytokines regulates the activity of chondrocytes 
and maintenance of the ECM, with no single cytokine able to stimulate all required 
metabolic activities in healthy cartilage. Homeostasis of ECM metabolism balances the 
degradation of macromolecules of the ECM with their replacement by newly 
synthesised macromolecules. Proteoglycan turnover can take up to 25 years, while the 
half-life of collagen is estimated as being beyond several decades (67, 68). 
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 Col II accounts for 90% of the total collagen content of articular cartilage. Fibrils 
of Col II are stabilised by Col IX and Col XI. The individual Col II molecules comprise 
a triple helix of three α-chains covalently linked at each end (69). The native collagen 
fibrils are very resistant to proteases. The initial cleavage of Col II is mediated by the 
collagenases MMP1, MMP8, and MMP13 at a single site close to the C-terminus. The 
resulting fragments of Col II are further degraded by gelatinases (MMP2 and MMP9) 
and stromelysin (MMP3) (70). Degradation of Col II can be stimulated by IL1 and 
plasminogen, and also involves induction of IL6 and IL8 (71, 72). 
 In healthy cartilage, the extracellular proteolytic enzymes are present in latent 
forms. The presence of specific tissue inhibitors of metalloproteinases (TIMPs) 
regulates the activity of the proteolytic enzymes. TIMP3 can inhibit both MMPs and 
ADAMTSs (A Disintegrin And Metalloproteinase with Thrombospondin Motif), it is a 
central regulator of normal turnover of cartilage macromolecules. In healthy cartilage, 
approximately 10-15% of the ACAN molecules are present in a non-aggregated state, 
and lack their N-terminal region (73). The presence of fragmented ACAN reflects the 
normal turnover of ACAN within the ECM. Other proteinases, such as m-calpain, may 
also contribute to extracellular cleavage of ACAN (74). ACAN fragments are 
internalised within chondrocytes and degraded within lysosomes by cathepsins, which 
are activated by interacting with glycosaminoglycans (GAGs) (75). The degradation of 
endocytosed GAGs within lysosomes is highly ordered and involves endoglycosidases, 
exoglycosidases, sulfatases, and non-catalytic proteins. 
Physiological mechanical stimulation is necessary for homeostasis of normal 
cartilage. Mechanical load causes movement of synovial fluid, and facilitates the 
diffusion of molecules between the cartilage and synovial fluid that is important for the 
nutrition of cartilage (76). Mechanical stimulation increases ACAN production and 
reduces MMP3 expression by human chondrocytes, and inhibits IL1α and TNFα-
induced catabolic processes (77, 78). Sensors of mechanical stimulation in chondrocytes 
include integrins, cell surface receptors such as syndecans, and the primary cilium. 
The primary cilium is a non-motile organelle that projects from the cell to 
function as a mechanical sensor and contributes to cartilage homeostasis through 
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regulation of intracellular signalling (79, 80). Detection of mechanical stimulation by 
the primary cilium in chondrocytes is exerted through integrins and calcium channels 
(81). Primary cilia are critical for chondrocyte organisation and normal deposition of 
matrix constituents (82, 83). The primary cilium regulates hedgehog (HH) signalling 
pathways in chondrocytes, important for the maintenance of normal articular cartilage 
structure (82). Furthermore, induction of inflammatory pathways involving 
prostaglandin E2 (PGE2) and nitric oxide (NO) in chondrocytes are also regulated by 
the primary cilium (84). 
Due to the avascular nature of articular cartilage and a long diffusion distance 
from nourishing arteries, chondrocytes are particularly well adapted to survival in a 
hypoxic tissue microenvironment. Oxygen and nutrients are delivered to the articular 
cartilage from the vascular supply to the joint capsule, synovium, and subchondral bone. 
Hypoxia promotes a protective environment for chondrocyte metabolism in which 
production of Col II is relatively high, and the release of IL1α, TNFα, MMP1 and 
MMP13 are relatively low, compared to normoxic conditions (85, 86). Hypoxia 
inducible factor 1α (HIF1α) protein levels are responsive to tissue oxygen levels; it is 
present in cartilage and is crucial in promoting chondrocyte activity and viability (87). 
 
1.2.2.9 Mechanobiology of articular cartilage 
Mechanical loading results in compression of articular cartilage, deformation of the 
ECM, and stimulates chondrocyte metabolism. Unloading of articular cartilage leads to 
an influx of nutrients into the cartilage from the adjacent synovial fluid. Different joints 
are exposed to different compressive forces, with pressures of between 0.1 to 4 
megapascal (MPa) occurring in human hip joints during walking (88). During 
monolayer chondrocyte cell culture, cyclical mechanical stimulation and intermittent 
hydrostatic pressure at physiological levels leads to increase ACAN and Col II gene 
expression (89). In three-dimensional (3D) chondrocyte cultures, intermittent dynamic 
compression, or strain, at physiological levels also increases proteoglycan synthesis and 
proliferation of chondrocytes (90, 91). Cyclical compression of cartilage explants also 
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stimulates the expression of fibronectin and COMP (92). In contrast to mechanical 
loading within a physiological range, static and pathological mechanical forces induce 
catabolic responses in articular cartilage with increased expression of MMP3, MMP9, 
MMP13, IL1β and TNFα, and reduced expression of ACAN and Col II (93, 94). 
Compression of articular cartilage also leads to changes in the ECM, chondrocyte 
metabolism, hydrostatic pressure gradients, water content of the ECM, the osmotic 
pressure gradient, and concentration of ions (95). Chondrocyte mechanoreceptors, 
including mechanosensitive ion channels, integrins, the primary cilium, and non-
selective cell surface channels, mediate mechanotransduction in cartilage (96). 
 The pericellular matrix (PCM) is a 1-5 μm region that surrounds the 
chondrocyte. In the PCM, Col VI and perlecan are highly expressed, whereas the 
expression of Col II is relatively low compared to the surrounding matrix (97). The 
PCM has fundamental mechanosensing properties and may amplify mechanical signals 
transmitted through the ECM (98). Transmission of mechanical signals from the ECM 
may be mediated by interaction of the chondrocyte with molecules within the PCM, 
such as integrins and discoidin domain receptors (99). Biglycan and decorin are small 
leucine rich repeat molecules that may connect type II and type VI collagen between the 
PCM and territorial matrix (100). 
 Mechanical stimulation of cartilage results in the activation of ion channels in 
chondrocytes, permitting the influx of ions such as calcium, and leads to the activation 
of intracellular signalling pathways. This is associated with alterations of the actin 
cytoskeleton and activation of intracellular signalling molecules including 
phospholipase C, calmodulin, tyrosine protein kinase, and protein kinase C (88). 
Loading of chondrocytes also leads to hyperpolarisation of the cell membrane due to 
activation of slow conductance Ca2+ sensitive K+ channels (101). Mechanical 
stimulation of chondrocytes also activates stretch activated calcium channels, L-type 
calcium channels, which are involved in the regulation of protein synthesis in response 
to mechanical loading (102). 
Integrins are heteromeric transmembrane glycoproteins that consist of α and β subunits, 
the combination of which contributes to the ligand specificity of the receptor. Integrins 
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are located between the ECM and the chondrocyte cytoskeleton and act as 
mechanoreceptors. Chondrocytes express several integrins in healthy adult cartilage in 
situ (103). The α5β1 integrin is an important mechanoreceptor in articular chondrocytes, 
which can control the flow of K+ ions across the cell membrane, activation of cell 
signalling molecules, expression of COMP, and regulation of proteoglycan synthesis in 
response to dynamic mechanical stimulation (104, 105). Integrin mechanoreceptor 
expression and interaction between integrins and the ECM are also modulated by growth 
factors. Both IGF1 and TGFβ increase chondrocyte cell surface expression of integrins 
and stimulate adhesion of chondrocytes to fibronectin and Col II (106). Basic fibroblast 
growth factor (bFGF) also mediates the release and activation of chondrocyte growth 
factors from within the ECM (107). In response to mechanical stimulation, both bFGF 
and integrin-mediated signalling induce ERK activation. Substance P can also regulate 
integrin activity (108). IL4 is another important mediator of electrophysiological 
responses by chondrocytes to mechanical stimulation. IL4 is another important mediator 
of chondrocyte responses to loading, and can stimulate increased expression of ACAN 
by influencing integrin signalling pathways (78, 108). G-protein coupled receptors 
(GPCRs) are also involved in hyperosmotic stress induced volume changes and calcium 
flux in chondrocytes, and may be associated with integrins in mechanotransduction 
(109). Cyclic adenosine monophosphate (cAMP) activates protein kinase A and is also 
an important mediator of chondrocyte responses to mechanical stimulation (110). 
 Chondrocyte volume is directly influenced by osmolarity, and this has a 
significant effect on cellular responses by chondrocytes, including ECM metabolism 
(111). Alterations of the osmotic environment regulate the expression of the 
chondrogenic transcription factor Sox9, which may regulate expression of genes 
encoding ECM proteins, including Col2a1 and ACAN (112). Increasing osmolarity 
results in reduced chondrocyte necrosis following pathological loading and iatrogenic 
injury to cartilage (113-115). Osmotic changes also initiate signalling cascades that 
involve regulation of intracellular Ca2+ concentration, which play a role in chondrocyte 
cell death (116-118). The mean osmolarity of human synovial fluid is approximately 
400 milliosmoles (mOsm). Cartilage contains a high concentration of free cations, 
predominantly Na+, and a low concentration of free anions, mainly Cl-, compared to the 
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surrounding synovial fluid (119). Proteoglycans carry fixed negative charges and attract 
a high concentration of cations. The local proteoglycan concentrations in cartilage 
therefore determine the ionic composition and extracellular osmolarity of cartilage. The 
extracellular osmolarity within cartilage is higher than that in the surrounding tissues, 
and the resultant swelling pressure is resisted by an intact collagen network (114). 
Consequently, the net result of ECM degradation, such as occurs in OA, is cartilage 
swelling and a decrease in extracellular osmolarity (114). 
 
1.2.2.10 Aggrecanolysis and degradation of ECM macromolecules in OA 
Degradation of collagen and ACAN in the ECM of cartilage is key to the pathogenesis 
of OA. ACAN is a large proteoglycan containing the hydrophilic GAGs chondroitin 
sulphate and keratan sulphate, which confer resistance to compressive forces upon 
articular cartilage. Proteolysis of ACAN occurs at several sites along the protein. In the 
development of OA, the most important site of cleavage of ACAN is in the interglobular 
domain (IGD) between the N-terminal G1 and G2 globular domains. Cleavage of 
ACAN at this site releases the GAG-binding region of ACAN, leading to loss of both 
GAGs and the function of ACAN. Studies demonstrating cartilage degradation 
following treatment with papain or vitamin A provided initial evidence that cartilage 
proteoglycans, of which ACAN is the most abundant, are vulnerable to proteolytic 
degradation (120, 121). Metalloproteinases present in both bone and cartilage were 
identified as able to degrade proteoglycans at a physiological neutral pH (122, 123). 
MMP3 present in human articular cartilage was subsequently demonstrated as capable 
of cleaving the Asn341-Phe342 bond in the IGD of ACAN (124). This site has also been 
found to be cleaved by other MMPs including MMP1, MMP2, MMP7, MMP8, MMP9, 
and MMP13, which may also act at additional cleavage sites at the C-terminus of 
ACAN (125-127).  
However, the majority of ACAN fragments present in synovial fluid of patients 
with OA are generated from cleavage at the Glu373-Ala374 bond, rather than at the 
Asn341-Phe342 site of the IGD (128). In vitro studies in bovine and murine cartilage 
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subsequently identified several ADAMTS metalloproteinases as capable of cleavage of 
ACAN at the Glu373-Ala374 bond site in the IGD (129). In vitro and in vivo studies in KO 
mice demonstrated that ADAMTS-5, followed by ADAMTS-4, is the most active 
aggrecanase in articular cartilage and of most pathological significance to the 
development of OA (124, 130). ADAMTS4 mRNA is induced by cytokines such as 
IL1β and TNFα in human cartilage and chondrocytes, but ADAMTS5 mRNA is not 
regulated by cytokines and it expressed more constitutively in human cartilage (131). 
The relative contribution of ADAMTS-4 and ADAMTS-5 in pathological degradation 
of human cartilage is incompletely understood, as their activity is influenced by multiple 
processes including promoter activity, epigenetic modifications, alternative splicing, and 
non-coding RNA activity (132). However, proteolysis of ACAN at the Glu373-Ala374 site 
is the most important mechanism of pathological aggrecanolysis in osteoarthritic 
cartilage. Aggrecanolysis at the Asn341-Phe342 site may also occur to a lesser extent 
during advanced stages of OA. Cleavage of ACAN at the Asn341-Phe342 C-terminal site 
by MMPs has less pathological significance as it does not result in the release of the 
GAG-binding region of ACAN (133). 
 The order in which the principal components of the ECM of cartilage are 
degraded in the development of OA is incompletely understood, though ex vivo studies 
indicate that collagen degradation is initiated only after depletion of ACAN from 
cartilage has occurred (134). Loss of collagen, but not ACAN, is an irreversible process 
in the progression of OA (135). MMP13 is the most significant collagenase in the 
development of OA, possibly due to its very deep S1’ subsite (136). MMP3 is the most 
abundant MMP in osteoarthritic cartilage, though its expression may be reduced in end-
stage OA (137). MMP3 may activate other MMPs, including MMP1 and MMP13, 
contributing to the development of OA by activating other latent collagenases (138). 
 
1.2.2.11 COMP 
The degradation of COMP may also have a significant role in the pathogenesis of OA. 
COMP fragments have been demonstrated in cartilage and synovial fluid of patients 
with primary OA (139). Several MMPs and ADAMTS4 have been identified as capable 
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of cleaving COMP (140). IL1β and TNFα also induce expression of ADAMTS7 and 
ADAMTS12, which can degrade COMP (141). COMP also interacts with granulin-
epithelin precursor (GEP). GEP is a growth factor expressed by chondrocytes. GEP 
inhibits ADAMTS7 by inhibiting the effect of TNFα and by directly interrupting the 
association of ADAMTS7 and ADAMTS12 with COMP. As such, ADAMTS7, 
ADAMTS12, COMP, GEP, and inflammatory cytokines interact to also regulate the 
degradation of the ECM. 
 
1.2.2.12 Retinoic acid 
Retinoic acid (RA) is also a potent inducer of aggrecanolysis. ACAN fragments 
generated by ADAMTS4 and ADAMTS5-mediated cleavage have been identified in 
response to retinoic acid (142). RA is preferentially bound by the α, β, and γ retinoic 
acid receptors (RARs). In chondroprogenitor cells, activation of retinoid receptors 
decreases Sox9 activity at the Col2a1 enhancer and reduces the content of GAGs in the 
ECM (143). Increasing RA levels accelerates hypertrophy of chondrocytes, and 
contributes to the progression of degenerative joint diseases (144). RARs have a 
prominent role in growth plate and skeletal development, and regulate both ACAN 
expression and content (145). RA also regulates MafB, a transcription factor that 
mediates chondrocyte gene expression and ECM formation through regulation of 
ACAN, MMP3, and MMP13 expression (146). 
 
1.2.3 Subchondral bone 
The subchondral bone is porous and calcified, provides structural support for overlying 
articular cartilage, is separated from the articular cartilage by calcified cartilage, and 
may be divided into cortical and trabecular regions (147). The thin layer of cortical 
subchondral bone is hypovascular, non-porous, and calcified. The cortical subchondral 
bone is supported by trabecular subchondral bone, which is cancellous and less dense, 
and contains the haematopoietic bone marrow (148). 
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Osteoid, also known as unmineralised bone matrix, comprises a fibrillar network 
of type I collagen (Col I) and mucopolysaccharide. Homeostasis of the bone matrix is 
maintained by the coordinated activity of osteoblasts, osteoclasts, and osteocytes (149). 
Osteoblasts derive from MSCs and are responsible for the synthesis of the substance of 
bone matrix. Soon after osteoid is synthesised, inorganic salts are deposited in the 
osteoid to form mineralised bone. Osteoblast differentiation is initiated by BMPs that 
induce the expression of the transcription factors Runx2 and osterix (150). As 
osteoblasts mature, they may become encompassed by mineralised osteoid and develop 
into osteocytes, or survive at the bone surface as inactive osteoblasts (148). Osteoclasts 
differentiate from macrophages and function primarily to resorb mineralised bone 
matrix through the secretion of hydrogen ions and proteolytic enzymes that degrade the 
hydroxyapatite nanocrystals and Col I network, respectively. The differentiation of 
promyeloid precursors into osteoclasts is stimulated by receptor activator of nuclear 
factor (NF)-κB ligand (RANKL), osteoprotegerin ligand (OPGL), and osteoclast 
differentiation factor (ODF) (151). 
The remodelling of bone involves the action of several cytokines including 
RANKL (also known as tumour necrosis factor ligand superfamily member 11 
(TNFSF11), TNF-related activation-induced cytokine (TRANCE), OPGL, and ODF. 
RANKL binds the receptor activator of nuclear factor NFκB (RANK) receptor, 
activating a signalling pathway that culminates in osteoclastogenesis and bone 
resorption (148). The activity of RANKL is antagonised by osteoprotegerin (OPG), 
which can effect osteoclast apoptosis (151). Endocrine factors, including parathyroid 
hormone, calcitriol, and vitamin D3 also affect bone matrix homeostasis by regulating 
calcium levels. The metabolic activity of bone can also be regulated by thyroid 
hormones, systemic glucocorticoids, and oestrogen. The principal growth factors 
affecting bone remodelling include IGF, FGF, TGFβ, BMPs, and vascular endothelial 
growth factor (VEGF), and the cytokines IL1β and TNFα promote osteoclast 
differentiation, whereas IL6 is involved in the coupling between both bone formation 
and resorption (152, 153). 
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1.2.4 Joint pathology and progression of OA in articular cartilage 
OA develops due to failure of the repair mechanisms of cartilage in response to 
biochemical and biomechanical changes in the joint. During the early phases of OA, 
clusters of chondrocytes develop in areas of degenerate cartilage with an associated 
increase in concentration of growth factors in order to effect cartilage regeneration 
(154). As cartilage repair fails, the production of the degradative proteinases such as 
MMPs and aggrecanases increases, chondrocyte apoptosis increases, and ECM synthesis 
becomes insufficient, resulting in an ECM that cannot tolerate physiological mechanical 
stress (155). Thus, articular cartilage gradually degenerates due to an imbalanced 
synthesis and turnover of ECM. Clinical symptoms and signs often develop relatively 
late in the disease process, at which point the innervated and more vascular components 
of synovial joints may also be affected. 
Although cartilage is particularly affected by the pathophysiology of OA, an 
integrated process involving subchondral bone and synovial tissue to varying degrees of 
severity exists (156). Inflammation and hypertrophy of the synovium correlates closely 
with clinical signs and symptoms in patients with OA, such as joint effusion and pain; 
synovitis develops in response to increasing fragmentation of cartilage and catabolic 
cytokines present in the synovial fluid. In response, synovial macrophages secrete 
inflammatory mediators, further disrupting the normal homeostasis of articular cartilage 
(157). Characteristic changes that develop in subchondral bone include osteophyte 
formation, remodelling, sclerosis, and cystic changes. Synovitis and subchondral bone 
changes develop gradually throughout the progression of OA from mild to severe joint 
disease (158). 
 
1.2.4.1 Effects on chondrocytes, cartilage homeostasis, and ECM 
During the development of OA, articular chondrocytes undergo a phenotypic shift from 
a normal quiescent state to an activated state, typified by chondrocyte proliferation, 
formation of clusters, abnormal hypertrophy, and an increased synthesis of matrix 
proteins and MMPs (159). This is associated with increased calcification of cartilage by 
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chondrocyte-derived apoptotic bodies, advancement of the cartilage tidemark, and 
vascular invasion from the underlying subchondral bone (160). 
Hypertrophic chondrocytes in osteoarthritic cartilage express genes encoding 
RUNX2, MMP13, and Col X. The normal pattern of primary cilia on the chondrocyte 
also becomes dysregulated in OA, which may be a direct cause of, or result from the 
loss of, cartilage homeostasis (82, 161). Vascular invasion of the osteochondral junction 
exposes cartilage to soluble mediators secreted by osteoblasts and osteoclasts; TGFβ1 is 
produced by osteoclasts of the subchondral bone upon initiation of OA, and 14-3-3ε 
protein secreted by osteoblasts directly stimulates chondrocytes to secrete catabolic 
cytokines (162, 163). As neovascularisation of the calcified cartilage progresses, sensory 
nerve terminations also develop, which may sensitise the subchondral junction, and 
correlate with exacerbation of clinical symptoms (164). Exacerbation of pain in OA also 
correlates with the development of lesions in the adjacent bone marrow. 
 
Chapter 1 - Introduction 
 22 
1.2.4.2 Molecular mechanisms related to OA pathogenesis 
The primary enzymes responsible for the degradation of cartilage are zinc-dependent 
metalloproteinases, including MMPs and ADAMTSs enzymes. The main collagenases 
are MMP1 and MMP13, the latter being particularly effective in the degradation of Col 
II, and also MMP3, which is highly efficient in activating both aggrecanase and 
additional MMPs. ADAMTS4 and ADAMTS5 also act predominantly as aggrecanases 
in articular cartilage. In OA, the normal balance between TIMP3 and ADAMTS4 
synthesis is disturbed in favour of catabolism. This disturbance could be attributed to de 
novo synthesis of ADAMTS4 and may also involve post-translational activation of 
ADAMTS4 and ADAMTS5 (165, 166). Cathepsin-K, in addition to other serine and 
cysteine proteases, is another matrix-degrading enzyme acting within cartilage (167). 
The arrangement of chondrocyte integrin receptors responds to detected 
alterations in mechanical stress or inflammatory stimuli. The association of Col II with 
proteoglycans in the interterritorial region of cartilage usually protects against 
degradation of Col II. Depletion of ACAN and activation of MMPs both contribute to 
the initiation of cartilage erosion; disruption of the collagen fibrillar network heralds 
subsequent irreversible cartilage degradation (168, 169). 
The expression of MMPs by chondrocytes may be induced by biomechanical 
stress and in response to matrix degradation. A mechanism by which mechanical 
stimulation can initiate MMP expression may involve the breakdown of the chondrocyte 
pericellular matrix by the protease High Temperature Requirement A1 (HTRA1) that 
then permits discoidin domain receptor 2 (DDR2) to interact with Col II, thus increasing 
expression of MMP13 (170, 171). As proteins of the ECM are degraded in osteoarthritic 
cartilage, chondrocyte integrin receptors detect fragments of matrix proteins, such as 
fibronectin, small leucine-rich proteoglycans, and collagen and initiate the production of 
pro-inflammatory cytokines, chemokines, and MMPs (172, 173). The innate immune 
system may also be activated in response to the presence of matrix degradation products 
in osteoarthritic cartilage. Fibromodulin and decorin, which are members of the small 
leucine-rich proteoglycan family, may activate the classic complement pathway, 
whereas COMP is an efficient activator of the alternative complement pathway, and 
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synovial fluid from osteoarthritic joints contain complexes of COMP and complement 
3b (C3b) (174). 
In addition to activation of MMPs, mechanical stimulation induces the 
production and release of cyclooxygenase-2 (COX2), microsomal prostaglandin E 
synthase-1 (mPGES1), soluble phospholipase A2 (sPLA2), and inducible nitric oxide 
synthase (NOS2) in osteoarthritic cartilage. These pro-inflammatory mediators are 
detected by chondrocytes, particularly those in clonal clusters, and respond by 
upregulating the expression of MMPs and pro-inflammatory cytokines (175). 
Subsequent cartilage degradation may be mediated by chondrocytes through both IL1β-
dependent and IL1β-independent signalling pathways (176). 
Abnormal biomechanical stress also stimulates the activation and translocation 
of NFκB, and mitogen-activated protein kinase (MAPK) signalling pathways, thereby 
influencing the expression of downstream target genes including MMP13, NOS2, COX2, 
ADAMTS, and IL1β (177, 178). Whether or not these are primary or secondary 
processes in cartilage degradation is not certain, but does indicate mechanisms by which 
feedback amplification and further matrix destruction may occur. Additional signalling 
pathways activated in osteoarthritic cartilage and which regulate the catabolic activity of 
chondrocytes include the extracellular-regulated kinase (ERK), c-Jun N-terminal kinase 
(JNK), and p38 MAPK cascades (175). Increased release of reactive oxygen species 
(ROS) through mechanical stress and generation of fragments of matrix proteins may 
also contribute to chondrocyte necrosis (179). With increasing severity of OA, the 
ability of chondrocytes to undergo autophagy, normally a protective mechanism for cells 
under physiological stress, also reduces (180). 
Osteoarthritic articular tissue also demonstrates a specific chemokine profile, 
with an increased expression of chemokine (C-C motif) ligand 19 (CCL19) and its 
ligand C-C chemokine receptor 7 (CCR7), correlating with exacerbation of joint 
symptoms in patients with OA (181). The recruitment of an inflammatory cell infiltrate 
into osteoarthritic joint tissue may in part be modulated by damage-associated molecular 
patterns (DAMPs), also known as alarmins, that interact with Toll-like receptors (TLRs) 
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expressed by chondrocytes with an increased abundance in OA (182, 183). DAMPs such 
as S100 calcium-binding protein A11 (S100A11) can enact chondrocyte hypertrophy 
and catabolic activity (184). A 32-mer ACAN cleavage fragment can also act as a 
DAMP, increasing MMP13 and ADAMTS5 expression and decreasing Col II and 
ACAN expression, effects that are NFκB dependent and mediated through TLR2 (185). 
High-mobility group box protein (HMGB) can potentiate the response of chondrocytes 
to DAMPs and contribute to a hypertrophic phenotypic shift of chondrocytes during the 
development of OA (186). 
A low-grade systemic inflammatory state associated with obesity may 
significantly contribute to the established association of an increased risk of OA in 
overweight patients. Mediators of joint inflammation may include adipokines produced 
by white adipose tissue acting as an endocrine tissue, or locally by chondrocytes. The 
expression of adipokines by chondrocytes can be stimulated by inflammatory cytokines, 
and adipokines such as leptin, adiponectin, and visfatin can increase the expression of 
MMPs and NOS2 by chondrocytes (187-189). Although an association with 
dysregulated cartilage homeostasis is recognised, the exact mechanisms by which 
individual adipokines contribute to the development of OA have not yet been 
determined. 
 
1.2.5 Grading of OA 
The diagnosis and monitoring of joint tissue damage currently utilises surrogate markers 
of actual joint degeneration. Biomarkers of OA are not yet validated for use in clinical 
practice. Cartilage can be visualised directly by arthroscopy, but this requires an 
invasive procedure and may not be sufficiently sensitive to detect different stages of 
joint degeneration and regeneration (190). Plain radiography is the gold standard for 
imaging of osteoarthritic joints. The severity of OA can be graded radiographically 
using the Kellgren and Lawrence classification (191). This classification system 
examines osteophyte formation, joint-space narrowing, and bone sclerosis in affected 
joints and it has been adapted to analyse radiographic features of hand, hip, and knee 
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joints (192). The most important variable in reproducibility of radiographic grading of 
OA is standardisation of the radiographs. Ultrasound may be used to examine 
osteoarthritic joints and is beneficial in evaluating the soft tissue changes associated 
with OA, but ultrasound is limited as a grading tool as it is very dependent on the 
experience and skill of the operator (193). Computed tomography (CT) can provide 
three-dimensional joint analysis, but, in addition to the disadvantages of plain 
radiography, requires a high radiation exposure (194). Magnetic resonance imaging 
(MRI) can provide detailed quantitative evaluation of the morphology and integrity of 
articular cartilage but is relatively expensive, time-consuming, and complex to analyse 
(195).  
The first histological grading system to evaluate cartilage degeneration was 
described by Collins and McElligott, in which sulphate uptake by chondrocytes 
correlates with cartilage structural changes; hypertrophic chondrocytes present in 
osteoarthritic cartilage exhibit increased sulphate uptake (196). The Mankin system 
grades cartilage degradation by determining glycosaminoglycan content by Safranin-O 
staining, assessing cellularity and scoring structural changes involving the tidemark. The 
most validated histological system for grading cartilage degeneration due to OA is the 
OARSI score. The OARSI score incorporates the histological staining described by 
Mankin with staging criteria depending on the depth of the cartilage erosion (197). The 
OARSI grading system is shown in Figure 1.3. 
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Figure 1.3 – OARSI histological grading system for OA in human articular cartilage; the 
histopathological features of each grade are shown. Staging describes the percentage area of affected 
cartilage. Adapted from Pritzker et al (197). 
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1.3 Evidence for a genetic predisposition to OA 
OA is considered to be a complex disease, the development of which is influenced by 
environmental, genetic, mechanical and systemic factors. The genetic influence on 
susceptibility to OA is polygenic. As for other diseases caused by complex trait 
genetics, susceptibility to OA is likely to be conferred by several common genetic 
variants each exerting a moderate effect on disease susceptibility (198). In addition to 
multiple genetic risk loci with modest individual effects, interrogation of the genetic 
susceptibility to OA is made challenging by the phenotypic variability associated with 
joint degeneration, with multiple phenotypes such as pain, joint morphology, and joint-
space narrowing each representing separate endophenotypes that may have different 
genetic aetiologies (199, 200). Distinct genetic predisposition may also exist for the 
association of OA with different ethnic groups, gender, and joints (198). Identification 
of genetic risk loci in affected populations therefore requires adequate sample size, 
carefully defined subjects, and robust phenotypic characterisation. 
In most ethnic groups OA is relatively common, with varying estimates of 
prevalence and incidence depending on the individual joints assessed, methods of 
detection, and diagnostic criteria. Prior to the advent of large-scale molecular genetic 
analyses, several epidemiological studies demonstrated a compelling genetic 
contribution to the susceptibility of OA, and characterising OA as a disease with a 
complex, polygenic predisposition. Familial inheritance of Heberden’s nodes, a cardinal 
feature of OA of the hand, was first described in 1941, with an increased incidence in 
females (201). An early epidemiological study in the UK also implied a polygenic 
predisposition to the development of both Heberden’s nodes and more generalised OA 
(202). The Framingham Offspring Study and the Baltimore Longitudinal Study of 
Aging demonstrated an increased risk of developing hand and knee OA among persons 
with affected relatives and that inheritance of susceptibility to OA exhibited a recessive 
Mendelian pattern (203, 204). Several European sibling studies also demonstrated that 
individuals with a sibling who had undergone joint replacement surgery for OA, were at 
an increased risk of developing OA themselves when compared to control subjects (205-
209). As both shared environmental and genetic factors may influence disease 
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susceptibility amongst related individuals, the genetic contribution to OA was further 
examined in twin studies, which can better scrutinise the genetic contribution to the 
development of disease independent of environmental risk factors. In a classic twin 
study of mono- and di-zygotic female twins, it was estimated that the heritability of 
hand and knee OA was between 39-65%, and subsequently, in an extension of this study 
heritability for hip OA was estimated at 60% (210, 211). Interestingly, similar estimates 
of heritability for hip OA have been reproduced in studies of hip OA amongst mono- 
and di-zygotic male twins in the United States of America (USA). 
Epidemiological studies of OA susceptibility thus indicated that the disease 
exhibited a non-Mendelian, and likely complex polygenic pattern of inheritance. The 
genetic susceptibility to OA was subsequently investigated further in genetic linkage 
studies of small- to medium-sized cohorts, identifying broad genetic regions associated 
with the development of OA. More significant progress in identifying OA risk alleles 
has been achieved recently using genome-wide association (GWAS) in large case-
control studies and detailed sampling of polymorphic markers. GWAS studies have 
further been complemented by expression and functional studies in joint tissues that 
have begun to elucidate the molecular mechanisms that are responsible for the genetic 
predisposition to OA. 
 
1.3.1 Linkage studies and candidate genes 
Linkage studies, or genetic association analyses, utilise genetic markers such as single 
nucleotide polymorphisms (SNPs) and short tandem repeats (microsatellites) to identify 
regions of genetic linkage that co-segregate with OA phenotypes. Using this 
methodology, several candidate genes have been identified as containing risk alleles for 
OA and supported on the basis that the encoded proteins modulate joint development, 
maintenance or morphology (212). These studies have highlighted that OA risk alleles 
are often specific to ethnic groups or individual joints; this is a reflection of the differing 
frequencies of risk alleles and genetic background in populations of different ethnicity, 
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that non-genetic factors also influence the effect of the risk alleles, and that OA may be 
a more joint-specific disease rather than a systemic skeletal condition. 
The GDF5 (growth differentiation factor 5) gene located on 20q11.2 is the most 
established candidate association signal for OA, which was initially interrogated due to 
its role in skeletogenesis (213). GDF5 encodes growth differentiation factor 5, which is 
a growth factor belonging to the TGFβ superfamily (214); the associated single 
nucleotide polymorphism (SNP) rs143383 (rs; reference SNP) has been associated with 
knee OA in both European and Asian populations at highly significant levels of p < 5.0 
x 10-8 (215, 216). A meta-analysis study including both European and Asian cohorts 
later also identified an association with hip OA (217). A further meta-analysis of the 
rs143383 in association with knee OA in only European cohorts achieved genome-wide 
significance (p = 4.1 x 10-11; odds ratio (OR) 1.18, 95% confidence interval (CI) 1.12 - 
1.23) (218). This variant exerts its effect by regulating GDF5 transcription, whereby the 
susceptibility allele results in reduced expression levels (213). The differential allelic 
expression is itself regulated by four trans-acting factors Sp1 (trans-acting transcription 
factor 1), Sp3, P15, and DEAF-1 (deformed epidermal autoregulatory factor 1 homolog) 
that bind differentially to the alleles of rs143383 (219). DEAF-1, Sp1, and Sp3 form a 
repressive complex that binds and differentially modulates the expression of the C 
(cytosine) and T (thymine) alleles, whereas P15 may interact with this complex and 
other transcription factors (219). 
Linkage analysis also identified the DIO2 (type II iodothyronine deiodinase) 
gene, which is located at 14q24.2 - q24.3 and encodes the D2 (deiodinase 2) enzyme 
determining the availability of locally active thyroid hormone, as a susceptibility gene 
for OA (220). Differential allelic expression of DIO2 messenger ribonucleic acid 
(mRNA) has been demonstrated in musculoskeletal tissue, with the effect allele over-
expressed relative to the wild-type allele in heterozygous (HET) individuals, implicating 
a functional role for genetic variation at DIO2 in susceptibility to OA (221). 
Upregulation of DIO2 may mediate upregulation of cartilage degrading enzymes 
including MMP13 and ADAMTS5 (222). 
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SMAD3 (SMAD family member 3) is another highly compelling candidate 
association signal for OA; this association relates to the common SNP rs12901499 
within intron 1 of the gene region. SMAD3 encodes an intracellular signal transducer 
that is also involved in the TGFβ pathway, and the rs12901499 risk allele was associated 
with both knee OA (p = 7.5 x 10-6; OR 1.22, 95% CI 1.12 - 1.34) and hip OA (p = 4.0 x 
10-4; OR 1.22, 95% CI 1.09 - 1.36). Furthermore, rare and penetrant haploinsufficient 
mutations within SMAD3 are also associated with the development of the aneurysms-
OA syndrome, which is characterised by early-onset OA and vascular malformations 
(223). That both SNPs, which likely exert modest effects on gene function, (such as 
rs12901499) and detrimental mutations in SMAD3 both result in similar OA phenotypes 
strongly implicate SMAD3 as a candidate gene for susceptibility to OA. 
 
1.3.2 Genetic association analysis and GWAS  
In contrast to candidate gene studies, GWAS utilise a hypothesis-free approach to 
discover genetic susceptibility loci for complex diseases such as OA. Using high 
throughput microarrays, millions of SNPs may be genotyped in tens of thousands of 
affected individuals and disease-free control subjects. The strength of association of 
implicated variants is enhanced by initially genotyping a discovery cohort of both cases 
and control subjects, and subsequently prioritising any SNPs significantly associated 
with disease status for replication in a second larger cohort (224). 
GWAS utilise the co-segregation of alleles within the same genetic region, 
termed linkage disequilibrium (LD), to refine the number of SNPs required to be 
genotyped; several hundred thousand SNPs can be used to sufficiently cover over 85% 
of the Caucasian genome (225). As SNPs identified in GWAS studies as associated with 
disease status may not be the causal variant, but only in LD with the true causal variant, 
more detailed interrogation of the genetic loci surrounding implicated risk alleles is 
required (225). Additional genotyping of susceptibility can be performed by imputing 
information from data sets such as HapMap (http://hapmap.ncbi.nlm.nih.gov/) and 1000 
Genomes Project (http://www.1000genomes.org/) to determine the extent of regions 
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with LD at susceptibility loci (226). Fine-mapping of focused regions represented by the 
disease-associated allele can subsequently be performed, to discover true causal 
variant(s) and subsequently to perform functional studies in the relevant biological 
tissues, to further validate potential susceptibility genes in the pathogenesis of OA (227). 
By adopting a hypothesis-free study design and sampling the whole genome, GWAS 
enables the identification of novel pathways associated with complex diseases. 
 
1.3.2.1 arcOGEN and GWAS in OA 
The Arthritis Research UK OA Genetics Consortium (termed arcOGEN) study is the 
most powerful published GWAS investigating patients with OA (228, 229). It was the 
first GWAS investigating OA to identify multiple novel independent susceptibility loci 
with significance beyond the genome-wide significance threshold (p < 5 x 10-8) required 
after adjusting for the multiple tests performed during GWAS. The multicentre 
arcOGEN study investigated patients of European ancestry with primary OA of the hip 
or knee, defined as radiographic evidence of advanced disease (Kellgren-Lawrence 
grade > 2), of which 80% of patients had undergone total joint replacement (TJR). All 
cases were genotyped using the Illumina® 610-BeadChip, and genotypes for disease-free 
control subjects were retrieved from public databases including the Wellcome Trust 
Case Control Consortium (WTCCC), Type 1 Diabetes Genetics Consortium (T1DGC), 
Avon Longitudinal Study of Parents and Children (ALSPAC). 
In the initial stage 1 of arcOGEN, genotyping was performed in 3177 OA cases 
and 4894 control subjects for 514898 SNPs. In this interim analysis of 43.8% of the full 
GWAS sample size, SNPs associated with disease status were then replicated in silico in 
4124 OA cases and 37581 control subjects. Meta-analysis of 36 SNPs were selected for 
de novo replication in a further 6188 OA cases and 8280 control subjects and in silico 
replication in 213 OA cases and 2531 control subjects. None of the identified 
association signals in stage 1 of arcOGEN reached genome-wide statistical significance 
(228). This lack of success indicated that the genetic architecture of OA is likely to 
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consist of several signals of modest effect necessitating large sample sizes for their 
detection at genome-wide significance levels. 
The results of the full-scale GWAS were reported in stage II of arcOGEN, which 
performed genotyping of 485491 SNPs for 7410 unrelated OA cases and 11009 
unrelated control subjects from the UK (229). The most promising SNPs were then 
replicated in silico in 7473 OA cases and 42938 control subjects of either UK or 
European descent. Meta-analysis of discovery and replication cohorts identified five 
genome-wide significant loci (p < 5.0 x 10-8; Table 1.1) for association with OA and 
three loci just below this threshold. Three of the five genome-wide significant signals 
were specific for OA of the hip joint only, and did not show association with OA of the 
knee joint. This further indicated that the molecular genetic susceptibility to OA is not 
uniform across joint sites by demonstrating that a polymorphism (SNP) can be 
associated with OA at the hip without exhibiting association also at the knee, 
corroborating similar findings from epidemiological studies (230). 
 
 
Table 1.1 – New genome-wide significant susceptibility loci for OA identified by stage II of 
arcOGEN study (229). 
 
 Of the five identified loci with genome-wide significant association for OA, the 
locus associated with the greatest effect size was at 9q33.1, tagged by the rs4836732 
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SNP (OR 1.2, 95% CI 1.13 - 1.27). This polymorphism was specifically associated with 
females requiring THR for primary OA (representing a severe OA phenotype), and is 
located within intron 18 of the gene ASTN2 (astrotactin 2) (231). Two further protein-
encoding genes are present at this locus, tripartite motif-containing protein 32 
(TRIM32), and pappalysin 1 (PAPPA) (212).  This OA susceptibility locus is discussed 
in detail in section 1.3.2.2. 
 The locus with the greatest statistical significance, but not effect size, for 
association with TJR for hip or knee OA was at 3p21.1 and was tagged by two SNPs in 
perfect LD with each other (see Table 1.1; r2 = 1); rs11177, a missense polymorphism 
within exon three of the nucleostemin encoding gene guanine nucleotide binding 
protein-like 3 (GNL3) and rs6976, located in the 3’ untranslated (3’UTR) region of the 
glycosyltransferase 8 domain containing 1 (GLT8D1) gene. Although the exact role of 
GLT8D1 remains to be determined, the protein product belongs to the 
glycosyltransferase family of proteins (232); an altered pattern of glycosylation of 
articular glycoproteins or proteoglycans might alter their stability and subsequently the 
integrity of articular cartilage. GNL3 encodes the protein nucleostemin, a member of the 
Y1qF/YawG GTPases family of proteins (GTP; guanine triphosphate), which migrates 
between the nucleolus and nucleoplasm in response to intracellular and extracellular 
signalling (233, 234). 
 The three further loci identified in the arcOGEN stage II study as having 
genome-wide significance were specific for OA of the hip joint (Table 1.1). The 
polymorphism rs9350591 is located on 6q13 - q14.1 and two genes, sentrin specific 
peptidase 6 (SENP6) and filamin A interacting protein 1 (FILIP1) lie in close proximity, 
and type XII collagen (α1 chain) (COL12A1) is positioned 326 kilobases (kb) 
downstream on chromosome 6: COL12A1 is a fibril-associated collagen that regulates 
osteogenesis (235). Other genes within this susceptibility locus include transmembrane 
protein 30A (TMEM30A), cytochrome C oxidase subunit 7A2 (COX7A2), 
interphotoreceptor matrix proteoglycan 1 (IMPG1), and myosin VI (MYO6). Located 
within the locus tagged by rs10492367 is parathyroid hormone-like hormone (PTHLH), 
a strong candidate gene for OA due to its role in chondrocyte maturation, endochondral 
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ossification, and in human articular chondrocytes it up-regulates COL2A1 through SOX9 
(236). Also contained within this locus and in close proximity to rs10492367 is kelch 
domain containing 5 (KLHDC5). The final SNP associated with OA at genome-wide 
significance was rs835487, which is contained within intron 2 of carbohydrate 
(chondroitin-4)-sulfotransferase (CHST11) that regulates glycosaminoglycan synthesis 
and growth factor signalling, chondrogenesis, and osteogenesis; RNA expression levels 
are dysregulated in degenerate cartilage, indicating a role for CHST11 in the loss of 
normal cartilage homeostasis that occurs in OA (237, 238). 
 In addition to the five loci described, the arcOGEN study also identified three 
loci close to genome-wide significance. Firstly, rs12107036 located within intron 12 of 
tumour protein 63 (TP63) was associated with severe knee OA requiring TKR in female 
patients only. TP63 has a fundamental role in limb, epithelial, and craniofacial 
development (239, 240). OA in females was also associated with the rs8044769 
polymorphism, which resides within intron 1 of the fat mass and obesity associated gene 
(FTO). The FTO gene is also associated with susceptibility to obesity, which itself an 
established risk factor for OA (241). The only locus associated with OA specifically in 
male individuals was represented by the rs10948172 polymorphism. The genes in 
closest proximity to rs10948172 are suppressor of Ty3 homolog (SUPT3H), cell 
division cycle 5-like (CDC5L), and RUNX2, the latter of which is an important 
transcription factor in skeletogenesis (242). 
 Prior to arcOGEN, several susceptibility loci had been identified by GWAS in 
smaller cohorts and non-European populations. The rs7639618 SNP in DVWA (dual von 
Willebrand factor A domains), discovered in a GWAS of Japanese and Han Chinese 
patients, has been associated with knee OA (p = 7.3 x 10-8; OR = 1.54, 95% CI 1.32 - 
1.81) (243). DVWA is expressed specifically in cartilage and encodes a protein related to 
the von Willebrand factor type A domain (VWA domain); the DVWA protein itself 
interacts with β-tubulin. The association of this polymorphism with knee OA may be 
specific to Asian populations, as it was not replicated in a meta-analysis that also 
included European patients (244). Another GWAS in the Japanese population identified 
the rs10947262 SNP in the BTNL2 (butyrophilin-like 2) gene, in proximity to the HLAII 
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and HLAIII (human leucocyte antigen) genes as demonstrating genome-wide 
significance for association with knee OA (p = 6.73 x 10-8; OR 1.32, 95% CI 1.19 - 
1.46) (245). The BTNL2 gene is a member of the immunoglobulin gene superfamily. 
Importantly, this signal was maintained in a meta-analysis including European subjects 
(p = 5.1 x 10-9; OR 1.31, 95% CI 1.20 - 1.44) (245). A Dutch GWAS identified the 
common variant C-allele of rs3815148, in proximity to the GRP22 gene (glycine-
rich_protein_Aa1-291) as associated with the risk of developing knee and/or hand OA 
(p = 8.0 x 10-8; OR 1.14, 95% CI 1.09 - 1.19) (246). In subsequent functional studies, 
GRP22 expression was identified in murine articular chondrocytes upon the 
development of knee OA (246). In a GWAS of 3177 OA patients and 4894 control 
subjects, the rs11842874 SNP in MCF2L (MCF.2 cell-line-derived transforming 
sequence-like) was identified as a major novel risk variant (p = 2.1 x 10-8; OR 1.17, 95% 
CI 1.11 - 1.23) (247). Although the association did not surpass the accepted genome-
wide significance threshold, this remains an important susceptibility locus, as MCF2L 
modulates nerve growth factor, NGF, against which treatment with monoclonal 
antibodies in patients with knee OA is associated with reduced pain and improved joint 
function (248). 
 Following arcOGEN, several other genome-wide genetic association studies 
investigating OA in large cohorts have been reported. A meta-analysis of over 11277 
patients with hip OA and 67473 control subjects, all of European descent, identified a 
novel genome-wide significant polymorphism, SNP rs6094710 on chromosome 20q13, 
associated with hip OA (p = 7.9 x 10-9; OR 1.28, 95% CI 1.18 - 1.39) (249). Two 
candidate genes with strong biological plausibility for OA are located downstream of 
this polymorphism: NCOA3, which encodes the protein nuclear receptor coactivator 3, 
and SULF2 (sulfatase 2), which encodes the protein heparan sulphate 6-O endosulfatase 
2. RNA expression levels of NCOA3 have been demonstrated as reduced in degenerate 
articular cartilage compared to preserved cartilage from the same individuals (249). In 
contrast, RNA expression levels of SULF2 are increased in osteoarthritic cartilage 
compared to unaffected cartilage (250). The rs6094710 SNP is in perfect LD with 
several other SNPs at this locus, though none result in functionally significant alteration 
to the structure of either NCOA3 or SULF2, and it is more likely that polymorphisms at 
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this susceptibility locus may modulate expression of NCOA3 or SULF2 to exert their 
effect in the development of OA. 
 Another well-powered GWAS that examined specifically for association with 
OA of the hand identified a signal at 15q22, marked by the SNP rs3204689 (p = 1.1 x 
10-11; OR 1.46, 95% CI 1.31 - 1.63) (251). This SNP resides in the 3’UTR of ALDH1A2 
(aldehyde dehydrogenase 1 family member A2). This gene encodes an enzyme involved 
in the synthesis pathway for RA, which is a signalling molecule involved in several 
developmental pathways, including in skeletogenesis. The risk-conferring C-allele of 
rs3204689 correlated with reduced expression of the gene in both knee and hip cartilage 
from patients with OA, though expression in relevant tissue of affected joints of the 
hand was not assessed (251). However, in wider analysis, the SNP was specific for 
association with OA of the hand, but not at other skeletal sites. This may indicate that a 
functional effect may not directly correlate with a genetic risk. 
 A further recent GWAS investigating hip OA, defined by severe disease 
necessitating total hip joint replacement, and which included 654 patients with OA and 
4697 control subjects, discovered a signal at 7p12.3, tagged by the SNP rs788748 (p = 
2.0 x 10-8; OR 0.71, 95% CI 0.63 - 0.80) (252). Further combined analysis of the SNP 
for association with OA of the hip on five further cohorts and the discovery cohort 
identified that the SNP did not have genome-wide significance for association with hip 
OA (p = 0.02; OR 0.92, 95% CI 0.86 - 0.99). The lack of genome-wide significance 
upon replication in the larger combined cohorts may indicate a false-positive signal 
generated in the in the smaller discovery cohort. Further functional studies were 
performed to investigate IGFBP3 (insulin like growth factor binding protein 3), the gene 
closest to the disease-associated rs788748 SNP. It was reported that genotype of 
rs788748 correlated with serum levels of IGFBP3; suggesting that the risk A (adenine) 
allele of rs788748 might alter expression of IGFBP3 to effect the association with hip 
OA. This gene encodes insulin-growth factor binding protein 3; loss of expression and 
overexpression of the IGFBP3 protein resulted in significant effects associated with 
development of OA in articular cartilage, compared to control treatments in several 
chondrogenesis models. Knockdown of IGFBP3 in chondrocytes decreased chondrocyte 
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hypertrophy, whereas overexpression of IGFBP3 in chondrocytes resulted in cartilage 
catabolism and osteogenic differentiation. Although these functional results implicate 
IGFBP3 as having a role in cartilage homeostasis, direct effect of the risk allele of 
rs788748 on IGFBP3 expression in articular tissue has not yet been demonstrated and 
additional assessment of the association of rs788748 in additional large OA cohorts is 
needed to confirm or refute the association, and help determine whether or not the 
susceptibility locus containing IGFBP3 is a repository of genetic risk for OA. 
 A meta-analysis of recent GWAS in European populations comprising 9789 
patients with hip OA and 31873 control subjects has also identified a risk C-allele of 
DOT1L (DOT1 like histone H3K79 methyltransferase) rs12982744 to correlate with hip 
OA (p = 8.1 x 10-8; OR = 1.10, 95% CI 1.06 - 1.14) (253). The effect size was 
significantly greater in males compared to females, although genome-wide significance 
was demonstrated for both genders. The DOT1L gene encodes DOT1-like histone H3 
methyl-transferase, which has been implicated in endochondral bone formation (254). 
The associated polymorphism in DOT1L has previously been shown to be associated 
with minimum joint space width at the hip joint, which is itself greater in males than 
females, and may help to explain the gender dimorphism at this particular OA 
susceptibility locus (254).  
 The candidate gene analysis approach has also been subject to re-evaluation in a 
recent meta-analysis (255). In total, SNPs marking 199 candidate genes for association 
with OA were assessed by meta-analysis of nine GWAS including 9985 patients with 
hip or knee OA, and 34808 control subjects, all of European ancestry. After Bonferroni 
multiplicity correction for number of independent tests, no SNPs surpassed the 
significance threshold. Two genes contained SNPs that approached, but did not reach, 
statistical significance: one SNP within COL11A1 demonstrated association with hip 
OA (rs4907986 p = 1.29 x 10-5; OR 1.12, 95% CI 1.06 - 1.17), and one SNP at the 
VEGF gene showed association with hip OA specifically in male patients (rs833058 p = 
1.35 x 10-5: OR 0.85, 95% CI 0.79 - 0.91). The COL11A1 (collagen type XI alpha 1) 
gene encodes a component, the pro-alpha1 (XI) chain, of Col XI, and has an important 
role in both chondrogenesis and skeletogenesis as demonstrated by mutations in 
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COL11A1 that are associated with Stickler syndrome, lumbar disc degeneration and 
fibrochondrogenesis (256-258). VEGF encodes a protein fundamental in angiogenesis, 
which is also involved in endochondral ossification, physeal development, cartilage 
formation, and development of OA phenotype in animal models (259, 260). Although 
identification of variants within these two strong candidate genes as approaching 
significance for association with OA is encouraging, the results should be reviewed with 
caution as a relatively tolerant threshold was used for significance due to the focused 
analysis. Some limitations of this approach include the exclusion of relevant genetic 
variants that were not adequately covered, especially those with low frequency or 
multiple allelic polymorphisms. Nevertheless, the results of this meta-analysis indicate 
that the genetic association for OA is unlikely to be discovered through traditional 
candidate gene studies. The genetic risk for OA is more successfully investigated 
through the GWAS approach, with candidate gene studies more appropriate in the 
subsequent validation and refinement of genetic susceptibility loci identified from 
hypothesis-free genome-wide studies. The OA susceptibility loci with genome-wide 
significance identified by studies other than arcOGEN are shown in Table 1.2. 
 Comparison of the OA susceptibility loci with genome-wide significance 
identified by arcOGEN (Table 1.1) and other GWAS of OA (Table 1.2) reveals the 
identification of distinct susceptibility loci from separate studies. However, 
bioinformatics analysis of the association signals identified by arcOGEN and other 
GWAS studies has revealed a number of common biological pathways through which 
the genetic variants predisposing to OA may exert their effect. These include biological 
pathways involving skeletogenesis, differentiation of osteoblasts and chondrocytes, 
transcriptional regulation, and cell signalling (261). The differences in susceptibility loci 
identified between different GWAS studies may also be due to heterogeneity of the 
populations studied, as the same genetic variations may have unequal effects in the 
susceptibility to OA in different populations, as reflected by the genome-wide 
association of HLA class II/III and DVWA in Japanese populations, but not European 
populations (243, 245). Furthermore, genetic variants may also exert joint-specific and 
gender-specific effects on the susceptibility to OA, as highlighted by the results of the 
arcOGEN study (229). It is also notable that the arcOGEN study did not identify a 
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genome-wide association between OA susceptibility and GDF5 or the 7q22 locus, 
despite genome-wide associations being identified in previous studies (216, 246). This 
may be due to the limited statistical power of the first phase of the arcOGEN study, the 
allelic frequencies of the SNPs, and for GDF5, that the rs143383 SNP was not included 
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Table 1.2 – Genetic susceptibility loci for OA with genome-wide significance identified by studies 
other than arcOGEN (229). 
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 Despite the recent significant advances in identifying OA susceptibility loci 
using the GWAS approach, the heritability of OA risk is not yet fully explained. There 
are several possible aspects to the genetic architecture of susceptibility to common 
complex diseases, such as OA, that may contribute to this unexplained heritability. 
Many risk alleles are likely to be to present at a low frequency (minor allele frequency 
(MAF) < 1%) and therefore may not be captured by many of the genotyping platforms 
previously used (263). Genetic variants contributing to OA susceptibility may also have 
low effect sizes and, therefore, to have sufficient power to detect these small individual 
effects conferred by rare risk alleles, even larger multinational cohort studies will be 
required. In this regard, the advent of next generation sequencing (NGS), enabling 
multiplexed detailed fine-mapping of casual and rare variants in larger cohorts may be 
particularly informative (227). Furthermore, more detailed phenotypic characterisation 
of the OA patients and control subjects may permit detection of variants associated with 
finer endophenotypes that may not only enable identification of additional risk variants, 
but also inform the potential pathological nature of variants. In relation to OA, this was 
demonstrated with particular success in the association of the risk C-allele of DOT1L 
rs12982744 with reduced minimal hip joint space width and development of OA. More 
detailed clinical, demographic and radiological phenotypic characterisation of 
participants enrolled in genetic association studies may help address the missing 
heritability (254). 
 Finally, it is evident that a proportion of the genetic susceptibility to OA is 
conferred by variation other than SNPs. This may include copy number variants 
(CNVs), which are represented in relatively low number on current genotyping arrays 
(264). Epigenetic changes have been proposed as another form of genetic variation that 
may explain the small cumulative effect sizes of the existing susceptibility loci 
identified by GWAS investigating OA. This has been supported by initial functional 
studies that have demonstrated that risk alleles of certain SNPs can create CpG 
(cytosine-guanine dinucleotides) sites that may be regulated by deoxyribonucleic acid 
(DNA) methylation. Furthermore, OA is a phenotypically heterogeneous condition and 
epigenetic variation is also likely to be specific to patient subgroups or certain skeletal 
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sites. Joint site specificity may also exist in relation to epigenetic changes, and this may 
be elucidated as the pathological mechanisms are revealed. 
 
1.3.2.2 9q33.1 susceptibility locus for hip OA in females 
The susceptibility locus with the greatest effect size was that on chromosome 9q33.1 
(OR 1.20 [1.13-1.27]; p-value of 6.11 x 10-10), and which was associated with the 
specific phenotype of hip OA in females (Figure 1.4). This was the only locus that 
maintained its effect size estimate in both discovery and replication analyses. This locus 
is also delimited by two recombination hot-spots, and it contains only three protein-
coding genes, ASTN2, PAPPA, and TRIM32, in addition to five recently identified non-
coding genes PAPPA-AS1 (antisense RNA 1), ASTN2-AS1, LOC105376238, 
LOC105376239, and LOC105376240. 
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Figure 1.4 – Regional plot of the susceptibility locus at chromosome 9q33.1 for female hip OA 
centred on rs4836732; the data shown are from the arcOGEN study (229). Case-control results (-log10[p-
value]) for genotyped SNPs in the discovery set are plotted against genomic position for total hip 
replacement in female patients. The index genotyped SNP (rs4836732) is denoted by the purple diamond 
in the discovery set and by the purple square in the meta-analysis including discovery and replication sets. 
The circles indicate association results of genotyped SNPs in the region from the discovery analysis only; 
the colour reflects the correlation coefficient (r2) of each genotyped SNP with the index SNP estimated 
with the CEU HapMap II panel. The regional plot is annotated with the location and direction of 




Chapter 1 - Introduction 
 43 
 The ASTN2 gene at the 9q33.1 locus encodes a protein that is highly expressed in 
developing neurons, and GWAS studies have associated ASTN2 with the development 
of bipolar disorder, cognitive decline, migraine, adult attention-deficit/hyperactivity 
disorder, addiction vulnerability, autism, and schizophrenia (231, 265-269). The 
function of ASTN2 is most characterised in the neurocortex and hippocampus where it 
regulates the cell surface expression of ASTN1 (astrotactin 1), which is a critical cell 
adhesion molecule in neuron-glia binding during developmental periods of glial-guided 
neuron migration in the brain (231, 268). CNVs disrupting all transcripts of ASTN2 are 
significantly associated with neurodevelopmental disorders in humans (270). A 
significant association of genetic variants within ASTN2 with the age of onset of 
Alzheimer’s disease has also been demonstrated (271). ASTN2 therefore seems to be 
particularly important in the risk of neurodevelopmental, neurodegenerative, and 
neuropsychiatric disorders in humans. The expression of ASTN2 in musculoskeletal 
tissue has not previously been investigated. 
 Results from previous research indicate that two other genes at this locus, 
PAPPA and TRIM32, may have stronger biological relevance to the development of OA. 
The PAPPA gene encodes the pregnancy-associated plasma protein A (PAPPA) that is a 
zinc-binding metalloproteinase with IGFBP4 as its substrate. The IGFBP proteases 
regulate the structure, function and bioactivity of IGF1 and IGF2, which themselves are 
important determinants of fetal growth and postnatal development (272). PAPPA-
mediated IGF1 signalling is particularly important for postnatal skeletal development 
(273). Cleavage of IGFBP4 by PAPPA results in increased bioavailability and mitogenic 
effectiveness of IGFs in vitro. Overexpression of PAPPA has been shown to result in 
increased bone formation in transgenic mice, and this effect is primarily mediated by 
increasing the bioavailability of IGF (274). PAPPA proteolytic activity has been 
identified in cultured human fibroblasts and osteoblasts (275), human vascular smooth 
muscle cells (276), and ovarian granulosa cells (277). Mice with targeted inactivation of 
PAPPA exhibit delayed endochondral ossification, implicating a role for PAPPA in 
chondrocyte function, and growth retardation (274, 278). Loss of PAPPA activity in 
mice results in reduced cortical and trabecular bone thickness and bone mineral density 
compared to wild-type littermates (272). Loss of function of PAPPA2 (pappalysin 2), a 
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homologue of PAPPA, in mice leads to dysmorphic proximal femoral and pelvic girdle 
development, though the phenotype in articular cartilage and subchondral bone has not 
yet been investigated (279). Despite some potential role for PAPPA in skeletal 
development, this gene is located peripheral to the region marked by the rs4836732 SNP 
and recombination hotspots. 
 The TRIM32 gene at the 9q33.1 locus is ubiquitously expressed and encodes a 
protein with E3 ubiquitin ligase activity (280), and which is a member of the TRIM-
NHL protein family (NHL refers to NCL-1/HT2A/LIN-41, the proteins in which the 
domain was first identified), whose common features include Really Interesting New 
Gene (RING) finger, B-box, coiled-coil, and NHL repeat domains (281) (Figure 1.5). In 
TRIM-NHL proteins, the RING domain is characterised by a conserved sequence of 
cysteine and histidine residues in the core of the domain. This sequence controls the 
binding of two zinc ions that is fundamental to maintaining the domain structure. The 
RING domain can function as an E3 ubiquitin ligase (282). In TRIM32, the RING 
domain acts as an independent dimerisation unit and promotes formation of a TRIM32 
tetramer (283). The role of oligomerisation of TRIM32 on catalytic activity and 
substrate recognition is not yet known. The B-box domain also coordinates binding of 
two zinc ions in an interleaved fashion. The B-box domain may function together with 
the coiled-coil domain as a binding site for ubiquitination of substrates by the RING 
domain (284). B-box domains are divided into two types, termed B-box1 and B-box2, 
which regulate the binding of the two zinc proteins by slightly different mechanisms 
(285, 286). TRIM32 contains a single B-box2 domain. The B-box domain of TRIM32 
does not affect oligomerisation of the protein, and has only a small effect on catalytic 
activity (283). The coiled-coil domain usually comprises a non-conserved sequence of 
hundreds of amino acids. It is a structural motif in which usually two or three α-helices 
are coiled together, stabilised by hydrophobic interactions. This domain enables the 
formation of protein complexes, and may be involved in mRNA regulation by TRIM-
NHL proteins (287). The NHL domain comprises five or six repeats, each of 
approximately forty residues, which form a β-propeller structure. NHL domains often 
function in protein binding, but in TRIM-NHL proteins NHL domains may also directly 
interact with the RNA phosphate backbone, providing RNA regulatory activity (288). 
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 TRIM32 is a member of the RING finger E3 ligases (289), and the diverse 
pathological processes in which TRIM32 is implicated may be due to the variety of 
substrates that each E3 ligase can ubiquitinate (281). A recessive loss of function 
mutation in the B-box domain in one family was associated with the Bardet-Biedl 
syndrome (BBS) (290). Several BBS proteins have been shown to have nuclear export 
signals and to localise to the nucleus to interact with RING finger transcriptional 
repressors (291). Mutations in most of the 14 genes that cause BBS affect ciliogenesis 
(292). Mice with mutations in BBS 1, -2 and -6 genes have articular abnormalities 
including joint space narrowing and reduced proteoglycan content compared to wild 
type (WT) littermates, and a reduced proportion of ciliated cells in chondrocyte cultures 
(293). The expression pattern of TRIM32 shows significant positive correlation with 
other known BBS genes, loss of trim32 expression in zebrafish results in phenotypes 
identical to those of other known BBS genes, and functional studies of other TRIM-
NHL proteins indicates involvement with cytoskeletal elements (290). Kif3A mutant 
mice lack cilia and similarly have reduced proliferation and defective organisation of 
chondrocytes, and loss of cilia is associated with early signs of OA (290, 294). 
 
 
Figure 1.5 – Schematic of TRIM32 domain structure with known pathogenic mutations; adapted 
from Kudryashova et al (295). The schematic illustrates the domains of the TRIM32 protein including the 
RING domain that can function as an E3 ubiquitin ligase, B-box2 domain that may function with the 
coiled-coil domain as a binding site for ubiquitination of substrates by the RING domain, the coiled-coil 
domain that is also involved in forming protein complexes, and the NHL domain involved in protein 
binding and RNA regulation (282, 284, 287, 288). The pathogenic mutations displayed include the P130S 
allele in the B-box domain associated with development of the autosomal recessive ciliopathy BBS, and 
the R394H, D487N, T520TfsX13, and D588del alleles in the NHL domain associated with the 
development of the autosomal recessive limb-girdle muscular dystrophy LGMD2H (290, 296). 
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 TRIM32 also binds myosin heavy chain via the coiled-coil domain and 
ubiquitinates actin for degradation during muscle regeneration (281). Missense 
mutations in the NHL domain result in limb girdle muscular dystrophy (LGMD2H) 
(297). Loss of TRIM32 function causes myopathy by inhibiting skeletal muscle 
regeneration (298). The mutation associated with LGMD2H restricts TRIM32 
interacting with Piasy (protein inhibitors of activated STATs). By regulating Piasy 
stability, TRIM32 may control induction of apoptosis through induction of NFκB (299). 
TRIM32 has also been demonstrated to sensitise cells to TNFα-induced apoptosis by 
ubiquitinating X-linked inhibitor of apoptosis (XIAP) for proteasome-mediated 
degradation (300). In both neural and skeletal muscle stem cells, TRIM32 regulates 
proliferation and differentiation by ubiquitination of c-myc for degradation (298, 301). 
TRIM32 can suppress proliferation, functions as an activator of the microRNA 
(miRNA) pathway, and distributes asymmetrically to direct progenitor cell 
differentiation (301). It also concentrates in the retracting basal process (with which 
other BBS proteins associate), which is a structural feature of mammalian cells that is 
involved in directing asymmetric cell division, and which may also acts as a template 
for microtubule and cilia formation (281, 302). Lin-41, another TRIM-NHL family 
protein, interacts with integrin and actin cytoskeletal elements via the B-box and coiled-
coil domains (281). 
 The TRIM-NHL proteins have emerging roles in cell differentiation and 
proliferation, and potentially primary cilia development, homeostasis and signalling. 
These processes may be linked, as has been shown for the von Hippel-Lindau (VHL) 
protein, another E3 ubiquitin ligase, mutations in which cause microtubule 
disorientation, cilial dysfunction, and cell-cycle dysregulation, leading to the VHL 
syndrome (303). Potential mechanisms by which TRIM32 may influence the 
development of musculoskeletal disorders could include the role of TRIM32 in both cell 
differentiation and proliferation, and ciliogenesis in tissues expressing TRIM32. It will 
therefore be important to establish the expression, and also the function, of TRIM32 in 
joint tissues. 
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 Five further genes have been recently identified at the 9q33.1 locus. These 
include PAPPA-AS1, ASTN2-AS1, LOC105376238, LOC105376239, and 
LOC105376240. These five genes are non-coding RNA genes. Although these genes are 
untranslated, transcript variants (which have been demonstrated for LOC105376240) 
could influence the regulation of the other genes at this susceptibility locus. MicroRNAs 
specifically expressed in cartilage have previously been identified, and many miRNAs 
likely act as a network to control cartilage homeostasis and repair (304). 
 
1.3.3 Epigenetic modifications and OA 
Epigenetic variation includes several types of modifications that may be broadly 
categorised into DNA methylation, histone modification, nucleosome positioning, and 
miRNA expression. Epigenetic modifications are suggested as a mechanism that 
mediates the interaction between the environment and genetic influences on disease 
susceptibility. Traditional disease pathogenesis models of environmental factors acting 
upon a genetic predisposition to disease are thus becoming increasingly complex. 
Several environmental factors are known to affect the epigenome, including pollutants 
(such as tobacco smoke), chemicals (including silica), temperature, ultraviolet light 
exposure, and an individual’s diet (305). These factors may exert their effect on an 
individual’s epigenome from the earliest stages of foetal development and throughout an 
individual’s life (306). Indeed, the summation of environmentally mediated epigenetic 
modifications, termed ‘epigenetic drift’, may help explain differences in phenotype and 
disease risk between monozygotic twins. 
 Epigenetic modifications may also occur during normal ageing, irrespective of 
environmental factors. Such changes seem to occur in a locus-specific pattern. Indeed, 
hypermethylation tends to develop primarily at bivalent chromatin domains and CpG-
rich regions, whereas CpG-deficient regions tend to become hypomethylated over time 
(307). In addition to variations in DNA methylation, histone modifications and miRNA 
expression occur during normal ageing, though the processes governing these are largely 
unknown at present. 
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1.3.3.1 DNA methylation and OA 
DNA methylation is the most extensively studied epigenetic mechanism. It is usually 
used to describe the addition of a methyl group to the fifth carbon of a cysteine 
nucleotide (5-mC; 5-methylcytosine), though other forms of methylation have been 
described, including 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC), and 5-
carboxylcytosine (5-caC). Two types of enzymes mediate traditional 5-mC methylation: 
de novo methyltransferases (DNMT3A and DNMT3B) and maintenance 
methyltransferases (DNMT1). DNA methylation has been identified as fulfilling several 
purposes in humans, including gene expression regulation, genomic imprinting, 
inactivation of the X-chromosome, and genome defence. Methylation primarily occurs 
at CpG sites commonly found in DNA regions called CpG islands (CGIs), which are 
often concentrated in the promoter regions of genes. CpGs are also present at the 
periphery of CGIs, where they cluster to form CGI shores, in addition to being present 
within introns and exons. Methylation is a very stable modification, preserved through 
mitotic cell division and readily detectable in easily obtainable tissue such as saliva, 
plasma, serum and urine. Nevertheless, epigenetic modifications are believed to be 
specific to particular tissues or cell types within individuals and to also be regulated in a 
temporal manner. Analysis of DNA methylation patterns associated with disease is 
therefore facilitated by purification of biological samples into single-cell populations 
and application of bioinformatic approaches that utilise available reference epigenomes 
for specific cell types (308). 
One of the first studies of DNA methylation in OA, using chromatography, 
demonstrated no difference between osteoarthritic cartilage compared to controls, nor in 
measured levels of DNMT1 and DNMT3A (309). More thorough analyses of DNA 
methylation have since been performed. Using Illumina® methylation arrays examining 
over 27,000 CpG sites, focused on CpGIs of promoter regions of genes, DNA 
methylation was compared in trabecular bone from female patients with either OA or 
osteoporosis (310). Methylation status differed by more than 10% at 45 sites 
concentrated in genes associated with bone traits: 43 were hypermethylated in 
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osteoarthritic bone, especially within homeobox genes that are transcription factors 
involved in embryonic skeletal development. In subsequent functional studies, the 
expression levels of two of these genes correlated with disease status. 
A further study examined full-thickness cartilage retrieved from the tibial plateau 
of OA patients and control subjects, using the same Illumina® array. This study 
identified 91 sites differentially methylated between OA patients and normal controls. 
Significant hypomethylation, usually associated with increased transcription, was found 
in genes enriched in inflammatory pathways and positive control of transcription, 
including RUNX1, a transcription factor regulating chondrogenesis. Hypermethylation, 
which generally correlates with reduced transcription, was demonstrated at genes 
implicated in regulation of phosphorylation and mitogen-activated protein kinase 
activity; for example, in MSX1 (msh homeobox 1), a repressor of transcription. This 
study isolated a distinct group of OA patients with a specific methylation pattern from 
the rest of the study participants (311). As for genetic polymorphism association studies, 
correlating specific methylation patterns to detailed clinical phenotypic parameters in 
OA patients may improve discovery of causal variants and interpretation of their 
implications. 
A recent study of DNA methylation in association with OA examined hip and 
knee chondrocytes obtained from a larger sample of OA patients using the more 
comprehensive Illumina® methylation array covering 480,000 CpG sites (312). In this 
study, 5322 differentially methylated regions (DMRs) were identified between samples 
from OA patients and healthy control subjects. These DMRs were located at genes 
associated mainly with either inflammation or immunity. DMRs between osteoarthritic 
cartilage from hip and knee joints have been reproducibly demonstrated, which mark 
altered expression in homeobox genes (313). Articular cartilage is relatively unique in 
that it may be considered a unicellular tissue; thus, comparison of methylation profiles 
of DNA isolated from chondrocytes from the same joints of OA patients and unaffected 
individuals may identify epigenetic changes associated with development of disease. 
Early analyses of chick embryos in 1985 implicated mechanisms by which 
methylation of COL1A1 (type I collagen) and COL2A1 affected chondrogenesis (314). 
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Methylation profiling of individual candidate genes for OA susceptibility have since 
been performed. Differential methylation within the promoter regions of IL1β, MMP3, 
MMP9, MMP13, ADAMTS4, NOS2, SOX9, and LEP (leptin) have been demonstrated to 
relate to altered gene expression in osteoarthritic cartilage (315-318). 
The pathological mechanisms by which the altered methylation statuses of 
candidate genes exert their effect on the development of OA are starting to be clarified. 
The hypomethylated -110 site in MMP13 functions as a methylation-binding site for the 
catabolic cartilage transcription factor HIF2α (315). Two hypomethylated sites within 
the enhancer of NOS2, the inducible NO synthetase gene, were shown to mediate 
expression in OA cartilage by modulating an NFκB binding site (316). 
Hypermethylation at the promoter region of SOX9, an anabolic transcription factor, 
inhibited binding of the transcription factors NFYA (nuclear transcription factor Y 
subunit alpha) and CREB (cAMP response element-binding protein), and was associated 
with reduced expression of SOX9 in hip joint cartilage from OA patients (317). Genetic 
association studies have identified GDF5 as a robust candidate gene for OA risk via a 
C/T SNP that resides within its 5’untranslated region (5’UTR) (215). The risk C-allele 
alters GDF5 expression by forming a CpG dinucleotide that subsequently becomes 
methylated (319). Demethylation of the 5’UTR of GDF5 in osteoarthritic knee cartilage 
regulated the allelic imbalance of the rs1443383 polymorphism and may be responsible 
for the specific effect of this SNP on susceptibility to OA of the knee joint (320). 
Similar processes may account for the dysregulated deposition of ECM by chondrocytes 
that overexpress DIO2, polymorphisms of which predispose to OA (222). In addition to 
5-mC methylation, globally-increased 5-hmC methylation has been shown in 
chondrocytes from patients with knee OA compared to healthy control subjects (321). A 
summary of genes believed to have a role in the development of OA by epigenetic 
modification is shown in Table 1.3. 
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Table 1.3 – Genes implicated in the development of OA by epigenetic modifications in joint tissue; 
(AC, articular cartilage; ECM, extracellular matrix). 
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1.3.3.2 miRNA and OA 
miRNA are another component of epigenetic regulation. miRNA are short non-coding 
RNA molecules, comprising 20-30 single-stranded nucleotide chains. They are 
transcribed from intergenic regions in association with their own promoter, or from 
within an intron associated with a gene. The identified functions of miRNA molecules in 
metazoan genomes are the cleavage of mRNA, suppression of translation of mRNA, and 
regulation of DNA methylation to modulate gene expression (328). An essential enzyme 
for miRNA processing is Dicer, and depletion of this enzyme in growth plates in mice 
has confirmed its fundamental role for miRNAs in chondrogenesis and skeletogenesis 
(329). 
The results of studies investigating the role of miRNAs in the development of 
OA are exciting though full interpretation is challenging due to the diverse roles of 
miRNAs, their numerous targets, and limited replication of findings across studies to 
date. Conflicting findings have been described in two studies profiling miRNA patterns 
in osteoarthritic tissue (330, 331). More recent studies have provided greater insight into 
the role of miRNAs in OA: investigating RNA retrieved from cultured chondrocytes has 
demonstrated upregulation of miR-483 and downregulation of miR-149 (332). A 
particularly interesting miRNA is miR-140, which is specifically expressed in cartilage, 
critical to chondrogenesis, and depletion of which is associated with an accelerated 
development of OA in murine disease models (333). Although reduced levels of miR-
140 reported in osteoarthritic knee joint tissue were not reproduced in osteoarthritic hip 
joint tissue, this may not be directly conflicting evidence, but may instead indicate joint 
site specificity (334). The important miR-140 may regulate ADAMTS4 and may also 
function in consort with another miRNA, miR-455 whose expression is also increased in 
osteoarthritic cartilage, to suppress the SMAD3 gene expression and thus contribute to 
the generation of a catabolic chondrocyte phenotype (334). The expression of other 
miRNAs associated with OA and for which relevant molecular pathways are being 
investigated include miR-146a which may regulate IL1β signalling, miR-125b which 
may regulate ADAMTS4, miR-127-5p that may control MMP13 production, miR-148a, 
and miR-21 that may target GDF5 (335). 
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1.3.3.3 Histone modifications and OA 
In eukaryotes, DNA envelops histone proteins to form nucleosomes. Histone proteins 
can be modified after transcription by acetylation, phosphorylation, sumoylation, 
ubiquitination, or methylation. These post-transcription histone modifications can 
regulate DNA transcription by two primary mechanisms. Firstly, histone modification 
results in reconfiguration of chromatin and therefore the exposure of gene promoters for 
transcription factors. Secondly, histone modification may alter the binding of chromatin-
associated factors. Fundamental to the access of regulatory factors to transcription 
factors, and subsequent gene expression, is histone acetylation that is mediated by 
histone acetyltransferases (HATs). In contrast to HATs, the main role of histone 
deacytlase enzymes (HDACs) is histone deactylation, which is associated with 
suppression or termination of gene expression. Chromatin immunoprecipitation (ChIP), 
hybridisation to arrays, or a combination of these processes, termed ChIP-seq, are 
techniques that have been used to examine histone modifications in association with 
biological and pathological processes. 
The principal types of histone modifications that have been studied in relation to 
OA include acetylation and methylation. The phenotype of chondrocytes is particularly 
sensitive to acetylation and deacetylation. Several classical HDACs (HDAC1, HDAC2, 
and HDAC7) have been identified as upregulated in osteoarthritic chondrocytes, thereby 
stimulating their catabolic activity (336). The overexpression of HDAC1 and HDAC2 
results in the suppressed transcription of genes involved in the integrity of the ECM, 
including ACAN and COL2A1, whereas HDAC7 promotes transcription of MMP13 
(336). In an attempt to use histone modification as a therapeutic target, HDAC inhibitors 
have subsequently been developed, such as Trichostatin A (TSA) and butyric acid (BA) 
that inhibit proteoglycan release and degradation of cartilage in cartilage explants, in 
addition to suppressing the production of cytokine-induced iNOS (inducible nitric oxide 
synthase) and COX2 proteins and the transcription of MMP1, MMP13, ADAMTS4, and 
ADAMTS9 in vitro (337, 338). 
The sirtuin SIRT1, a subtype of HDAC, has also been implicated in the 
pathogenesis of OA. SIRT1 is a lysine deacytelase that prevents apoptosis in 
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chondrocytes. In osteoarthritic cartilage, reduced levels of SIRT1 may therefore 
potentiate the loss of chondrocytes evident in OA (339, 340). SIRT1 also facilitates the 
transcription of several genes associated with ECM production, including ACAN, 
COL2A1, COL9A1, and COMP by recruiting HATs and SOX9 and through inhibition of 
ADAMTS5 (340). Furthermore, SIRT1 may also act as a mediator of inflammation by 
modulating both IL1β and TNFα (341, 342). 
Finally, the impact of histone modification on the development of OA has not 
yet been as extensively studied as other epigenetic modifications. There is evidence 
indicating that levels of the histone methyltransferase SET-1A (SET domain-containing 
protein 1A) are increased in osteoarthritic cartilage and have been demonstrated in vitro 
to upregulate the expression of both COX2 and iNOS (343). These two genes are 
overexpressed in osteoarthritic cartilage, causing chondrocyte apoptosis, upregulated 
transcription of MMPs, and inhibition of collagen production (343). Dysregulated 
histone modification of the promoters of SOX9 and Nfat1 (nuclear factor of activated T-
cells) may also contribute to the pathogenesis of osteoarthritic cartilage (317, 344).  
 
1.3.3.4 Implications of epigenetic modifications in OA 
As epigenetic modifications associated with the development of OA are gradually 
characterised, these stable variations have emerged as potential novel therapeutic 
targets. A particularly attractive therapeutic strategy is hypomethylation of 
metalloproteinases to ameliorate the degradation of the ECM associated with their 
overexpression in articular cartilage (345). Metalloproteinase inhibitors have been 
developed but have not shown efficacy in OA, possibly due to their non-specific nature. 
Another clinical application of epigenetic modifications could be the use of miRNAs 
that are overexpressed in serum as disease biomarkers (346). Significant therapeutic 
potential may also derive from the inhibition of HDACs and SET-1 mediated expression 
of iNOS and COX2 (338). 
Further work is required to better determine the pathological implications of 
epigenetic modifications in OA. The majority of studies in OA have concentrated on 
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epigenetic changes identified in DNA retrieved from cartilage specifically. As several 
articular tissues are also involved in the aetiopathogenesis of OA, it may also be 
insightful to perform detailed characterisation of epigenetic profiles of synovium, 
subchondral bone, and adipose tissue from osteoarthritic and healthy joints. Indeed, 
tissue-specific genome-wide DNA methylation patterns have recently been reported for 
17 somatic tissues from autopsied humans (347). Further assessment of the direct, 
functional relationship between epigenetic and genetic variations at particular alleles is 
also required, as has been initiated for the rs143383 SNP related to GDF5 and the 
rs225014 SNP related to DIO2 and OA risk. Evaluation of direct functional interactions 
between epigenetic and genetic variation at individual alleles associated with OA risk is 
also required. This has only been reported for two candidate genes at present, namely for 
the rs143383 SNP related to GDF5, and the rs225014 SNP related to DIO2 and OA risk 
(348). Whether or not methylation status of the susceptibility locus can attenuate or 
amplify the risk effect associated with a risk polymorphism, by regulating gene 
expression, is a particularly interesting potential interaction.  
 
1.4 Experimental murine models of OA 
Thorough evaluation of potential pathogenic mechanisms and therapeutic targets in OA 
is difficult due to the limitations of in vitro tissue or organ culture techniques in 
comparison to the complex environment of articular joints in living organisms. 
Validation of pathogenic pathways is therefore conducted best using in vivo models of 
OA. Exacerbation or amelioration of OA in a genetically-modified animal, such as one 
in which the gene-of-interest has been deleted (such as a knockout (KO) mouse), using 
an in vivo OA model can provide compelling evidence for a critical role of that gene in 
the pathogenesis of OA (349). Detailed characterisation of the pathogenic molecular 
mechanisms in which that gene is involved can then be commenced to identify 
appropriate targets against which disease-modifying OA drugs (DMOADs) can be 
developed. Due to the heterogenic pathophysiology and phenotypic manifestations of 
OA in humans, no single animal model of OA can represent the spectrum of OA in 
humans. Evaluation of genetically modified mice using several models of OA can more 
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convincingly implicate a gene of interest in OA pathogenesis or indicate relevance to a 
particular subgroup of patients with OA. 
The molecular genetics of OA in humans has been most extensively studied in 
murine models of the disease. Over 90% of mouse genes have a homolog in humans and 
the majority of human diseases have a spontaneous or inducible equivalent in mice in 
which the associated pathology mirrors the human condition (350). The similarity of 
musculoskeletal physiology and disease between mice and humans, and the relative ease 
of breeding, husbandry, and genetic manipulation make genetic studies of OA 
particularly effective in mice (351-353). Murine models of OA include naturally 
occurring OA through ageing, transgenic models, and chemically or surgically induced 
OA. The application of the most appropriate model(s) of OA depends on the specific 
mechanism under investigation. Spontaneous OA models permit the monitoring of the 
development of OA from mild to severe disease, but are time-consuming, relatively 
expensive and may result in phenotypic variability. In contrast, in chemically or 
surgically induced OA models the disease process is accelerated and the phenotypic 
manifestations are more reproducible, though they often predominantly represent an 
inflammatory or post-traumatic form of OA, rather than spontaneous primary OA (354). 
 
1.4.1 Spontaneous and non-invasive OA models 
Spontaneous OA develops in some laboratory mice more rapidly than others, and can be 
influenced by genetic manipulation. Early degenerative changes representing OA 
develop in the knee joint of C57Bl/6 mice as early as 10 months of age, and severe 
changes develop by 17 months of age (355, 356). The STR/ort mice strain develop knee 
OA even earlier, by 5 months of age, which may be exacerbated by their 50% greater 
body weight than other strains (357). The histopathological joint changes that develop in 
these strains closely resemble OA in humans (358). Several genetically modified mouse 
strains have exhibited exacerbation or amelioration of OA. Mice deficient in genes 
related to the integrity of the ECM often develop OA more rapidly, including mice 
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carrying mutations in the genes for type II collagen, type IX collagen, and MMP13 
(359-361). 
 Obesity is also a risk factor for OA in humans, and findings in the STR/ort mice 
indicated that increased body mass may also contribute to the development of OA in 
mice (362). Due to the multifactorial nature of obesity, it is challenging to discern the 
causal mechanisms of OA in obesity. Modelling obesity by administering a high-fat diet 
to mice results in increased severity of OA (363). Moderate exercise in mice, in the form 
of voluntary wheel running, protects against OA, possibly by increasing musculoskeletal 
strength or by inducing weight loss (363). Further insights regarding the relationship 
between obesity and OA have been gained from studies of mice deficient in leptin or the 
leptin receptor. These mice lack satiety and subsequently develop significantly increased 
adiposity and weight. Despite both increased adiposity and weight, mice deficient in 
leptin or the leptin receptor do not have an increased incidence of knee OA (364). This 
suggests that adiposity and increased weight may not directly predispose to OA, and 
metabolic dysregulation may be a more profound risk factor for OA. Other non-invasive 
models used to recapitulate human OA in mice include cyclical tibial compression 
overloading (365), cyclical knee joint overloading (366), and closed intra-articular 
fracture of the tibial plateau (367). 
 
1.4.2 Chemically induced OA models 
The injection of several chemicals into joints has each been reliably shown to result in 
accelerated progression to severe OA. Monoiodoacetate (MIA) is an antagonist of the 
glycolytic pathway, the intra-articular injection of which causes widespread chondrocyte 
necrosis, neovascularisation, subchondral bone collapse, and extensive inflammation 
(368). Severe inflammatory OA is also caused by the injection of methylated bovine 
serum albumin (mBSA) (124). Other intra-articular injections that have previously been 
relatively frequently used include the injection of collagenase and papain; these 
enzymes cause direct enzymatic degradation of the cartilage ECM and damage to the 
knee ligaments and menisci creating secondary damage from joint instability (369). As 
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the chemically induced murine models of OA essentially generate a non-specific 
inflammatory form of OA, these models are now less frequently utilised, especially as 
more refined techniques for tissue-specific genetic manipulation, surgical models of OA, 
and assessment of disease have become available.  
 
1.4.3 Surgically induced OA models 
Surgically induced models of OA in mice cause direct joint instability and altered joint 
biomechanics, leading to secondary OA, and therefore most accurately model post-
traumatic, but also degenerative, OA in humans. The advantages of surgical models of 
OA are that they induce a rapid progression of disease, the temporality of the initiating 
event and onset of disease is clear and reliable, and the severity of cartilage degeneration 
required experimentally can be induced by surgically resecting different intra-articular 
structures. These models were developed as translational models, as injuries to the 
menisci and ligaments of the knee joint predispose to OA in humans. 
The anterior cruciate ligament transection (ACLT) model causes cartilage 
destruction and formation of osteophytes 8-12 weeks following surgery (370). As access 
to the central region of the joint is required to transect the anterior cruciate ligament 
(ACL), and damage invariably occurs to other structures of the knee joint, this 
procedure causes a relatively severe phenotype that may not be entirely clinically 
relevant. 
Several variations of menisectomy are described in murine OA studies, including 
partial, total, medial, or lateral excision. Partial medial menisectomy causes mild 
degeneration of articular cartilage by 8-12 weeks following surgery (371). Technical 
challenges of the menisectomy procedures include consistency in the quantity of 
meniscus removed, as this directly correlates with the extent of abnormal mechanical 
loading of the joint and the development of further joint lesions, and minimisation of 
iatrogenic damage to other joint structures, particularly to the articular cartilage itself. 
The destabilisation of the medial meniscus (DMM) procedure is the most 
commonly performed and validated surgical model of OA in mice. DMM is achieved by 
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incising the anteromedial insertion of the medial meniscotibial ligament, causing 
instability of the medial meniscus and medial compartment of the knee joint (372). This 
is a particularly favourable model for the evaluation of potential pathogenic and 
therapeutic mechanisms in OA because it is reliable, reproducible, results in structural 
joint changes that closely resemble OA in humans, and several histopathological, 
radiological, and pain-related end points have been established (373). The DMM 
procedure was initially utilised to demonstrate that ADAMTS5 KO mice, but not 
ADAMTS4 KO mice, developed less severe joint degeneration after surgical trauma, 
suggesting that ADAMTS5 is the critical aggrecanase in mice (168). The progression of 
OA after DMM has since been characterised in several transgenic mice strains. 
Following the DMM procedure, early osteophytes may be detected as early as seven 
days, and these osteophytes subsequently increase in size and number (374). Increased 
sclerosis of the subchondral bone plate and mild cartilage lesions may be detected at two 
weeks after DMM surgery (374, 375). Corticated osteophytes with expansion of the 
subchondral bone plate may be demonstrated at four weeks after the DMM procedure 
(374). Fibrillation of cartilage with loss of proteoglycan content is exhibited at 8 weeks 
following DMM, and these continue to progress thereafter (376). The subchondral bone 
gradually becomes sclerotic in the medial tibial plateau, then progresses to the lateral 
tibial plateau, though the greatest effect occurs at the medial tibial plateau of the 
operated knee joint (377). Other surgically induced models of OA that are utilised less 
frequently include ovariectomy and articular groove formation, in which an induced 
oestrogen deficiency and single-site cartilage defect, respectively, initiate degenerative 
changes within the joints (378, 379).  
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1.4.4 Assessment of OA in murine models 
Histopathological assessment of OA in animal studies initially utilised the grading 
system performed by Collins (380), and then subsequently the classic Mankin 
Histological–Histochemical Grading System (MHHGS) (381), which was developed in 
humans and utilised Safranin O staining, was applied to animals (382). Due to 
limitations of these scoring systems in categorising early OA changes, important for 
research applications, the OARSI histopathology initiative developed a universal scoring 
system for OA of the knee joint in mice (383). This scoring system focuses on the depth 
and extent of cartilage lesions, and also provides additional criteria by which to assess 
changes in synovium, subchondral bone, menisci, tendons, and ligaments. As these 
scoring systems are only semi-quantitative, they may be complemented by quantitative 
evidence from histomorphometric analyses of joints. 
The assessment of subchondral bone changes associated with OA in murine 
models of OA can be effectively performed using micro-computed tomography (μCT) 
scanning of murine joints ex vivo or in vivo (384). The trabecular separation, trabecular 
thickness, trabecular volume, cortical thickness, and subchondral bone plate can be 
measured using high-resolution scanners. Combining results of histological assessment 
of the cartilage with changes on imaging of subchondral bone may provide insights into 
specific focal changes associated with specific genetic modifications in mice and also 
the effects of treatments on bone and cartilage. The use of in vivo imaging can also 
provide longitudinal studies on the evolution of osteoarthritic changes and effects of 
treatments. High-resolution micro-MRI has also been recently utilised in the assessment 
of cartilage lesions in surgically induced models of rat OA, but standardisation and 
optimisation of this technique are still required (385).  
Investigating biomarkers in murine models of OA and human OA is a non-
invasive method to examine cartilage, bone or synovial turnover associated with disease. 
Biomarkers such as aggrecan and collagen neoepitopes, which may be sampled as 
breakdown products of the ECM of cartilage, have been analysed as predictors of the 
efficacy of novel therapeutic agents tested in murine models of OA (386). However, 
these particular biomarkers have significant variation between individuals and are very 
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dilute in the serum and urine. Further investigation of potential biomarkers will help 
identify those that can better monitor disease severity and the efficacy of treatments. 
Finally, several manifestations of pain secondary to OA pathology can be 
measured in murine models. There is a relative lack of standardised and validated 
methods for pain measurement, in addition to gait and functional evaluation, of OA in 
animal models, despite its significant potential for developing OA therapies. A biphasic 
pain response occurs following the DMM procedure: there is an initial early 
postoperative pain response that subsides, and then by 8 weeks post-operatively, 
reduced activity levels and specific pain responses due to joint degeneration may be 
reliably detected (373). Following the DMM procedure, a temporal expression of micro-
opioid receptors in the peripheral nerves supplying the knee joint occurs in the early 
stages of OA and delays the onset of pain (387). A particularly sensitive method to 
assess pain associated with the development of OA in mice is the measurement of tactile 
allodynia. Tactile allodynia describes pain behaviour in response to a stimulus that does 
not normally cause pain. This can be assessed using von Frey filaments, whereby 
microfilaments are applied in ascending size order at right angles to the plantar surface 
of the hind paw of mice until either the filament bends or the limb is withdrawn. A 
decrease in withdrawal thresholds of the operated limb compared to those of the 
unoperated control limb can indicate the development of tactile allodynia and is directly 
related to OA pathology induced by the DMM procedure (384). Other methods to assess 
pain include gait analysis, motor activity levels, dynamic weight bearing, thermal 
sensitivity, and measuring vocalisations on applications of pressure to the affected limb 
(388). 
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1.5 Aims and objectives 
The purpose of this research was to investigate the candidate gene with the greatest 
biological implication from the 9q33.1 OA susceptibility locus associated with OA in 
females in the arcOGEN GWAS. The role of TRIM32 in the development of OA was 
selected for further investigation. This project focused on TRIM32 because previous 
studies have demonstrated its expression in musculoskeletal tissue, and its role in 
cellular proliferation and regulating apoptosis. Furthermore, mutations in genes similar 
to TRIM32 result in articular pathology resembling OA in murine studies, and TRIM-
NHL proteins interact with cytoskeletal elements, especially the primary cilia, which are 
critical to normal chondrocyte homeostasis.  
 The hypothesis for this research was that TRIM32 might have a role in the 
development of OA in humans by influencing susceptibility to OA through genetic 
variation, or by affecting chondrocyte and cartilage homeostasis. 
The specific objectives of this thesis were to:  
1. Investigate the genetic variation of TRIM32 to identify novel or rare variants 
in TRIM32 that are associated with OA of the hip in females. 
2. Examine the expression of TRIM32 in articular tissues, and to determine 
whether TRIM32 expression is altered in female patients with OA of the hip. 
3. Investigate whether Trim32 affects the response of chondrocytes to anabolic 
and catabolic stimuli, and whether or not Trim32 affects the integrity of 
articular cartilage, in vitro. 
4. Analyse the effect of Trim32 knockout on the development of OA in vivo in 
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All reagents were obtained from Sigma Aldrich (Dorset, UK) unless otherwise stated. 
2.1 Variant screening of TRIM32 
2.1.1 Samples 
2.1.1.1 Patients’ DNA samples 
DNA sequencing of TRIM32 was performed in the 500 youngest available female 
patients with primary hip OA from the arcOGEN cohort; these patients had symptomatic 
hip OA and at least Kellgren Lawrence grade II OA on radiographic evaluation of the 
symptomatic hip, or had undergone total hip replacement for primary hip OA. Available 
samples from the youngest female patients were selected as genetic variants 
predisposing to primary OA may be enriched in these patients. The mean age of 
included patients was 60.1 years (range 41 – 67 years). 
 DNA samples for included patients were retrieved from the Bone Research 
Group (Centre for Genomics and Molecular Medicine, Institute for Genetics and 
Molecular Medicine, University of Edinburgh), or from the Centre for Integrated 
Genomic Medical Research (Institute for Population Health, Institute for Population 
Health, University of Manchester) at which samples from the arcOGEN study are stored 
centrally in the UK. 
 
2.1.1.2 DNA extraction 
DNA was previously extracted from blood samples from included patients with OA 
using the QIAmp® DNA blood kit (Qiagen®) by members of the Bone Research Group 
(Centre for Genomics and Molecular Medicine, Institute for Genetics and Molecular 
Medicine, University of Edinburgh) or by staff at other UK centres participating in the 
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2.1.1.3 DNA quantification and quality assurance 
DNA concentration was measured using a NanoDrop1000 v3.7.0 (Thermoscientific) and 
sample purity was assessed using the A260/A280 ratio. All samples used for DNA 
sequencing had A260/A280 ratios of ~2.0 to ensure high purity from potential 
contaminants such as proteins or phenol. 
 
2.1.2 Polymerase chain reaction (PCR) 
2.1.2.1 Primer design 
Primers for DNA sequencing of TRIM32 were designed using the H. sapiens (GRCh38) 
reference genome sequence NC_000009.12 (214) and the online primer design tool 
Primer3 v.0.4.0 ((389). Overlapping primers were designed to avoid annealing at known 
polymorphic sites, to cover all known TRIM32 transcript variants, and primer specificity 
was validated in silico using University of California Santa Cruz (UCSC) polymerase 
chain reaction (PCR) and UCSC Blat (390). 
Primers for the amplification of the proximal promoter (-200 base pairs (bp) 
upstream of the transcription start site), 5’UTR, both exons, and 3’UTR of TRIM32 are 
listed in Appendix 7.1.1 and were obtained from InvitrogenTM. 
 
2.1.2.2 Amplification 
All PCR reactions for amplifying the TRIM32 DNA sequence were prepared on ice, 
using Qiagen®Taq DNA polymerase with a final reaction volume of 25 microlitres (µl) 
and run on the MJ Research® thermocycler, using the reagent concentrations and PCR 
thermocycling conditions listed in Appendices 7.1.2 and 7.1.3. All samples were subject 
to the same PCR thermocycling conditions except for the use of different annealing 
temperatures appropriate for each primer pair (Appendices 7.1.1, 7.1.2, and 7.1.3). 
DEPC (0.1% diethylpyrocarbonate)-treated water (H2O) was used as a negative control 
for all PCR reactions.  
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2.1.2.3 Visualisation 
PCR amplification for each gene region reactions were performed in 0.2 millilitres (ml) 
96-well PCR plates (Thermoscientific). To confirm successful amplification, a single 
column of samples from each PCR plate was visualised. PCR products were diluted 1:1 
in 1X Orange-G loading dye (Appendix 7.4.1.2) and run parallel to a low molecular 
weight marker (New England BioLabs®) on a 1% agarose (Bioline)-
tris/borate/ethylenediaminetetraacetic acid (EDTA) (TBE) (1X) gel containing 1:10000 
SYBR® Safe (InvitrogenTM). Visualisation took place under ultraviolet light using 
GENEGenius (Syngene) and GeneSnap v6.05.01 (Syngene) software. 
 
2.1.3 DNA sequencing 
PCR reaction products were sequenced in both directions by the Human Genetics Unit 
(HGU) services (Medical Research Council HGU, Institute for Genetics and Molecular 
Medicine, University of Edinburgh). The sequences of the proximal promoter, 5’UTR, 
both exons, and 3’UTR of TRIM32 were then analysed for variants using Mutation 
Surveyor® software (version 3.97; Softgenetics). Only variants identified by sequencing 
in both directions were selected for further analysis. 
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2.1.4 Statistical analysis 
All statistical analyses were performed using Statistics Package for the Social Sciences 
(SPSS) Statistics Version 19.0.0 (IBM; Armonk, New York, U.S.A.). The frequency of 
confirmed variants identified by screening of TRIM32 DNA sequences of patients with 
hip OA from the arcOGEN cohort were compared with the population frequencies of 
known variants. Chi-squared (χ2) tests were performed to determine whether the minor 
allele frequencies observed among the youngest patients with hip OA from the 
arcOGEN cohort were significantly different from those expected in the control 
population (1000GENOMES:phase_3:EUR (391)), and odds ratios were calculated to 
estimate effect size for risk alleles. For the χ2 tests, one-degree of freedom was used in 
all tests, and statistical significance was accepted at p < 0.05. 
 
2.1.5 Bioinformatic analysis 
Several bioinformatic resources were utilised to further investigate the biological 
consequences and implications of polymorphisms identified by variant screening of 
TRIM32. Haploview 4.2 ((392) and SNAP (SNP Annotation and Proxy Search) were 
used to examine LD between polymorphisms and indicate whether variants were likely 
to co-segregate during recombination (393). Non-synonymous variants were assessed in 
silico using SIFT (Sorting Intolerant From Tolerant; version 4.0.3, J. Craig Venter 
Institute (394, 395)) and PolyPhen-2 software (Polymorphism Phenotyping; v.2.1.0 
(396, 397). The GTEX Portal and eqtl.uchicago.edu! online browsers were searched to 
investigate if any of the identified variants had previously been reported as expression 
quantitative trait loci (eQTLs); that is the variant is associated with altered gene 
expression or regulation (398, 399). Finally, the SwissRegulon Portal was reviewed to 
investigate whether or not any variants of interest were located within a transcription 
factor binding site or regulatory motifs that may be involved in expression of TRIM32 
(400). The Hardy-Weinberg equation (p2 + 2pq + q2 = 1) was used to determine whether 
or not observed genotype frequencies in female patients with OA deviated from Hardy-
Weinberg equilibrium.  
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2.2 The role of TRIM32 in human and murine articular tissue ex vivo 
2.2.1 Ethical approval and informed consent for human tissue samples 
Human hip cartilage samples from femoral heads were obtained from female patients 
undergoing hip arthroplasty surgery for either an acute fractured neck of femur or 
primary osteoarthritis. Control samples were obtained from female patients undergoing 
hip arthroplasty for fractured neck of femur and patients were excluded if they had any 
previous hip pain, rheumatological conditions, malignancy, or chronic steroid or 
antimetabolite medication use. Osteoarthritic samples were obtained from female 
patients undergoing hip arthroplasty for primary hip OA and patients were excluded if 
they had any previous hip joint deformity, infection, trauma, or avascular necrosis of the 
hip, further rheumatological conditions, malignancy, or chronic steroid or antimetabolite 
medication use. All patients completed full informed consent. Ethical approval for 
retrieval and analysis of human tissue samples was provided by the Lothian Research 
Ethics Committees (LREC reference number: 04/S1102/41). All samples were obtained 
from patients undergoing hip arthroplasty surgery at the Royal Infirmary of Edinburgh 
(NHS (National Health Service) Lothian) or the Victoria Hospital Kirkcaldy (NHS Fife). 
Immediately after retrieval of the femoral head during surgery, the femoral head was 
submerged in Dulbecco’s Modified Eagle’s medium (DMEM), and cartilage samples 
processed within 24 hours of tissue retrieval. 
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2.2.2 Immunostaining of TRIM32 and ASTN2 in human articular cartilage 
Hip cartilage samples from femoral heads from female OA and control patients were 
snap-frozen in liquid nitrogen prior to embedding in paraffin for sectioning. Frozen hip 
cartilage samples were sectioned at 4 micrometre (μm) thickness by Helen Caldwell 
(Division of Pathology, University of Edinburgh) using a Leica CM1850 Cryostat. All 
sections were placed on glass slides (VWR InternationalTM Superfrost® Plus) and fixed 
with acetone. Archival sections of knee joint cartilage from human patients were kindly 
donated by Professor Donald Salter. Slides were stored at -20oC and brought to room 
temperature before use. Immunostaining signals for TRIM32 protein in hip and knee 
cartilage sections were visualised using Dako Envision®+ System-horseradish 
peroxidase (HRP) diaminobenzedine (DAB). Slides were washed with 0.05% phosphate 
buffered saline (PBS) (1X) (InvitrogenTM)-Tween 20 (PBS-T), treated with 0.9% 
hydrogen peroxide (H2O2) and peroxidase-blocked for 10 minutes. Samples were 
incubated for 1 hour at room temperature with primary monoclonal mouse anti-TRIM32 
antibody (Abnova®, H00022954) used at 1:750 dilution, or primary monoclonal mouse 
anti-ASTN2 (Sigma®, SAB1407191) used at 1:400 dilution. Tumour tissue microarrays 
(provided by Division of Pathology, University of Edinburgh) were used for controls. 
Murine serum was used as negative controls in place of the primary anti-TRIM32 or 
anti-ASTN2 antibodies to demonstrate lack of non-specific staining. Slides were then 
washed with 0.05% PBS-T and incubated for 30 minutes at room temperature with 
HRP-linked secondary antibodies, polyclonal rabbit anti-mouse at 1:200 dilution 
(P0260, Dako). Excess antibodies were then removed with 0.05% PBS-T. Liquid DAB+ 
substrate-chromogen was used to visualise the antibody binding. 
 Samples were counterstained with haematoxylin blue (ThermoFisher Scientific) 
for 5-20 seconds, rinsed in Scott’s tap water solution, dehydrated through increasing 
industrial methylated spirits (Genta Medical) concentrations and xylene (Genta 
Medical). A glass coverslip was then mounted using di-n-butylphthalate in xylene 
(DPX) mounting medium (Fisher Scientific) and then the slides were left to dry in air. 
Haematoxylin stained slides were visualised on a Zeiss Axio Imager A1 microscope. 
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2.2.3 Isolation and culture of human articular chondrocytes 
Isolation and culture of chondrocytes from human tissue samples was performed 
according to standard protocols (401). Cartilage was dissected from the joint surface of 
the femoral head, and cut into 1-2 millimetre (mm)3 pieces, then stored in antimicrobial 
solution (5% Fungizone (Gibco®), 5% L-glutamine (Sigma®), 5% penicillin-
streptomycin (Gibco®) in PBS (1X)) for 1 hour. Cartilage pieces were washed with PBS 
(1X) and incubated in 0.25% trypsin-EDTA (Sigma®) and incubated for 30 minutes at 
37oC and 5% carbon dioxide (CO2). The trypsin-EDTA solution was then removed, the 
cartilage washed with PBS (1X) and then immersed in collagenase II (Clostridium 
histolyticum¸ Gibco®) for 24 hours. Digested cartilage was strained through a sterile 
sieve into a 50 ml polypropylene tube (BD FalconTM) and washed three times by 
suspension in PBS (1X) and centrifugation (Sigma® 4K15, 2000 revolutions per minute 
(rpm), 5 minutes). The cell pellet was then re-suspended in 1 ml of complete Iscove’s 
modified Dulbecco’s medium (IMDM, Sigma®) with 10% FCS (First Link (UK) Ltd), 
1% Fungizone, 1% L-glutamine, and 1% penicillin-streptomycin and strained through a 
70 μm cell strainer (BD FalconTM). Cell counting was performed using Trypan Blue dye 
to ensure > 95% cell viability, and chondrocytes were seeded in 75 centimetre (cm)2 
culture flasks (Greiner Cellstar®) at a density of 5 x 104 cells/ml in 20 ml of complete 
IMDM. Primary chondrocytes were not passaged and were grown as a monolayer 
culture for up to 10 days, exchanging complete IMDM medium every 3-4 days. At 75% 
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2.2.4 Total protein extraction and quantification 
At 75% cell confluence or 10 days’ of culture, all culture media was removed from 
human primary chondrocyte cultures. Cells were then washed twice with PBS (1X) 
containing 0.1 millimolar (mM) sodium vanadate (Na3VO4). Total protein extraction 
was then performed on ice. The cells were covered with lysis buffer (Protease inhibitor 
cocktail tablet (Roche Diagnostics), 1.0 mM sodium vanadate (Na3VO4), 1% Igepal in 
10 ml PBS (1X) for 30 minutes. Cells were then scraped from the flask, placed in a 1.5 
ml tube (Eppendorf®) and centrifuged (Eppendorf® 5415R) at 13000 rpm for 15 minutes 
at 4oC. The protein-containing supernatant was then transferred to a clean tube and 
frozen at -80oC until further use. 
 A Pierce protein assay was used to determine the protein concentration of the 
samples. In a 96 well plate, 10 μl of each sample, diluted 1:4 and 1:1 in H2O (Gibco®), 
was aliquoted in duplicate; pre-diluted bovine serum albumin (BSA) standards 
(Thermoscientific) were used. Copper (II) sulphate was then diluted 1:50 in 
bicinchoninic acid and 200 μl was added to each well. Plates were then sealed and 
incubated at 37oC for 15 minutes. The absorbance of each well at 562 nanometres (nm) 
was measured using a BIO-TEKTM SynergyHT plate reader. Protein concentration was 
then calculated, using Gen5TM software, by colorimetric comparison of each sample 
against the standard curve. 
 
2.2.5 Western blot detection of TRIM32 in human articular chondrocytes 
Before loading protein samples for gel electrophoresis, 25 micrograms (μg) of protein 
was denatured through incubation at 95oC for 5 min in 5X loading buffer (Appendix 
7.4.2); two molecular weight standards were also incubated, Magic MarkTM XP (Life 
TechnologiesTM) and Kaleidoscope (Bio-Rad). Samples and standards were then loaded 
into a CriterionTM XT precast (12% bis-tris) polyacrylamide gel immersed in XT MOPS 
(3-(N-morpholino)propanesulfonic acid) (1X) running buffer (Bio-Rad) in an 
electrophoresis tank (Bio-Rad). Gels were then run at 200 volts (V) for 45 minutes. 
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 A polyvinylidene difluoride (PVDF) membrane (GE Healthcare Amersham 
HybondTM-P) was activated in 100% methanol for 5 minutes and then equilibrated for 
10 minutes in transfer buffer (Appendix 7.4.3). The gel containing the sample proteins 
and standards was removed from the electrophoresis tank and cassette, and then placed 
into transfer buffer for 5 minutes. Extra thick blot paper pre-soaked in transfer buffer 
was then placed on the negative electrode of the transfer apparatus (Hoeffer TE77XP). 
A blotting sandwich was then created within the transfer apparatus comprising the 
sequential layering of the PVDF membrane, the polyacrylamide gel, and a further layer 
of extra thick blot paper against the positive electrode. The electrophoretic transfer of 
proteins from the gel to the PVDF membrane was then performed at 90 milliamperes 
(mA) for 120 minutes. 
 The PVDF membrane containing the transferred proteins was then incubated for 
30 minutes at room temperature in 5% w/v (weight/volume) skimmed milk (Marvel) – 
tris buffered saline (TBS) (1X)-Tween 20 (TBS-T) (Appendix 7.4.5) as a blocking 
solution against non-specific binding sites. The PVDF membrane was then washed with 
TBS (1X)-T and incubated overnight at 4oC in primary monoclonal mouse anti-TRIM32 
(Abnova, H00022954) antibody solution at 1:1000 dilution in 5% (w/v) milk-TBS (1X)-
T solution. The next day, the PVDF membrane was washed in TBS (1X)-T for one hour 
for three times, and then incubated for one hour at room temperature in the secondary 
HRP-linked donkey anti-mouse (Jackson-ImmunoResearch Laboratories Inc, 715-035-
151) antibody solution at 1:10000 dilution in 5% (w/v) milk-TBS (1X)-T solution. The 
PVDF membrane was again washed in TBS (1X)-T for one hour for three times. All 
washes and incubations were performed in a rocker (Biometra®) to ensure even 
distribution over the PVDF membrane. 
 Prior to performing chemiluminescent protein detection, the PVDF membrane 
was washed in TBS (1X) (Appendix 7.4.4.2) for 10 minutes at room temperature to 
ensure optimal efficiency of the chemiluminescence by removal of any Tween 20. 
Protein expression was then detected using 1 ml of Immun-StarTM WesternCTM 
chemiluminescence HRP-detection reagents (Bio-Rad), prepared in accordance with the 
manufacturer’s instructions. Images were captured using a Syngene GeneGnome Bio 
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Imaging System using GeneSnap v.7.05.02 (Syngene) image software. Protein 
expression was quantified using GeneTool v.3.06.04 (Syngene) software. Automatic 
correction was performed for background fluorescence. Care was taken not to 
overexpose captured images. Protein expression levels were normalised against 
expression levels of β-Actin that were detected using 1:1000 primary rabbit antibody 
(Sigma®, A5060) and 1:10 000 secondary HRP-linked donkey anti-rabbit secondary 
antibody (Jackson-ImmunoResearch Laboratories Inc, 711-035-152). 
 
2.2.6 Isolation and culture of murine femoral head cartilage explants 
Isolation and culture of murine femoral head cartilage explants was performed 
according to established protocols (402). Femoral heads were retrieved from wild type 
and Trim32 knockout (KO) (Trim32-/-) mice aged 3 weeks. Mice were culled by 
inhalation of escalating concentration of CO2. The skin was sterilised with 70% ethanol 
(ETOH). The skin overlying the hip joint was incised and the hip joint identified by 
dissecting the proximal femur free of muscle. The hip joint was disarticulated by placing 
opposing forces on the acetabulum and proximal femur, thereby exposing the femoral 
head. Fine-pointed forceps were used to create a fracture through the capital femoral 
epiphysis, thereby releasing the entire cartilaginous femoral head. The extraction 
process was then performed for the contralateral femoral head. Pairs of femoral heads 
from each mouse were immediately incubated in culture wells of a 48-well flat bottom 
microtiter plate (Greiner Bio-One, 677180) containing 400 μl of DMEM (supplemented 
with 10% foetal calf serum (FCS), 1% penicillin-streptomycin, 1% L-glutamine, and 20 
mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES))) for 48 hours. 
Femoral head explants were then washed with serum-free media (DMEM supplemented 
with 1% penicillin-streptomycin, 1% L-glutamine, and 20 mM HEPES) and transferred 
into wells of fresh 48-well flat bottom microtiter plates containing 400 μl of serum-free 
media containing either 10 micromolar (μM) RA (Sigma®, R2625) or 10 nanograms/ml 
(ng/ml) human recombinant IL1α (Sigma®, I2778) and cultured for 72 hours; control 
samples were incubated in 400 μl of serum-free media with no additional stimulation. 
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Conditioned media was then aspirated from each well, and stored in 1.5 ml tubes 
(Eppendorf®) at -20oC until used for the glycosaminoglycan (GAG) dye-binding assay. 
 
2.2.7 Papain digestion of murine femoral head explants 
Pairs of femoral heads were retrieved from each well of 48-well microtiter plates 
following treatments described in section 2.2.6, placed in a 1.5 ml tube (Eppendorf®), 
and subjected to papain digestion to liberate GAGs that were not extracted during 
previous incubations. Pairs of femoral heads were submerged in 125 μg/ml papain 
solution (Sigma®, P3125) in 200 μl of papain buffer (Appendix 7.4.7), and incubated 
overnight at 60oC on a rocker (Biometra®). Upon completion of papain digestion the 
next day, samples were stored at -20oC until used for the GAG dye-binding assay. 
 
2.2.8 Glycosaminoglycan dye-binding assay 
Dimethylmethylene blue (DMMB) dye-binding assay was performed to measure GAG 
content of conditioned media following stimulation of murine femoral head cartilage 
explants (section 2.2.6), and murine femoral head cartilage explants following papain 
digestion (section 2.2.7). Flat bottom 96-well microtiter plates (Greiner Bio-One, 
655101) were prepared with 40 μl of chondroitin sulphate (Sigma®, C4384) standards in 
duplicate from 0 to 60 μg/ml. Serum-free culture media was used for blank samples. 
Samples were added in duplicate to the microtiter plate; conditioned media was assayed 
at 1:4 dilution, and papain-digested samples were assayed at 1:16 dilution. 150 μl of 
DMMB solution (Appendix 7.4.6) was added to the standards, blanks, and samples. The 
absorbance of the wells was then measured immediately using a FLUOstar Omega 
microplate reader (BMG Labtech) set at a wavelength of 595 nm, with a reference 
wavelength of 655 nm. The absorbance of the standards was plotted as a function of the 
concentration of the chondroitin sulphate in the standards. The standard curve was then 
used to determine the quantity of GAG present in each sample. Total GAG for each 
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sample was calculated as the sum of GAG released in the media and papain digests. The 
cumulative release of GAG into the media was calculated as a percentage of total GAG. 
 
2.2.9 Isolation and culture of immature murine chondrocytes 
Immature murine articular chondrocytes for primary culture were isolated according to 
standard techniques (403). Mice used for isolation of murine chondrocytes were 
generated from mating breeding pairs of either WT mice or homozygous Trim32 KO 
(Trim32-/-) mice (for details regarding construct and generation of Trim32 KO mice, see 
section 2.3.1). Femoral heads were harvested from newborn (5-10 days’ of age) wild 
type and Trim32 KO mice. Mice were culled by inhalation of escalating concentration of 
CO2. The skin was sterilised with 70% ETOH. The skin overlying the hip joint was 
incised and the hip joint identified by dissecting the proximal femur free of muscle. 
Gentle opposing forces on the femur and pelvis enabled disarticulation of the hip joint to 
expose the femoral head. Fine-pointed forceps were used to carefully retrieve the 
entirely cartilaginous femoral head, which was then placed in a universal tube 
containing complete culture media (DMEM (supplemented with 10% FCS, 1% 
penicillin-streptomycin, 1% L-glutamine, and 20 mM HEPES)). The extraction process 
was then performed for the contralateral femoral head. Pooled femoral heads from WT 
or Trim32-/- mice were then transferred to a sterile 100 mm (58 cm2) culture dish 
(Greiner, CELLSTAR®) and incubated in 20 ml of 3 mg/ml collagenase II (Clostridium 
histolyticum¸ Gibco®) prepared in culture media (DMEM supplemented with 1% 
penicillin-streptomycin, 1% L-glutamine, and 20 mM HEPES) for 45 minutes at 37oC 
with 5% CO2. The femoral heads were then agitated using a sterile pastette for 30 
seconds, then transferred to a fresh sterile 100 mm culture dish and submerged in 20 ml 
of fresh 3 mg/ml collagenase II for a second incubation period of 45 minutes at 37oC. 
The femoral heads were agitated again, then transferred to a fresh sterile 100 mm culture 
dish and submerged in 20 ml of 0.5 mg/ml collagenase II and incubated at 37oC 
overnight. The next day, the femoral heads were agitated again, and the cell suspension 
mixed thoroughly before the cell suspension was aspirated and passed through a 48 μm 
nylon mesh into a sterile 50 ml universal tube (BD FalconTM) to remove any soft tissue 
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debris. The filtered cell suspension was centrifuged for 10 minutes at 1500 rpm, 
following which the supernatant was discarded. The cell pellet was washed in PBS (1X; 
InvitrogenTM) by further centrifugation for 10 minutes at 1500 rpm; the resultant 
supernatant was discarded. The cell pellet was resuspended in 3 ml of complete culture 
media (DMEM supplemented with 10% FCS, 1% penicillin-streptomycin, 1% L-
glutamine, and 20 mM HEPES) and cell counting was performed using Trypan Blue dye 
to ensure > 95% cell viability. 
 Chondrocytes were then seeded at a density of 1 x 105 cells/cm2 in complete 
culture media in 24-well culture plates (Corning®, Costar®) and incubated overnight 
(37oC, 5% CO2). The next day, the media was removed and seeded chondrocytes were 
washed with serum-free media. The seeded chondrocytes were then incubated for 48 
hours in serum-free media containing no treatment (unstimulated), murine recombinant 
TNFα (100 ng/ml; R&D®, 410MT010), human recombinant IL1α (10 ng/ml; Sigma®, 
I2778), recombinant murine Oncostatin-M (OSM, 100 ng/ml; R&D®, 495MO025), or 
human recombinant IGF1 (100 ng/ml; R&D®, 291G1200), after which cultures were 
processed for total RNA extraction of treated chondrocytes. 
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2.2.10 RNA extraction and quantification 
RNA was extracted from immature murine chondrocytes using the GenEluteTM 
Mammalian Total RNA kit (Sigma®). RNA was extracted from murine chondrocytes in 
culture plates according to the manufacturer’s instructions. Lysis solution was prepared 
comprising 10 µl of β-mercaptoethanol for each 1 ml of lysis solution required. Lysis 
solution contained guanidine thiocyanate to lyse adherent cells; β-mercaptoethanol acts 
to inactivate any RNAses. Media was aspirated from the culture wells, and adherent 
cells were submerged in 500 µl of lysis solution for 2 minutes. The lysed cell suspension 
was then collected and centrifuged at 14000 rpm for 2 minutes. The filtered lysate was 
then thoroughly mixed with 500 µl of 70% ETOH (Sigma®) using a P1000 pipette 
(Eppendorf®). The lysate/ethanol mixture was then centrifuged in 500 µl aliquots at 
14000 rpm for 15 seconds in a RNA-binding column, to remove DNA and cellular 
debris. The lysate was centrifuged in a silica column with wash solutions containing 
ethanol (Sigma®) twice (14000 rpm for 15 seconds). The RNA was then eluted from the 
column by a final centrifugation with elution solution (14000 rpm for 1 minute). RNA 
concentration was measured using a NanoDrop1000 v3.7.0 (Thermoscientific) and 
sample purity was assessed using the A260/A280 ratio. All samples used for subsequent 
complementary DNA (cDNA) synthesis had A260/A280 ratios of ~2.0 to ensure high 
purity from potential contaminants such as proteins or phenol. The RNA was then stored 
at -80oC until used for cDNA synthesis. 
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2.2.11 Reverse transcription cDNA synthesis 
The RNA samples were reverse transcribed to produce cDNA using qScriptTM cDNA 
Supermix (Quanta BiosciencesTM) reagents. All reactions were performed on ice in a 
laminar flow hood (Envair Ltd) using RNAse-free equipment. All incubation steps were 
performed using a MJ Research® thermocycler. An equal quantity of RNA (1000 ng) 
was combined in a microcentrifuge tube with 4 µl of qScriptTM cDNA Supermix (5X) 
and the requisite volume of DEPC-treated H2O for a total reaction volume of 20 µl. 
Microcentrifuge tubes were then incubated at 25oC for 5 minutes, 42oC for 30 minutes, 
and 85oC for 5 minutes. After completion of cDNA synthesis, cDNA was stored at 4oC 
for a maximum of 2 weeks until utilised for quantitative PCR. 
 
2.2.12 qPCR amplification and analysis 
Quantitative PCR (qPCR) reactions were performed to assess the expression of 
chondrocyte markers following treatment of murine immature chondrocytes with 
anabolic and catabolic cytokines. All reactions were prepared on ice and protected from 
direct light. Reactions were performed using cDNA produced by reverse transcription 
using primers and TaqMan probes specific to the genes being studied (Appendix 7.2). 
Primers were designed using the Roche Universal Probe Library (UPL) Assay Design 
Center (available at www.universalprobelibrary.com). The TaqMan probes have two 
labels, one that fluoresces, and another that quenches that fluorescence. During the 
extension phase of the PCR reaction, the Taq polymerase cleaves the probe from its 
target sequence causing the fluorescent reporter label to be separated from the quencher, 
thereby permitting it to fluoresce. Fluorescence resulting from qPCR reactions was 
detected and quantified using a MJ Research® Chromo 4 Real Time PCR thermocycler 
and MJ OpticonMonitor 3.1 analysis software. The cDNA and reagents were combined 
in the proportions shown in Table 2.1, and reactions performed using the thermocycling 
conditions shown in Table 2.2. 
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Reagent Volume (µl) Final Concentration 
2X SensiFAST probe No-
ROX  
10 1X 
10 µM Forward primer 0.8 400 nM 
10 µM Reverse primer 0.8 400 nM 
10 µM Probe 0.2 100 nM 
cDNA template 2 - 
RNAse-free H2O 6.2 - 
Total volume 20 - 
 
Table 2.1 – Reagent concentrations for qPCR reactions; (nM, nanomolar)  
 
 
Step Temperature (oC) Time 
1. Denature template 95 5 minutes 
2. Denature template 95 10 seconds (40 cycles of steps 2-5) 
3. Anneal primers 60 30 seconds 
4. Extend primers 72 15 seconds 
5. Read fluorescence - - 
6. Completion 4 Incubate 
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All cDNA samples used in qPCR reactions were generated using equal quantities 
of RNA template (1000 ng). All qPCR reactions to evaluate gene expression of 
chondrocyte markers were run simultaneously alongside reactions to evaluate the 
expression of the housekeeping gene GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase) from the same sample. Chondrocyte marker target gene expression was 
determined relative to GAPDH gene expression using the ‘delta-delta Ct’ method, 
without efficiency correction: the relative target gene expression (R) quantification is 
established using the equation R = 2-∆∆Ct (404). All experiments were performed in 
triplicate with three replicates from independent samples.  
 
2.2.13 Statistical analysis 
All statistical analyses were performed using SPSS Statistics Version 19.0.0 (IBM; 
Armonk, New York, U.S.). All continuous dependent variables measured for 
independent groups were assessed for conformity with a normal distribution using the 
Shapiro-Wilk Test of Normality, with p < 0.05 indicating deviation from a normal 
distribution. Student’s t-Test was performed to compare normally distributed continuous 
dependent variables for two independent groups. For comparison of continuous 
dependent variables for two independent groups in which the dependent variable did not 
conform to a normal distribution in either group, a Mann-Whitney U test was 
performed. 
 TRIM32 protein expression by human femoral head primary articular 
chondrocytes between control patients and patients with hip OA, and the age of control 
patients and patients with hip OA, were compared using Student’s t-Test, with statistical 
significance accepted at p < 0.05. 
 Total ACAN content, ACAN content of femoral head explants, ACAN release 
by femoral head explants, and percentage ACAN release by femoral head explants from 
WT and Trim32-/- mice following treatment with no stimulation, IL1α, or RA were 
compared using Student’s t-Test, with statistical significance accepted at p < 0.05. 
Comparisons of groups of data that did not conform to a normal distribution, and which 
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were analysed using the Mann-Whitney U test, are indicated within the results section 
(see section 4.4.3; statistical significance accepted at p < 0.05). For analysis of the 
percentage aggrecan release by femoral heads (section 4.4.3.3, Figure 4.7), a two-way 
analysis of variance (ANOVA) with post-hoc Tukey tests was performed as 
comparisons were made between both genotype and treatment groups, with statistical 
significance accepted at p < 0.05. 
 Trim32 mRNA expression by primary chondrocytes from WT and Trim32-/- 
mice following cytokine treatments was analysed using Student’s t-Test, with statistical 
significance accepted at p < 0.05. The expression of differentiation markers by primary 
chondrocytes from WT and Trim32-/- mice following treatment with no stimulation, 
IL1α, TNFα, OSM, or IGF1 was compared using Student’s t-Test, with statistical 
significance accepted at p < 0.05. Comparisons of groups of data that did not conform to 
a normal distribution, and which were analysed using the Mann-Whitney U test, are 
indicated within the results section (see sections 4.4.4 and 4.4.5). A Bonferroni 
correction was performed to correct for multiple testing in all comparisons of the 
expression of differentiation markers by primary chondrocytes following cytokine 
treatments, with statistical significance accepted at p < 0.0025. All results are mean +/- 
standard deviation (SD). 
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2.3 The role of Trim32 in the development of OA in vivo: surgically induced and 
ageing induced OA in Trim32 knockout mice 
2.3.1 Trim32 knockout mice 
Breeding pairs of C57Bl/6 mice with Trim32 haploinsufficiency were obtained by 
collaboration with Dr Jens Schwamborn of the University of Münster. These mice carry 
a gene trap insertion in the Trim32 gene within exon 2, which includes the entire open 
reading frame (ORF) (Fig 2.1). Trim32 is located on mouse chromosome 4 and resides 
within an intron flanked by exons 16 and 15 of the Astn2 gene, which is transcribed in 
the opposite direction on chromosome 4. The tissue expression of Astn2 is fully 
preserved and Trim32 expression is disrupted in mice homozygous for the Trim32 gene 
trap insertion (Trim32-/- mice) (295). These mice have normal size, reproduce normally, 
have normal survival, but have been reported to develop a mild skeletal myopathy after 
5 months of age, and also to exhibit increased weight after 8 weeks of age (295). The 
WT and Trim32-/- (KO) mice used in the ageing and DMM experimental OA models 
were generated by mating heterozygote breeding pairs. The mice were housed in 
pathogen-free rooms of a designated animal facility, at constant temperature, under a 12-
hour dark-to-light cycle with water and pelleted standard commercial diet made 
available ad libitum. The Animal Welfare and Ethical Review Body of the University of 
Edinburgh approved all animal experiments, which were performed in accordance with 
the UK Animals (Scientific Procedures) Act 1986. All animal experiments were 
performed under the Home Office project licence number 70/7964, and under the 
University of Edinburgh establishment licence number 6002605. 
 
Figure 2.1 – Gene trap insertion generating Trim32 deficient mice; schematic of the Trim32 gene with 
integrated β-geo cassette disrupting the entire open reading frame. Adapted from Kudryashova et al (295). 
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2.3.2 Genotyping of Trim32 transgenic mice 
DNA was extracted from murine ear notches using the Invisorb® Spin Tissue Mini Kit 
(STRATEC Molecular). Genotyping of extracted DNA was performed by PCR using 
the oligonucleotide primer pairs listed in Table 2.3 for the WT Trim32 allele and the β-
geo fusion vector element. PCR amplification was performed using the Qiagen® Taq 
DNA polymerase reagents prepared on ice and as shown in Table 2.4, PCR cycling 
conditions as shown in Table 2.5, and processed using the MJ Research® thermocycler. 
Water was used as a negative control in all PCR reactions. All amplified products were 
diluted 1:1 in 1X Orange-G loading dye and run parallel to a low molecular weight 
marker (LMW) (New England BioLabs®) on a 1% agarose (Bioline)-EDTA-TBE (1X) 
gel containing 1:10000 SYBR® Safe (InvitrogenTM). Visualisation took place under 
ultraviolet light using GENEGenius (Syngene) and GeneSnap v6.05.01 (Syngene) 
software. A representative image from reactions for genotyping Trim32 transgenic mice 












caaatggcgattaccgttga tgcccagtcatagccgaata 625 
Trim32 agcttctcacctgaacctggatgc agccttataccttgcctgaagatccc 535 
 
Table 2.3 – Oligonucleotide primer sequences for PCR genotyping of Trim32 transgenic mice 
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Reagent Volume (μl) 
Taq Reaction Buffer 2.5 
dNTPs 2 
Forward Primer 1.25 
Reverse Primer 1.25 
Distilled H2O 7.875 
Q solution 5 
DNA 5 
Q-Taq Polymerase 0.125 
Total 25 
 







1. Denature template 94 3 minutes 
2. Denature template 94 45 seconds (30 cycles of steps 2-4) 
3. Anneal primers 55 30 seconds 
4. Extend primers 72 90 seconds 
5. Extend primers 72 10 minutes 
6. Completion 4 Incubate 
 
Table 2.5 – PCR cycling conditions for genotyping Trim32 transgenic mice 
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Figure 2.2 - PCR genotyping of Trim32 heterozygous mice and wild-type mice; a 1% agarose gel 
showing products from PCR genotyping for Trim32-disrupting gene trap insertion B-Geo (B-Geo, 625 
base pairs (bp)) and Trim32 (T32, 535 bp) using DNA from wild-type C57BL/6 mice (WT) and mice 
heterozygous for the gene trap disruption (HET). Lanes: 1) LMW bp ladder (L); 2) -ve control for Trim32 
(no DNA); 3) -ve control for B-Geo (no DNA); 4) Trim32 for WT mouse 1 (WT1); 5) B-Geo for WT1; 6) 
Trim32 for WT mouse 2 (WT2); 7) B-Geo for WT2; 8) Trim32 for HET mouse (HET); and 9) B-Geo for 
HET. Both B-Geo and Trim32 is detected in heterozygote mice; only Trim32 is detected in wild-type 
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2.3.3 Destabilisation of the medial meniscus (DMM) surgically induced OA model 
Osteoarthritis was surgically induced in female mice by performing DMM surgery at 
eight weeks of age, in a manner similar to the initial reports of the procedure (405). 
General anaesthesia (GA) was induced by administering inhaled isoflurane (IsoFlo®, 
Abbott Laboratories, UK) at a concentration of 3-5% mixed in oxygen through an 
anaesthetic circuit and delivered using a nose cone. Maintenance of anaesthesia was 
achieved by administering isoflurane at 1-2%. Prior to the start of the procedure, mice 
were also administered 0.3 milligrams (mg)/ml buprenorphine (Vetergesic®, Champion 
Alstoe, UK; diluted in sterile water) by subcutaneous injection. The right lower limb 
was shaved to remove hair, and prepared with povidone-iodine (Videne®, EcoLab Ltd, 
UK). The mice were placed on a sterile heated stage under a surgical microscope (Leica 
S6D, Leica Microsystems, UK). All surgical instruments were obtained from Wetlab 
(Kenilworth, UK), except for microsurgical knives (3 mm blade size, WPI, UK); all 
instruments were sterilised pre-operatively. Using sterile technique, a 1 cm anterior 
paramedian skin incision was performed centred over the medial joint line. A 0.5 cm 
vertical incision in the capsule of the medial aspect of the knee joint was then 
performed. The medial meniscotibial ligament (MMTL) was identified and transected at 
its mid-portion to enact full release of the anterior portion of the medial meniscus, which 
was confirmed intra-operatively during each procedure (Figure 2.3). Direct care was 
taken not to cause iatrogenic injury to the cruciate ligaments, medial collateral ligament, 
or articular surfaces throughout the procedure. After thorough irrigation of the wound 
with sterile saline, the wound was closed with two or three 5-0 absorbable sutures 
(Vicryl, Ethicon, UK). The mice were recovered from GA in an incubation chamber at 
25oC. Mice were returned to fresh cages and housed as previously described, but 
provided with standard commercial mashed diet for first 24 hours post-operatively. 
There were no wound problems and no post-operative morbidity in any mice following 
the procedure.  
Following DMM surgery, mice were followed-up for eight weeks and culled at 
16 weeks of age by inhalation of escalating concentration of CO2. The lower limbs were 
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carefully dissected free, the skin was removed and the limbs were fixed for 24 hours in 
4% formaldehyde, and then transferred into 70% ETOH until further analysis. 
Sham surgery (skin and joint capsule incision, but no transection of MMTL) was 
not performed on the contralateral knee as a control in these experimental mice. No 
sham surgery was selected to protect animal welfare, because previous studies have 
demonstrated no significant difference in histological OA scores between sham-operated 
and non-operated knee joints following DMM surgery on the contralateral knee joint, 
and because the primary objective in this research was to investigate the response to 
DMM surgery in Trim32-/- mice, Trim32+/- mice, and WT mice (387, 405). In the 
analysis of the operated right knee for the development of OA by histological and 
histomorphometric measurements, the non-operated left knee of each mouse was used as 
an internal control. DMM surgery was performed on the right knee, and the contralateral 
left knee was used as the control knee. As the contralateral left knee was used as an 
internal control, and sham surgery was not performed in separate control group of mice, 
randomisation was not performed for the DMM procedures. At the time of performing 
DMM surgery, the operator was blinded to the genotype of the mice, and only aware of 
the study ID number of the mice. 
As the 9q33.1 locus in which Trim32 resides was associated with hip OA in 
females, the DMM procedure was performed in female WT, Trim32+/- (HET), and 
Trim32-/- (KO) mice (229). Previous studies have demonstrated the response (change in 
histological cartilage degradation scores at 8 weeks) of female mice to the DMM 
procedure (376). Using data, from this study, it was determined that to detect a one SD 
difference in the histological total knee cartilage degradation scores at 8 weeks 
following the DMM procedure, with a significance threshold of 0.05, and 80% power, a 
total of 14 female mice would be required in the WT, HET, and KO groups. During the 
course of the experiments, it was possible to include a total of 14 WT, 14 Trim32+/-, and 
13 Trim32-/- mice in the DMM surgically induced OA experiments, providing an 
approximate 80% power to detect a one SD difference in the histological cartilage 
degradation scores, with a significance threshold of 0.05. 
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Figure 2.3 – Schematic diagram illustrating the medial meniscotibial ligament before and after 
transection by destabilisation of the medial meniscus (DMM) surgery; the normal bony and 
ligamentous architecture of the knee joint in mice is shown in panel A; panel B shows the transected 
medial meniscotibial ligament (highlighted by a red circle) and subsequent instability of the medial 
compartment of the knee joint after DMM surgery. 
 
2.3.4 Ageing induced OA 
A second OA model was utilised, in which the severity of spontaneous OA induced by 
ageing was compared in female WT, Trim32+/-, and Trim32-/- mice that had not 
undergone any specific experimental procedures. At 10 months of age mice were culled 
by inhalation of escalating concentration of CO2. The right lower limb was carefully 
dissected free, the skin was removed, and the limb fixed for 24 hours in 4% 
formaldehyde, and then transferred into 70% ETOH until later assessed for the 
development of hip and knee OA by both joint histology and histomorphometry.  
As the 9q33.1 locus in which Trim32 resides was associated with hip OA in 
females, the experiments evaluating the development of spontaneous OA in aged WT, 
Trim32+/-, and Trim32-/- mice included female mice only. Previous studies have 
demonstrated the response (change in histological knee cartilage degradation scores) in 
aged C57Bl/6 mice (406). Using data, from this study, it was determined that to detect a 
one SD difference in the histological total knee cartilage degradation scores in aged 
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mice, with a significance threshold of 0.05, and 80% power, a total of 16 female mice 
would be required in the WT, HET, and KO groups.  During the course of the 
experiments, it was possible to include a total of 12 WT, 12 Trim32+/-, and 13 Trim32-/- 
mice in the ageing induced OA experiments. This provided a 70% power to detect a one 
SD difference in the histological cartilage degradation scores, with a significance 
threshold of 0.05. 
 
2.3.5 Micro-computed tomography (µCT) of murine joint tissue 
Analysis of periarticular bone of hip and knee joints from murine lower limbs was 
performed by µCT using a Skyscan 1172 instrument (Bruker, Belgium) set at 60 
kilovolts (kV) and 167 microamperes (µA), at a resolution of 5 µm. Following 
acquisition of images for each sample, the images were reconstructed using the Skyscan 
NRecon programme and analysed using Skyscan CTAn software. The regions of interest 
(ROI) analysed were the subchondral trabecular bone situated within the distal femoral 
and proximal tibial epiphyses and the subchondral bone plates of the distal femur and 
proximal tibia; these regions were analysed separately in both the medial and lateral 
compartments of the knee joint (Appendix 7.3.1A). For analysis of hip joints, the 
subchondral trabecular bone and the subchondral bone plate were analysed in the 
proximal femoral epiphyses of the femoral head (Appendix 7.3.1B). A constant number 
of consecutive image sections were included across all samples for the analysis of 
subchondral and trabecular bone of the hip and knee joints. Image contrast thresholds 
for the detection of subchondral and trabecular bone were constant across all samples 
for the analysis of hip and knee joints. The µCT analyses were performed in the coronal 
plane. Representative 3D reconstructions of the µCT images of subchondral and 
trabecular bone of the hip and knee joints from mice studied in the experimental OA 
models are shown in Appendix 7.3.2. During capture and analysis of µCT data, blinding 
of the mice genotype from which samples were retrieved was performed, with only the 
study ID number of the mice known. 
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2.3.6 Histological analysis of murine joint tissue 
Hip and knee joints were dissected from lower limbs previously fixed in 4% 
formaldehyde and 70% ETOH. Individual joints, with the majority of muscle removed 
were then decalcified in 10% formic acid for 48 hours at 4oC with agitation, with two 
exchanges of the formic acid. Samples were washed in distilled H2O, and stored in 70% 
ETOH for 24 hours prior to paraffin embedding. Paraffin embedding was performed for 
individual joints by immersing sequentially for one hour each in 80% ETOH, 95% 
ETOH, three exchanges of 100% ETOH, three exchanges of xylene, and then wax 
embedding for three hours for three cycles, the third cycle performed under vacuum. 
Orientation of knee joints for mounting in blocks was standardised with the 
medial aspect down and proximal (femoral) extent positioned superior for subsequent 
sectioning using a Leica RM2235 microtome (Leica Microsystems, UK) in the sagittal 
plane. Blocks were trimmed until articular cartilage was evident. For each knee joint, 
sections of 3 µm thickness were obtained at 40 µm intervals through the joint from 
medial to lateral aspects until articular cartilage was no longer evident; this yielded 15-
20 sections for each knee joint. Orientation of hip joints for mounting in blocks was 
standardised with the anterior aspect down and proximal extent positioned superior for 
subsequent sectioning in the coronal plane. Blocks were trimmed until articular cartilage 
was evident. For each hip joint, sections of 3 µm thickness were obtained at 40 µm 
intervals through the joint from anterior to posterior aspects until articular cartilage was 
no longer evident; this yielded 10-15 sections for each hip joint. Sections were mounted 
on slides, then incubated at 85oC for 30 minutes, and then overnight at 55oC. Hip and 
knee joint sections were deparaffinised and gradually hydrated to H2O, stained in 
Toluidine Blue for 1 minute, washed in H2O for 3 minutes, dehydrated in acetone twice 
for 3 minutes, cleared in xylene and re-mounted on slides. 
Histological evaluation of the severity of OA in each joint section was performed 
with blinding to mouse genotype (only the study ID number of the mice was known) 
and according to the OARSI scoring system validated for histological assessments in the 
mouse (Table 2.6; Figure 1.3). Joint sections were reviewed by each assessor for 
microtomy artefacts; joint sections demonstrating microtomy artefacts were not included 
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in the scoring of OA severity, to avoid assessing slides with possible cutting artifacts. 
Microtomy artefacts were indicated by gross fragmented tissue, or incomplete joint 
sections on the slide. Joint sections were also reviewed by each assessor for iatrogenic 
surgical artefacts that would be indicated by coarse blade injury to the cartilage on slides 
corresponding to the anteromedial aspect of the knee joint and adjacent to the medial 
meniscal tibial ligament; no slides were excluded due to iatrogenic surgical artefacts. 
For knee joint sections, scores were generated separately for four regions of the joint: 
the medial tibial plateau (MTP), the medial femoral condyle (MFC), the lateral tibial 
plateau (LTP), and the lateral femoral condyle (LFC) (Figure 2.3). For hip joint sections, 
scores were generated from the articular surface of the femoral head only to determine 
the hip joint section score. As 15-20 sections were assessed in each knee joint, and 10-
15 sections assessed for each hip joint, the most severe score of each region for each 
joint was used for further analyses. For each knee joint, the most severe scores were 
then summed from the tibial and femoral articular cartilage to provide a summed score 
for the medial and lateral compartments of the knee (ranging from a minimum possible 
score of 0 to a maximum possible score of 12). Finally, total scores for each whole knee 
joint were calculated by combining the scores for the medial and lateral compartments 
of each joint (ranging from a minimum possible score of 0 to a maximum possible score 
of 24). A second observer, who was also blinded to genotype, assessed a randomly 
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Grade Structural appearance of articular cartilage 
0 Normal 
1 Small fibrillations without loss of cartilage 
2 Vertical clefts to beneath superficial layer; some loss of surface lamina 
3 Vertical clefts/erosion to calcified cartilage affecting <25% of articular surface area 
4 Vertical clefts/erosion to calcified cartilage affecting 25-50% of articular surface area 
5 Vertical clefts/erosion to calcified cartilage affecting 50-75% of articular surface area 
6 Vertical clefts/erosion to calcified cartilage affecting 75-100% of articular surface area 
 
Table 2.6 – OARSI scoring system for assessment of OA in mice; the criteria for the nature and extent 
of structural changes associated with increasing severities of OA are shown; adapted from Glasson et al 
(383). 
 
2.3.7 Nociception testing 
Hypersensitivity to somatosensory stimuli was measured following DMM surgery in a 
second group of Trim32 transgenic mice. DMM surgery was performed in female WT 
and Trim32-/- mice at eight weeks of age. Hypersensitivity to somatosensory stimuli, 
reflecting a reduced pain threshold due to chronic pain, was assessed by separately 
measuring the limb withdrawal threshold upon application of brief mechanical stimuli to 
the operated and non-operated hind limbs of mice eight weeks following the DMM 
surgery. Mice were placed on a wire-mesh floor within a cage. Von Frey filaments 
(bending force range used from 0.16 grams (g) to 8 g) were applied in ascending order 
of bending force at right angles to the mid-plantar surface of the hind paw through the 
mesh floor until limb withdrawal occurred. Each filament was applied to the hind paw 
until either filament bending or limb withdrawal occurred. Five-second time intervals 
between filament applications were used. The process was reported three times for the 
operated and non-operated limb of each animal, with intervals of 15 minutes between 
each set of tests. The lowest force recorded to induce withdrawal of each limb was used 
for analyses. A total of seven WT, and eight Trim32-/- mice were studied in nociception 
testing of operated and non-operated limbs in mice following induction of OA by DMM 
surgery. The operator performing nociception testing was blinded to mice genotype and 
limb of DMM surgery, with only the study ID number of the mice known. 
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2.3.8 Grip strength testing 
The Trim32-/- mice have been reported to develop a mild skeletal myopathy after 5 
months of age (295). To investigate any variation in muscle strength that may contribute 
to the development of OA, in addition to other mechanisms disrupted by deficiency of 
Trim32, limb grip strength testing was performed in each animal following completion 
of nociception testing (see 2.8.7). To measure limb grip strength, mice were assisted in 
grasping a pull bar of a grip strength meter with both fore limbs, and the peak force 
applied before loss of grasp was recorded (the animals could readily release the grip 
prior to any discomfort). The limb grip strength testing was performed in triplicate for 
each mouse, and mean scores for each animal used for further analyses. A total of seven 
WT, and eight Trim32-/- mice were studied in fore limb grip strength. The operator 
performing grip strength testing was blinded to mice genotype, with only the study ID 
number of the mice known. 
 
2.3.9 Statistical analysis 
All statistical analyses were performed using SPSS Statistics Version 19.0.0 (IBM; 
Armonk, New York, U.S.), and statistical significance was accepted at p < 0.05, unless 
specifically stated. Power calculations for the murine studies were performed using 
Minitab 17 (Minitab; State College, Pennsylvania, U.S.). All continuous dependent 
variables measured for independent groups were assessed for conformity with a normal 
distribution using the Shapiro-Wilk Test of Normality, with p < 0.05 indicating 
deviation from a normal distribution. Student’s t-Test was performed to compare 
normally distributed continuous dependent variables for two independent groups. A 
Mann-Whitney U test was performed for comparison of continuous dependent variables 
for two independent groups in which the dependent variable did not conform to a normal 
distribution in either group, or of ordinal variables for two independent groups. One-way 
ANOVA with post-hoc Tukey tests was performed to compare a normally distributed 
variable between greater than two independent groups with differences between each 
group subsequently examined. Kruskal Wallis test with post-hoc Dunn’s tests was 
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performed to compare ordinal variables, or dependent variables that did not conform to a 
normal distribution, between greater than two independent groups with differences 
between each group subsequently examined. 
Comparison of number of cagemates and weight of mice between wild type and 
Trim32 deficient mice were performed using Student’s t-Test. Subchondral bone 
parameters were compared between WT and Trim32 deficient mice by one-way 
ANOVA followed by post-hoc Tukey tests to further investigate significant differences 
between mice of different genotypes and to control for multiple comparisons. 
Data for both hip and knee joint OARSI scores after DMM and ageing deviated 
from a normal distribution (Shapiro-Wilk tests: unoperated knee medial compartment 
OARSI scores, p = 0.000008; unoperated knee lateral compartment OARSI scores, p = 
0.00001; operated knee medial compartment OARSI scores, p = 0.02; operated knee 
lateral compartment OARSI scores, p = 0.01; unoperated knee total joint scores, p = 
0.0001; operated knee total joint OARSI scores, p = 0.03; aged knee medial 
compartment OARSI scores, p = 0.001; aged knee lateral compartment OARSI scores, p 
= 0.01; aged knee total joint scores, p = 0.04; and aged hip OARSI scores, p = 0.00003). 
Hip and knee joint OARSI scores were therefore compared between WT and Trim32 
deficient mice by Kruskal Wallis test with post-hoc Dunn’s tests to further investigate 
significant differences between mice of different genotypes and to control for the effect 
of multiple comparisons. The inter-observer correlation of OARSI scores observed by 
independent observers was analysed using Spearman’s rank correlation coefficient.  
The covariate effect of mice weight on knee joint OARSI scores was 
investigated using a generalised linear model (GLM). Meta-analysis of hip and knee 
joint scores in WT and Trim32 KO mice following ageing and DMM surgery was 
performed using Review Manager Version 5.3.5 software (The Cochrane Collaboration, 
Copenhagen). Nociception, measured by hind limb withdrawal thresholds, was 
compared between WT and Trim32 KO mice using the Mann-Whitney U test (Shapiro-
Wilk tests: WT operated limb, p = 0.001; KO operated limb, p = 0.0003; WT unoperated 
limb, p = 0.001; KO unoperated limb, p = 0.001). Grip strength was compared between 
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3.1 Summary 
The aim of this chapter was to investigate genetic variation within TRIM32 to identify 
novel or rare variants that are associated with OA of the hip in females. TRIM32 is one 
of three protein-coding genes at the 9q33.1 susceptibility locus (tagged by the index 
SNP rs4836732) for hip OA in females. TRIM32 encodes a protein with E3 ubiquitin 
ligase activity and may have biological relevance to OA through its role in 
ubiquitination, muscle regeneration, differentiation, proliferation, and ciliogenesis.  
Variant screening of TRIM32 was performed by sequencing the proximal promoter, 
5’UTR, both exons, and 3’UTR of TRIM32 in the youngest 500 female patients with hip 
OA from the arcOGEN study patient cohort. Variants detected by screening of TRIM32 
were further evaluated by comparing their frequency in females with hip OA with a 
control population (data from 1000 Genomes Project), analysing LD with the index SNP 
rs4836732, assessing consequent amino acid and protein modifications, and 
bioinformatic analyses of transcription factors and regulatory motifs. 
 Nine variants were detected in female patients with hip OA: rs811457 located in 
the proximal promoter; rs12342207 located in the 5’UTR; rs141806013, rs3747835, and 
rs1661300 that reside within the coding region of exon 2; and rs3019, a novel variant 
(c.13277C>C/T), rs22816277, and rs761458746 that reside in the 3’UTR of TRIM32. 
None of the variants were in LD with the index SNP rs4836732. Two variants, rs811457 
and rs3019 were detected in female patients with hip OA at disproportionate frequencies 
compared to the control population. The rs811457 variant was present at a reduced 
frequency in females with hip OA and may be protective against hip OA (p = 0.001; 
OR: 0.238 [0.092 – 0.617]). The rs3019 variant was present at an increased frequency in 
female patients with hip OA and was associated with an increased risk of hip OA in 
female patients (p = 0.036; OR: 1.512 [1.081 – 2.115]. 
 The identification of rare variants in the proximal promoter and 3’UTR of 
TRIM32 that are present at disproportionate frequencies in female patients with hip OA 
compared to the control population further implicates TRIM32 in the genetic 
predisposition to OA and supports the further study of TRIM32 in the pathophysiology 
of OA.  
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3.2 Introduction 
The overall aim of the experiments described in this chapter was to identify genetic 
variants within TRIM32 and to identify novel or rare variants in TRIM32 that are 
associated with OA of the hip in female patients. The TRIM32 gene lies within the 
susceptibility locus with the greatest effect size identified by the arcOGEN GWAS of 
hip and knee OA, which was that on chromosome 9q33.1 (represented by the index 
genotyped SNP rs4836732; OR 1.20 [1.13 – 1.27], p = 6.11 x 10-10), and which was 
associated with the specific phenotype of hip OA in females (Figure 1.4 (229)). The top 
hit SNP rs4836732 may only be representative of true causal variants within this locus, 
and may be in LD with other causal SNPs at this locus. This locus contains three 
protein-coding genes (ASTN2, PAPPA, and TRIM32). Although variants in multiple 
genes may be represented by the previously identified association signal, the 
experiments in this chapter focused on detailed evaluation of TRIM32. TRIM32 encodes 
a protein with E3 ubiquitin ligase activity, which may have biological relevance to the 
development of OA through its role in ubiquitination, musculoskeletal regeneration, and 
regulation of differentiation, proliferation, and ciliogenesis (281, 298, 301, 303). 
 Screening of TRIM32 was performed by sequencing the proximal promoter, 
5’UTR, both exons, and the 3’UTR in the youngest 500 female patients with hip OA 
from the arcOGEN study cohort. The youngest 500 female patients with hip OA were 
selected because the association of the index SNP rs4836732 was gender-specific, and 
the frequency of causal variants at this locus may be enriched in patients predisposed to 
the development of early-onset hip OA. Variants detected by screening of TRIM32 in 
this cohort were then evaluated by comparing their frequency in female patients with 
OA with a control population (using data from the 1000 Genomes Project), analysing 
LD with the index SNP rs4836732, assessing consequent amino acid and protein 
modifications, and investigating if the variant was reported as an eQTL or located within 
a transcription factor binding site or regulatory motif.  
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3.3 Aims 
The aims of the experiments described in this chapter were to: 
1. Investigate the genetic variation of TRIM32 to identify novel or rare variants 
in TRIM32 that are associated with OA of the hip in females. 
2. Investigate the biological implication of variants in TRIM32 identified as 
associated with OA of the hip in females using bioinformatic analyses. 
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3.4 Results 
3.4.1 Variants identified by DNA sequencing of TRIM32 
To investigate the genetic variation of TRIM32 to identify novel or rare variants in 
TRIM32 that are associated with OA of the hip in females, TRIM32 was sequenced 
using DNA from the youngest available 500 female patients with hip OA from the 
arcOGEN study (229). The proximal promoter, 5’UTR, both exons, and 3’UTR of 
TRIM32 were successfully amplified and sequenced in these patients. Variant screening 
was then performed and the frequency of any previously known variants from this 
cohort was compared against that of control population data retrieved from the 1000 
Genomes Project (391). This enabled identification of any variants that are more or less 
prevalent in patients with hip OA, and associated with risk of developing hip OA. The 
identified variants are shown in Figure 3.1. Details of the nine variants identified in 
TRIM32 in patients with hip OA, are shown in Table 3.1, including the location of each 
polymorphism within TRIM32, the Single Nucleotide Polymorphism database (dbSNP) 
identification number (if the variant has previously been reported), the associated 
genotypes and amino acid substitutions, genotype frequency, allele frequency in patients 
with hip OA and the control population, and estimation of the effect size of each variant 
in relation to the risk of developing hip OA. A schematic demonstrating the position of 
the identified variants within TRIM32 is shown in Figure 3.2. Detailed description of the 
variants in each region of TRIM32 is provided in the subsequent sections in this chapter 
(3.4.1.1 (5’UTR), 3.4.1.2 (Exon 2), 3.4.1.3 (3’UTR)). None of the nine identified 
variants deviated from Hardy-Weinberg equilibrium. 
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Figure 3.1 – Variants identified by DNA sequencing of TRIM32; variants identified by DNA 
sequencing of the proximal promoter, 5’UTR, both exons, and 3’UTR of TRIM32 in the 500 youngest 
female patients with hip OA from the arcOGEN study cohort are shown; wild type and variant sequences 
are shown. Chromatogram images were generated using Mutation Surveyor® software (version 3.97; 
Softgenetics) with nucleotide sequences for the sense strand shown; adenine (green), cytosine (blue), 
guanine (black), thymine (red). Polymorphism identification (ID) numbers from dbSNP are shown for 
previously known variants, black bars indicate amino acid codons, and the variant TRIM32 genotype and 
any corresponding amino acid change indicated beneath each chromatogram. 




Table 3.1 – Variants identified by DNA sequencing of TRIM32; variants identified by DNA sequencing of the proximal promoter, 5’UTR, both 
exons, and 3’UTR of TRIM32 in the 500 youngest female patients with hip OA from the arcOGEN study cohort are shown; consequent heterozygote 
and homozygote variant genotypes are shown with any associated amino acid changes. Polymorphism ID numbers from dbSNP are shown for 
previously known variants. Genotypes are shown for TRIM32 sequence as the forward strand. The minor allele frequency (MAF) for the control 
population was retrieved from data from the 1000 Genomes Project for the CEU population of European ancestry (1000GENOMES:phase_3:EUR 
(391)). Statistical analysis was performed by chi-squared (χ2) test to determine whether the minor allele frequencies observed among patients with hip 
OA were significantly different from those expected from the control population, and odds ratios were determined to estimate effect sizes of risk 
alleles; statistically significant results are annotated with (*) and presented in bold. OA: osteoarthritis; UTR: untranslated region; C: cytosine; G: 
guanine: T thymine: A: adenine; N/A: data not available; 95% CI: 95% confidence interval. 
Chapter 3 – Variant screening of TRIM32 
 104 
 
Figure 3.2 – Schematic of TRIM32 demonstrating position of identified variants in female patients 
with hip OA; the position of the nine variants identified by DNA sequencing of TRIM32 in the youngest 
500 female patients from the arcOGEN study cohort are shown (229). The black bars indicate the position 
of the identified variants rs811457, rs12342207, rs141806013, rs3747835, rs1661300, rs3019, rs2291627, 
rs761458746, and the novel variant (c.13277C>C/T). The red triangle indicates the binding site for 
transcription factors TFAP2C and TFAP2A. The histogram beneath the TRIM32 gene schematic shows 
the levels of enrichment of the H3K4me3 histone mark, often found near promoters, across TRIM32 (the 
different colours indicate H3K4Me3 enrichment levels in different cell lines. The TRIM32 schematic is 




Table 3.2 – Species conservation for sites identified in variant screening of TRIM32; data was 
retrieved using the UCSC Human Genome Browser (408). The conservation of nucleotides across 
different species at the positions of the nine variants identified by sequencing TRIM32 in 500 female 
patients with hip OA is shown. Comparison of the nucleotide at the position of each variant in the human 
genome is made with known nucleotides at each position for rhesus monkey, mouse, dog, elephant, 
chicken, and zebrafish genomes. N/A: data not available. For nucleotides, A = adenine, C = cytosine, G = 
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3.4.1.1 Variants in proximal promoter and 5’UTR of TRIM32 
The proximal region of TRIM32 was sequenced using DNA from the youngest 
available 500 female patients with hip OA from the arcOGEN study (229), including the 
proximal promoter and the 5’UTR of TRIM32. Mutation screening of the proximal 
promoter region identified the known SNP rs811457, c.1-139G>G/C (Figure 3.1 and 
Figure 3.2). This variant was identified in five HET patients with primary hip OA (Table 
3.1). This variant results in a guanine to cytosine alteration and lies immediately 
proximal (-3 bp) to the CGI of the TRIM32 promoter region. Although it is not itself 
reported to lie within a transcription factor binding site, it lies adjacent (-10 bp) to 
binding sites for transcription factor AP-2 gamma (TFAP2C) and transcription factor 
AP-2 alpha (TFAP2A) and in a region marked by very high levels of histone H3 lysine 4 
methylation (H3K4me3; Figure 3.2). This variant, rs811457, was found to be present at 
a lower frequency in female patients with hip OA compared to the control population (p 
= 0.001; Table 3.1). The protective allele (C) for OA had an effect size of 0.238 [0.092 – 
0.617] (Table 3.1). However, this variant was not in LD (r2 = 0.058) with the index SNP 
(rs4836732) at the 9q33.1 locus identified as associated with hip OA in female patients 
in the arcOGEN study (Figure 1.4 (229)). This variant has not previously been reported 
as an eQTL for any genes in any tissues, and the polymorphism is not at a position that 
is highly conserved across species (Table 3.2). Furthermore, none of the remaining 
variants have been reported as an eQTL for any genes in any tissues. 
Another variant, rs12342207, was identified that is located in the 5’UTR of 
TRIM32 and which resulted in a change from guanine to cytosine (Figure 3.1 and Figure 
3.2). This variant was identified at a relatively high frequency, but its frequency in 
female patients with OA did not differ significantly from the control population (p = 
0.770; Table 3.1). Furthermore, this variant was only in moderate LD with the index 
SNP, rs4836732, at this susceptibility locus for OA (r2 = 0.431). 
Sequencing of the proximal promoter and 5’UTR of TRIM32 in female patients 
with hip OA therefore identified two known variants, rs811457 and rs12342207. The 
rs12342207 variant was not present at significantly different frequencies between female 
patients with OA and the control population (p = 0.770). However, the rs811457 variant 
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was present at a lower frequency in female patients with OA compared to the control 
population (p = 0.001). 
 
3.4.1.2 Variants in exon 2 of TRIM32 
Exon 2 of TRIM32 was also sequenced in 500 female patients with hip OA. 
Three variants were identified in exon 2, which contains the entire ORF for TRIM32 
(Figure 3.1 and Figure 3.2). The rs141806013 variant results in an alanine to threonine 
amino acid change in exon 2, in a region of TRIM32 between the coiled-coil and NHL 
repeat domains (Figure 1.5). In silico assessment of the rs141806013 variant indicated 
that it is a benign and tolerated variant within the coding region of TRIM32. The 
rs3747835 variant results in an arginine to cysteine amino acid change within the NHL 
repeat domain of TRIM32 (Figure 1.5). In silico assessment of the rs3747835 variant 
indicated that it is a deleterious variant. However, neither rs141806013 nor rs3747835 
were detected at a significantly different frequency in patients with hip OA compared to 
the control population (rs141806013: p = 0.563, rs3747835: p = 0.563; Table 3.1). LD 
data for rs141806013 and rs3747835 in relation to the index rs4836732 SNP were not 
available, as these variants were not covered by the available databases. The third 
variant identified in exon 2, rs1661300, is a synonymous mutation involving a guanine 
to adenine alteration (Table 3.1). This variant was not in LD with the index SNP 
rs4836732 (r2 = 0.067), and was not present at a significantly different frequency in 
female patients with OA compared with the control population (p = 0.147). All three 
variants identified in exon 2 of TRIM32 are at sites demonstrating high cross-species 
conservation (Table 3.2). 
 Sequencing of exon 2 of TRIM32 in female patients with hip OA therefore 
identified three known variants, rs14180013, rs374785, and rs1661300. However, none 
of these variants were present at significantly different frequencies between female 
patients with hip OA and the control population.  
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3.4.1.3 Variants in 3’UTR of TRIM32 
Finally, the 3’UTR region of TRIM32 was sequenced in 500 female patients with hip 
OA. Four variants were identified in the 3’UTR of TRIM32 (Figure 3.1 and Figure 3.2; 
Table 3.1). A novel variant, c.13277C>C/T, was identified that represents a cytosine to 
thymine alteration and which has not previously been reported. This novel variant was 
present in HET form in only two patients with hip OA. The rs2281627 variant results in 
a thymine to cytosine alteration in the 3’UTR of TRIM32. This variant was in moderate 
LD with the index SNP rs4836732 (r2 = 0.395), but was present at a similar frequency in 
female patients with hip OA compared to the control population (p = 0.857). The 
rs761458746 variant represents a change from thymine to cytosine in the 3’UTR of 
TRIM32 and was identified in HET form in a single female patient with hip OA; MAF 
and LD data for this SNP were also not available. 
Finally, the rs3019 variant in the proximal 3’UTR of TRIM32 was detected at a 
significantly higher frequency in female patients with hip OA compared to the control 
population (p = 0.036; Table 3.1). This variant, c.12503T>T/C, results in a thymine to 
cytosine alteration. The C risk allele was associated with an increased risk of hip OA in 
female patients, with an odds ratio of 1.512 (95% CI: [1.081 – 2.115]; Table 3.1). The 
rs3019 variant was not in LD with the previously reported index SNP rs4836732 at the 
9q33.1 susceptibility locus for hip OA in females (r2 = 0.017). However, the rs3019 
variant is located at a site demonstrating high cross-species conservation (Table 3.2). 
None of the identified variants were in LD with each other. 
 Sequencing of the 3’UTR region in female patients with hip OA therefore 
identified four variants, rs3019, a novel variant (c.13277C>C/T), rs2281627, and 
rs76148746. However, only the rs3019 variant was identified as present at a 
significantly different frequency in female patients with hip OA compared to the control 
population. The rs3019 variant was detected at a significantly higher frequency in 
female patients with hip OA compared to the control population (p = 0.036).  
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3.5 Discussion 
The experiments described in this chapter aimed to investigate the genetic variation of 
TRIM32 to identify novel or rare variants in TRIM32 that are associated with OA of the 
hip in females. Sequencing of the proximal promoter, 5’UTR, both exons, and 3’UTR of 
TRIM32 in the youngest 500 females patients with hip OA from the arcOGEN patient 
cohort detected nine variants; two of which were present at disproportionate frequencies 
in female patients with hip OA compared to the control population, and may therefore 
contribute to the genetic predisposition to hip OA in females. 
 Sequencing of the proximal promoter and 5’UTR of TRIM32 identified two 
known variants, rs811457 and rs12342207 (Figure 3.1). The rs12342207 variant is 
relatively common with a MAF of 0.312 in female patients with hip OA, though this 
was not significantly different from the control population (Table 3.1; p = 0.770). 
However, rs811457 was present at a reduced frequency in female patients with OA 
compared to the control population; the MAF in patients with OA was 0.007 (Table 3.1; 
p = 0.001). The variant C allele may therefore confer protection against OA compared to 
the more common G allele. The rs811457 variant (c.1-139G>G/C) lies adjacent to the 
CGI in the TRIM32 promoter and in a region marked by very high levels of H3K4me3 
(Figure 3.2). H3K4me3 is localised in close proximity to the transcriptional start sites of 
actively transcribed genes regulating transcription factor binding (409-411). The 
rs811457 variant also resides adjacent to the binding site for the transcription factors 
TFAP2A and TFAP2C, members of the AP-2 family of transcription factors. These 
factors, especially TFAP2A have important roles in chondrogenesis and skeletogenesis 
(412). TFAP2A is expressed in growth plate and articular cartilage and is a negative 
regulator of chondrocyte differentiation (412, 413). TFAP2A activity suppresses Col II 
expression, and also inhibits ACAN and Col X production (414). The rs811457 variant 
in the proximal promoter region of TRIM32 may therefore be a functional variant 
affecting TRIM32 expression in chondrocytes (415). 
 Three variants were identified in the protein-coding region of exon 2 of TRIM32 
(Figure 3.1). The two missense variants, rs3747835 and rs141806013 were both detected 
in HET form in one and two female patients with hip OA, respectively (Table 3.1). The 
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third variant, rs1661300, which is a synonymous variant, was detected more frequently 
(Table 3.1). However, the variants detected in exon 2 in female patients with hip OA are 
unlikely to have functional significance as their MAFs were similar to the control 
population, and none were in LD with the rs4836732 SNP that was associated with the 
development of hip OA in female patients in the arcOGEN GWAS (Table 3.1) (229). 
 Sequencing of the 3’UTR also identified four variants within TRIM32 in female 
patients with hip OA (Figure 3.1, Table 3.1). Variants specifically in the 3’UTR may 
alter mRNA stability and translation through effects on polyadenylation and interactions 
between both regulatory proteins and mRNA, and microRNA and mRNA (416, 417). 
Polymorphisms in the 3’UTR region can lead to translational inhibition or mRNA 
degradation, and by altering miRNA binding sites can result in increased or decreased 
expression (418, 419). The novel variant, c.13277C>C/T, identified in the 3’UTR was 
only present in HET form in two patients with hip OA, while the rs761458746 variant 
was identified in HET form in a single patient. MAF and LD information for these 
variants was not available, though these variants are unlikely to have functional 
significance. 
The rs3019 and rs2281627 variants detected in the 3’UTR may have relevance to 
the pathogenesis of OA (Figure 3.1). The rs2281627 variant is relatively common (MAF 
= 0.315) in female patients with hip OA and was in moderate LD (r2 = 0.395) with the 
index SNP rs4836732 at the 9q33.1 locus for OA susceptibility. The rs3019 variant was 
detected at a significantly higher frequency in patients with OA compared to the control 
population (p = 0.036; Table 3.1), and resides at a site of high cross-species 
conservation, indicating that the variant could be deleterious (Table 3.2). Although the 
frequency of the rs3019 variant in female patients with hip OA was only just statistically 
significant (p = 0.036), this may still be a robust finding as sequencing was performed in 
the youngest cohort (n = 500) of female patients from the arcOGEN study and in whom 
variants associated with OA are likely to be enriched, and because the 9q33.1 locus 
within which TRIM32 resides was previously demonstrates as associated with hip OA in 
females with genome-wide significance (229). TRIM32 is targeted by miR-511; the 
rs3019 and rs2281627 variants occur at binding sites of miR-511. Haplotypes involving 
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the rs3019 and rs2281627 variants lead to disruption of seed sites for miR-511, resulting 
in impaired interactions of miR-511 with TRIM32 (420). miR-511 is a potent regulator 
of the inflammatory response (421). miR-511 can target and regulate TLR4, inhibit the 
activation of TLR4-dependent inflammatory cytokine production, and control the 
activation and recruitment of macrophages (421, 422). A pathological role for miR-511 
in joint inflammation has previously been demonstrated; miR-511 is upregulated in 
synovial monocytes in patients with rheumatoid arthritis (423). miR-511 is also 
associated with altered expression of several genes including ALDH1A1, a member of 
the ALDH gene superfamily, members of which are associated with altered chondrocyte 
phenotype and OA, and have fundamental roles in embryogenesis, RA signalling, limb 
development, and protection against oxidative stress (424-428). The identification of the 
rs3019 variant in the 3’UTR of TRIM32 as being over-represented in female patients 
with hip OA therefore further implicates TRIM32 in the pathogenesis of OA, especially 
as presence of the variant may alter interaction of TRIM32 with microRNA involved in 
regulating joint inflammation.  
 Although none of the nine variants detected in TRIM32 in female patients with 
hip OA were in significant LD with the rs4836732 polymorphism, such linkage could be 
further explored by conditional analysis of the rs3019 or rs811457 variants with 
rs4836732, or its immediately adjacent SNPs, for association with hip OA in female 
patients. The cohort examined in these experiments (n = 500) was relatively low 
compared to the arcOGEN study cohort that identified the 9q33.1 locus as associated 
with hip OA in female patients; examination of the polymorphisms in TRIM32, 
especially those under or over-represented in females with hip OA, in a larger cohort of 
patients or by comparison with a confirmed disease-free control population matched for 
age and gender could further validate these findings. It may also be informative to 
examine any association of the variants significantly associated with hip OA for 
association with other endophenotypes relevant to hip OA, such as radiographic 
parameters of hip morphology, which may indicate discrete developmental dysplasias, 
or joint space width as an indicator of early OA (254). Additional transcription factor 
binding sites have also been identified in more proximal regions of the TRIM32 
promoter (429). Further disease-associated variants could be identified by more 
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extensive sequencing of the promoter and intronic regions; the proximal promoter, 
5’UTR, both exons, and 3’UTR of TRIM32 were focused on in these experiments to 
prioritise regions of high functional relevance. 
 The rs811457 and rs3019 variants could also be investigated further by analysing 
the effect of these variants on chondrocyte function, which may help to identify the 
associated pathological molecular mechanisms. As the rs811457 variant lies adjacent to 
the TFAP2A/TFAP2C transcription factor binding site (Figure 3.2), the expression of 
TRIM32 in chondrocytes expressing this variant could be measured, as could the ability 
of the TFAP2A/TFAP2C transcription factors to bind the altered sequence in the 
proximal promoter of TRIM32 by ChIP analysis. As the rs3019 variant in the 3’UTR of 
TRIM32 may affect TRIM32 expression by disrupting a binding site of miR-511, which 
can target TRIM32 in joint tissue, the expression of TRIM32 and miR-511 in 
chondrocytes expressing the rs3019 variant could be assessed (420, 423). Examining the 
effect of these two variants on the expression of TRIM32 and associated regulatory 
factors in chondrocytes may help to investigate the role of TRIM32 in pathological 
mechanisms contributing to the OA disease process. 
The Sanger sequencing and variant analysis methodology utilised in these 
experiments are effective for identification of SNPs, though it is acknowledged that 
other forms of variation such as insertions, deletions, CNVs, and epigenetic 
modifications could also contribute to the genetic predisposition to OA at this locus, as 
well could variants in other genes. The variants detected at disproportionate frequency 
in females with hip OA in these experiments could also be part of a larger haplotype 
conferring risk for hip OA. 
 The results of variant screening of TRIM32 identified several variants. The 
rs811457 variant in the proximal promoter was under-represented in female patients 
with hip OA and may be protective against hip OA. The rs3019 variant was over-
represented in female patients with hip OA and may be associated with increased risk of 
hip OA. The rs811457 and rs3019 variants may affect TRIM32 expression and post-
transcriptional regulation, respectively. Correlating the putative effect of these variants 
with studies of in vitro and in vivo altered expression of TRIM32 in chondrocytes and 
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articular tissue may further validate TRIM32 in the pathogenesis of OA. The role of 










The role of TRIM32 in human and murine articular tissue ex 
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4.1 Summary 
This chapter aimed to investigate the role of TRIM32 in human and murine articular 
tissue ex vivo, by investigating TRIM32 expression in human articular cartilage, and the 
effect of Trim32 knockout (Trim32-/-) on both GAG release by murine femoral head 
explants and primary murine chondrocyte phenotype following stimulation with 
catabolic and anabolic cytokines. 
 Immunostaining for TRIM32 and ASTN2, the protein-coding genes within the 
recombination hotspot at the 9q33.1 locus associated with OA in female patients, 
demonstrated expression of TRIM32, but not ASTN2, in the superficial and mid zones 
of articular cartilage of the knee; TRIM32 expression was also observed in human 
femoral head cartilage. Western blot analysis demonstrated reduced expression of 
TRIM32 in human femoral head primary articular chondrocytes from patients with hip 
OA compared to control patients (p = 0.03). 
 The total GAG content of femoral head explants from WT and Trim32-/- mice 
was similar. Significantly greater GAG release occurred in femoral head explants from 
Trim32-/- mice after no stimulation (p = 0.04 WT vs KO) and IL1α treatment (p = 0.02 
WT vs KO), but was most marked following treatment with RA (p = 0.003 WT vs KO). 
 Trim32 expression by WT primary murine chondrocytes was reduced following 
treatment with OSM (p = 0.0002) and IGF (p = 7.92 x 10-6), but not IL1α or TNFα. 
Unstimulated Trim32-/- primary murine chondrocytes expressed reduced Col2a1 (p = 
8.53 x 10-5 WT vs KO), and increased Acan, Col10a1, and Sox9 compared to WT 
primary murine chondrocytes (Acan: p = 0.001; Col10a1: p = 2.18 x 10-5, Sox9: p = 2.35 
x 10-6 WT vs KO). Upon treatment with IL1α, Trim32-/- primary murine chondrocytes 
expressed increased Col10a1 mRNA (p = 0.0003 WT vs KO). Upon OSM and IGF1 
stimulation, Trim32-/- primary murine chondrocytes expressed increased Col2a1 (OSM: 
p = 0.001; IGF: p = 0.0001 WT vs KO). Following IGF1 stimulation, Trim32-/- primary 
murine chondrocytes expressed reduced Sox9 (IGF: p = 0.0007 WT vs KO). 
 These results indicate that altered TRIM32 expression by primary human 
articular chondrocytes may be associated with OA, and that Trim32 knockout may be 
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associated with increased GAG release in stimulated murine femoral head cartilage 
explants. Finally, Trim32 deficiency may be associated with increased expression of 
genes associated with chondrocyte hypertrophy following catabolic cytokine 
stimulation, and dysregulation of Col2a1 and Sox9 expression upon anabolic cytokine 
stimulation. 
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4.2 Introduction 
In Chapter 3, DNA sequencing studies identified genetic variants within TRIM32 that 
are present at a disproportionate frequency in association with hip OA in female 
patients, implicating a role for TRIM32 in the aetiopathogenesis of OA in humans. The 
majority of genes studied following implication in the development of OA by GWAS 
(see Tables 1.1 and 1.2) have been demonstrated as expressed in human articular 
cartilage. However, the expression and role of TRIM32 in articular tissue is not known. 
The overall aim of the experiments described in this chapter was to investigate the 
expression of TRIM32 in human and murine articular tissue ex vivo, and to investigate 
the effect of Trim32 knockout on both the integrity of murine articular cartilage and the 
response of Trim32-deficient primary murine chondrocytes to catabolic and anabolic 
cytokine stimulation. 
 The expression of TRIM32 in human articular knee and femoral head cartilage is 
evaluated by immunostaining of cartilage sections from joint explants. The expression 
of ASTN2, the other protein-coding gene within the recombination hotspot at the 9q33.1 
OA susceptibility locus, is also examined. Western blot analysis of TRIM32 expression 
by primary articular chondrocytes from femoral head cartilage from female patients with 
hip OA and control patients is evaluated to determine any alteration in TRIM32 
expression associated with hip OA. 
 The effect of Trim32 knockout on the integrity of articular cartilage is 
investigated by measuring GAG release, as a surrogate marker of aggrecanolysis, by 
femoral head explants from WT and Trim32 KO mice. GAG content of femoral head 
explants and conditioned media are both measured to enable comparison of the 
percentage GAG release by femoral head explants from WT and Trim32 KO mice. GAG 
release is assessed in response to no stimulation, and treatment with IL1α or RA, two 
potent inducers of aggrecanolysis. 
 Finally, the phenotype of primary articular chondrocytes from WT and Trim32 
KO mice is evaluated by measuring gene expression following stimulation with 
catabolic and anabolic cytokines. Expression of Col2a1 and Acan (the main components 
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of healthy articular cartilage), Col10a1 (a marker of hypertrophic chondrocytes in OA 
cartilage), and Sox9 (a transcriptional regulator of the chondrocyte phenotype) is 
measured by qPCR in response to stimulation with catabolic cytokines, IL1α, TNFα, or 
OSM, and the anabolic cytokine IGF1.  
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4.3 Aims 
The aims of the experiments described in this chapter were to: 
1. Investigate the expression of TRIM32 in human articular cartilage, and to 
determine whether TRIM32 expression is altered in articular cartilage from 
female patients with OA of the hip. 
2. Investigate the effect of TRIM32 on the integrity of articular cartilage in 
vitro, by measuring GAG release by femoral head explants from Trim32 KO 
mice. 
3. Evaluate the effect of Trim32 knockout on chondrocyte phenotype in vitro, 
by measuring gene expression by primary chondrocytes from Trim32 KO 
mice following catabolic and anabolic cytokine stimulation. 
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4.4 Results 
4.4.1 Immunostaining for TRIM32 and ASTN2 in human articular cartilage 
4.4.1.1 Immunostaining for TRIM32 in human knee joint cartilage 
To investigate TRIM32 expression in human articular tissue, protein expression was 
initially investigated in human knee joint samples. To investigate whether or not 
TRIM32 protein was expressed in articular cartilage, immunostaining for TRIM32 was 
performed in archival human knee joint cartilage samples (Figure 4.1); TRIM32 
expression was detected in knee joint cartilage. Positive staining was demonstrated in 
chondrocytes of the articular cartilage of the knee joint (indicated by arrows in Figures 
4.1D and 4.1E). 
  
Chapter 4 – The role of TRIM32 in human and murine articular tissue ex vivo 
 120 
A    B    C 
   
D    E 
  
Figure 4.1 – Immunostaining of TRIM32 in human knee joint cartilage; TRIM32 protein expression 
was assessed in knee joint cartilage from human patients. Immunostaining signals for TRIM32 were 
visualised using DAKO Envision with HRP-linked secondary antibodies, and slides were counterstained 
with haematoxylin blue. Panel A shows negative control using murine serum in place of the primary 
antibody to demonstrate lack of non-specific staining, panel B demonstrates TRIM32 immunostaining of 
human renal tissue (negative control using primary antibody), panel C shows TRIM32 immunostaining of 
human ovarian tissue (positive control using primary antibody), panel D shows TRIM32 immunostaining 
of human knee cartilage, and panel E shows TRIM32 immunostaining of chondrocytes within human 
knee cartilage (high magnification). Arrows indicate positive staining for TRIM32 in photomicrographs of 
representative knee joint cartilage sections. Scale bars in panel A-D represent 50 μm, and the scale bar in 
panel E represents 25 μm. 
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4.4.1.2 Immunostaining for ASTN2 in human knee joint cartilage 
ASTN2 resides on the opposite strand to TRIM32 at the 9q33.1 locus in humans. It was 
therefore important to also determine the expression of ASTN2 in human articular 
tissue. ASTN2 expression was investigated using sections from the same human knee 
joint samples used to investigate the expression of TRIM32 (Figure 4.2). Positive 
immunostaining for ASTN2 was not identified in cartilage section from human knee 
joint samples (Figure 4.2D). 
 
 
A     B 
   
C     D 
  
     
Figure 4.2 – Immunostaining for ASTN2 in human knee joint cartilage; ASTN2 protein expression 
was assessed in knee joint cartilage from human patients. Immunostaining signals for ASTN2 were 
visualised using DAKO Envision with HRP-linked secondary antibodies, and slides were counterstained 
with haematoxylin blue. Panel A shows negative control using murine serum in place of the primary 
antibody to demonstrate lack of non-specific staining, panel B demonstrates ASTN2 immunostaining of 
human colon tissue (negative control), panel C shows ASTN2 immunostaining of human renal tissue 
(positive control), and panel D shows ASTN2 immunostaining of human knee cartilage. Scale bars in 
panels A-C represent 50 μm, and the scale bar in panel D represents 25 μm. 
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4.4.1.3 Immunostaining for TRIM32 in human femoral head cartilage 
As the 9q33.1 locus at which TRIM32 resides in humans was associated with the 
development of hip OA in the arcOGEN study, TRIM32 expression was then assessed 
by immunostaining of human femoral head cartilage samples from the hip joint (Figure 
4.3). Positive staining was also demonstrated in sections of femoral head cartilage, with 
positive staining for TRIM32 identified in primary articular chondrocytes (indicated by 
arrows in Figures 4.3D and 4.3E). 
A    B    C 
   
D    E 
  
Figure 4.3 – Immunostaining for TRIM32 in human femoral head cartilage; TRIM32 protein 
expression was assessed in femoral head cartilage from human patients. Immunostaining signals for 
TRIM32 were visualised using DAKO Envision with HRP-linked secondary antibodies, and slides were 
counterstained with haematoxylin blue. Panel A shows negative control using murine serum in place of 
the primary antibody to demonstrate lack of non-specific staining, panel B demonstrates TRIM32 
immunostaining of human colon tissue (negative control using primary antibody), panel C shows TRIM32 
immunostaining of human ovarian tissue (positive control using primary antibody), panel D shows 
positive TRIM32 immunostaining of femoral head articular cartilage (arrows) in human hip cartilage 
sections, and panel E show TRIM32 immunostaining of chondrocytes within human femoral head 
cartilage (high magnification). Arrows indicate positive staining for TRIM32 in photomicrographs of 
representative femoral head cartilage sections. Scale bars in panel A-D represent 50 μm, and the scale bar 
in panel E represents 25 μm.  
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4.4.2 Western blot analysis of TRIM32 expression in human femoral head 
primary articular chondrocytes 
To further evaluate the expression of TRIM32 protein in human articular cartilage, the 
expression levels of TRIM32 in cultured human femoral head primary articular 
chondrocytes was assessed by Western blot analysis. The expression levels of TRIM32 
were compared between cultured femoral head primary articular chondrocytes from 
control patients (patients undergoing hip arthroplasty for acute fractured neck of femur 
and without previous hip pain, or medical comorbidities or treatments that may affect 
chondrocyte metabolism (see section 2.2.1)) and patients with severe hip OA 
undergoing total hip arthroplasty (Figure 4.4). Patients were matched for age (control 
patients 72.3 ± 7.76 years, hip OA patients 67.7 years ± 8.66 years; p = 0.35) and gender 
(all patients were female). 
 TRIM32 expression was detected in primary femoral head articular chondrocytes 
from both control patients and patients with hip OA (Figure 4.4A). Densitometry 
analysis demonstrated that TRIM32 protein expression was significantly lower in 
primary femoral head articular chondrocytes from patients with hip OA compared to 
control patients (control patients 12.2 ± 6.1% relative to β-Actin expression, hip OA 
patients 6.5 ± 3.0%; p = 0.03). However, this should be reviewed with caution as the 










Figure 4.4 – TRIM32 protein expression in human femoral head primary articular chondrocytes; 
protein detection by chemiluminescence following Western blotting of protein extracts from cultured 
human femoral head primary articular chondrocytes. Panel A shows images captured upon 
chemiluminescent detection of TRIM32 (36 kDa) and β-Actin (42 kDa) in patients without OA (controls; 
n = 6) and patients with hip OA (OA cases; n = 6). Panel B shows densitometry analysis of TRIM32 
expression by human femoral head primary articular chondrocytes detected in Panel A, normalised against 
β-Actin expression levels. Lines represent mean ± SD. Statistical analysis of relative TRIM32 expression 
levels in human femoral head primary articular chondrocytes between control patients and hip OA 
patients was performed by Student’s t-Test, with statistical significance accepted at p < 0.05: *p = 0.03 
compared to control patients. 
  
Chapter 4 – The role of TRIM32 in human and murine articular tissue ex vivo 
 125 
4.4.3 Aggrecanolysis in femoral head explants from Trim32 knockout mice 
Proteolytic cleavage of ACAN, the most abundant species of proteoglycan in cartilage, 
is a key event in the pathogenesis of OA. To investigate any effect of Trim32 knockout 
on enzymatic degradation of ACAN in vitro, aggrecanolysis was estimated using 
femoral head explants from 3-week old WT and Trim32 KO mice after treatment with 
no stimulation, IL-1α, or RA (see section 2.2.6); murine proximal femoral epiphyses are 
entirely cartilaginous at this age. GAG release was measured, as a surrogate marker of 
aggrecanolysis, in femoral head explant cultures from WT and Trim32 KO mice. The 
total GAG content of femoral head explants from WT and Trim32 KO mice was 
determined by measuring and summing the GAG content of femoral head explants and 
the quantity of GAG released into culture media after each treatment. Finally, the 
proportion of GAG released into media as a percentage of the total GAG content of 
femoral heads was calculated for explants from WT and Trim32 mice after treatment 
with no stimulation, IL-1α, or RA (see sections 2.2.6, 2.2.7, and 2.2.8). 
 
4.4.3.1 Total glycosaminoglycan content of femoral head explants from Trim32 
knockout mice 
To determine whether or not GAG release upon cytokine stimulation by femoral head 
explants was different between WT and Trim32 KO mice, it was important to first 
establish whether or nor there was any difference in the initial total GAG content of 
femoral head explants from WT and Trim32 KO mice. The total GAG content of 
femoral heads from WT and Trim32-/- mice was determined by summing the GAG 
content of femoral head explants with the corresponding values for quantity of GAG 
released into culture media for each sample. Importantly, there was no difference in the 
total GAG content of unstimulated femoral heads from WT and Trim32-/- mice (WT 
100.6 ± 10.7 µg, KO 101.2 ± 11.3 µg; p = 0.94 (Figure 4.5)). There was also no 
significant difference in the total GAG content of femoral heads from WT and Trim32-/- 
mice after treatment with either IL1α (WT 89.3 ± 2.4 µg, KO 107.8 ± 20.1 µg; p = 0.12) 
or RA (WT 94.1 ± 14.7 µg, KO 87.5 ± 7.7 µg; p = 0.45 (Figure 4.5). This indicates that 
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the GAG content of femoral head explants from immature Trim32-/- mice is equivalent 
to that of WT mice. 
 
  
Figure 4.5 – Total glycosaminoglycan content of femoral heads from wild type (WT) and Trim32-/- 
(KO) mice following treatment with no stimulation, IL1α or retinoic acid; total glycosaminoglycan 
(GAG) content of pairs of femoral heads was assessed in WT (n = 4) and Trim32-/- mice (n =4). Absolute 
values (lines represent mean ± SD) for total GAG content of femoral heads from WT and Trim32-/- mice 
are shown, as assessed using the DMMB dye-binding assay. Total GAG content of femoral heads was 
determined by summing the GAG content of femoral head explants with GAG released into media by 
femoral head explants, for each sample. Total GAG content of femoral heads was assessed following 
treatment with no stimulation (unstimulated), 10 ng/ml IL1α, or 10 µM retinoic acid for 72 hours. 
Statistical analysis of total GAG content of femoral heads between WT and Trim32-/- mice groups was 
performed by two-tailed Student’s t-Test, with statistical significance accepted at p < 0.05. 
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4.4.3.2 Glycosaminoglycan retention and release by femoral head explants from 
Trim32 knockout mice 
To establish the proportion of GAG release upon cytokine stimulation by femoral head 
explants from WT and Trim32 KO mice, the quantity of GAG retained and released by 
femoral head explants from WT and Trim32 KO mice was measured. The quantity of 
GAG retained by femoral head explants from WT and Trim32 KO (Trim32-/-) mice was 
assessed following treatment with no stimulation, IL-1α, or RA. There was no 
difference in the quantity of GAG retained by femoral head explants from WT or 
Trim32-/- mice, either after no stimulation (mean ± SD: WT 88.4 ± 10.4 µg, KO 78.4 ± 
4.3 µg; p = 0.13) or treatment with IL-1α (WT 42.6 ± 1.6 µg, KO 35.7 ± 8.1 µg; p = 
0.15 (Figure 4.6A)). However, GAG retention by femoral head explants from Trim32-/- 
mice was significantly lower compared to that of WT mice, after treatment with RA 
(WT 66.7 ± 15.5 µg, KO 30.9 ± 8.7 µg; Mann-Whitney U test p = 0.03 (Shapiro-Wilk 
Test for GAG content in WT group p = 0.04; Figure 4.6A)). 
 
The quantity of GAG released into culture media by femoral head explants from 
WT and Trim32 KO (Trim32-/-) mice was then assessed following treatment with no 
stimulation, IL-1α, or RA. There was no difference in the quantity of GAG released by 
femoral head explants from WT and Trim32-/- following no stimulation (WT 12.3 ± 0.7 
µg, KO 22.8 ± 10.0 µg; p = 0.08 (Figure 4.6B)), or following stimulation with IL1α 
(WT 46.8 ± 1.3 µg, KO 72.1 ± 18.6 µg; Mann-Whitney U test p = 0.34 (Shapiro-Wilk 
Test for GAG release in KO group p = 0.016; Figure 4.6B)). The quantity of GAG 
released by femoral head explants from both WT and Trim32-/- mice was greater 
following treatment with RA, compared with no stimulation (Figure 4.6B). GAG release 
was significantly greater by femoral head explants from Trim32-/- mice compared to WT 











Figure 4.6 – Glycosaminoglycan retention and release by femoral head explants from wild type 
(WT) and Trim32-/- (KO) mice following treatment with no stimulation, IL1α or retinoic acid; 
glycosaminoglycan (GAG) retention (panel A) and release (panel B) by pairs of femoral head explants 
were assessed in WT (n = 4) and Trim32-/- mice (n =4). Absolute values (lines represent mean ± SD) for 
GAG quantity retained and released by femoral head explants from WT and Trim32-/- mice are shown, as 
assessed using the DMMB dye-binding assay. Femoral head explants and conditioned media were 
assessed for GAG content following treatment with no stimulation (unstimulated), 10 ng/ml IL1α, or 10 
µM retinoic acid (RA) for 72 hours. Statistical analysis of GAG retention and release by femoral head 
explants between WT and Trim32-/- mice groups was performed by two-tailed Student’s t-Test, except for 
comparison of GAG content of femoral head explants between WT and Trim32-/- mice groups following 
treatment with RA as data for the WT group deviated from normal distribution (Shapiro-Wilk Test p = 
0.044) and comparison of GAG release by femoral head explants between WT and Trim32-/- mice groups 
following treatment with IL1α that was analysed by Mann-Whitney U test as data for the Trim32-/- group 
deviated from normal distribution (Shapiro-Wilk Test p = 0.016): statistical significance was accepted at p 
< 0.05, *p = 0.03 compared to WT mice; **p = 0.0005 compared to WT mice. 
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4.4.3.3 Relative glycosaminoglycan release by femoral head explants from Trim32 
knockout mice 
The quantity of GAG retained and released upon cytokine stimulation by femoral head 
explants from WT and Trim32 KO mice was then used to determine the proportion of 
GAG release into culture media by the femoral head explants after each stimulation. The 
proportion of GAG released into culture media by femoral head explants upon treatment 
with no stimulation, IL1α, or RA was compared between WT and Trim32-/- mice 
(Figure 4.7). Significantly greater GAG was released by unstimulated femoral head 
explants from Trim32-/- compared with WT mice (WT 12.3 ± 1.0 %, KO 22.0 ± 7.1 %; p 
= 0.04). Significantly greater GAG release by femoral head explants from Trim32-/- 
compared with WT mice, was also identified following treatment with IL1α (WT 52.4 ± 
0.9 %, KO 66.2 ± 8.5 %; p = 0.02). Significantly greater GAG release was also 
demonstrated in femoral head explants from Trim32-/- compared with WT mice, upon 
treatment with RA (WT 29.6 ± 9.5 %, KO 65.1 ± 7.3 %; p = 0.003 (Figure 4.7)). 
The increased proportion of GAG released by femoral head explants from 
Trim32-/- compared with WT mice was particularly exaggerated following treatment 
with RA (Figure 4.7). The difference between the percentage GAG release by femoral 
head explants from Trim32-/- mice compared with WT mice was more significant in 
response to treatment with RA compared to unstimulated controls or following IL1α 
stimulation (WT v KO, unstimulated p = 0.04; WT v KO, IL1α stimulation p = 0.02; 
WT v KO, RA stimulation p = 0.003). 
 These results indicate that GAG loss, as an indicator of aggrecanolysis and a key 
event in the pathogenesis of OA, is significantly greater in Trim32-/- mice compared 
with WT mice in vitro. These results also indicate that the increased GAG release by 
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Figure 4.7 – Percentage glycosaminoglycan release by femoral head explants from wild type (WT) 
and Trim32-/- (KO) mice following treatment with no stimulation, IL1α or retinoic acid; percentage 
glycosaminoglycan (GAG) release by pairs of femoral head explants was assessed in WT (n = 4) and 
Trim32-/- mice (n =4). Absolute values (lines represent mean ± SD) for percentage GAG release by 
femoral heads from WT and Trim32-/- mice are shown, as assessed using the DMMB dye-binding assay. 
Percentage GAG release was determined by dividing the GAG content of conditioned media by the total 
GAG content of femoral head explants, for each sample. Percentage GAG release by femoral head 
explants was assessed following treatment with no stimulation (unstimulated), 10 ng/ml IL1α, or 10 µM 
retinoic acid for 72 hours. Statistical analysis of percentage GAG release by femoral head explants 
between WT and Trim32-/- mice groups and treatment groups was performed by two-way ANOVA with 
post-hoc Tukey tests: statistical significance was accepted at p < 0.05, * p = 0.04 (Unstimulated WT vs 
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4.4.4 Trim32 expression in primary chondrocytes from wild type mice following 
catabolic and anabolic cytokine stimulation 
To further investigate whether or not Trim32 has a role in chondrocyte metabolism, the 
expression of Trim32 in primary chondrocytes from WT mice was investigated 
following stimulation with catabolic and anabolic cytokines. In OA cartilage, 
chondrocytes show a dysregulated expression of catabolic and anabolic genes, resulting 
in imbalanced homeostasis. IL1, TNFα, and OSM are particularly implicated in the 
degradation of articular cartilage in OA and induction of catabolic responses by 
chondrocytes (159, 430). IGF1 is an anabolic cytokine that stimulates proteoglycan 
production by chondrocytes (431). The expression of Trim32 mRNA by primary 
chondrocytes from WT mice was assessed in response to no stimulation, and following 
stimulation with catabolic (IL1α, TNFα, and OSM) and anabolic (IGF1) cytokines. 
 The expression of Trim32 in primary chondrocytes from WT mice following 
treatment with IL1α, TNFα, OSM, and IGF1 was compared to Trim32 expression in 
unstimulated primary chondrocytes from WT mice (Figure 4.8). There was no 
difference in Trim32 mRNA expression in primary chondrocytes from WT mice after 
treatment with either IL1α (p = 0.78) or TNFα (p = 0.58). Significantly reduced Trim32 
mRNA expression by primary chondrocytes from WT mice was demonstrated following 
treatment with both OSM (Figure 4.8, p = 0.0002; mean ± SD: 70.33 ± 4.04% compared 
to unstimulated controls) and IGF1 (p = 7.92 x 10-6; 66.00 ± 2.00% compared to 
unstimulated controls). 
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Figure 4.8 – Trim32 mRNA expression in primary chondrocytes from wild type mice following 
treatment with IL1α, TNFα, Oncostatin-M (OSM), or IGF1; quantitative reverse transcription-
polymerase chain reaction was used to measure Trim32 mRNA expression in primary murine 
chondrocytes from wild-type (WT) mice following treatment with IL1α (10 ng/ml), TNFα (100 ng/ml), 
OSM (100 ng/ml), or IGF1 (100 ng/ml) for 48 hours. Trim32 mRNA expression levels are expressed 
relative to Trim32 mRNA levels in unstimulated primary murine chondrocytes (controls) after 48 hours’ 
culture and were calculated from ∆∆Ct values. Absolute values (lines represent mean ± SD) for percentage 
Trim32 mRNA expression compared to unstimulated controls are shown for each experiment (n = 3 
replicates from independent experiments for each group). Ct values are shown (mean ± SD). Statistical 
analysis of Trim32 expression levels between cytokine-treated and unstimulated primary chondrocytes 
was performed by two-tailed Student’s t-Test: after Bonferroni correction for multiple tests, statistical 
significance was accepted at p < 0.0025, ***p = 0.0002 (OSM stimulation, compared to unstimulated 
controls), ***p = 7.92 x 10-6 (IGF1 stimulation, compared to unstimulated controls). 
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4.4.5 Gene expression by primary chondrocytes from Trim32 knockout mice 
following catabolic and anabolic cytokine stimulation 
In previous sections 4.4.3 and 4.4.4, increased GAG release by femoral head cartilage 
explants, and reduced expression of Trim32 by primary chondrocytes in response to 
catabolic and anabolic cytokines from Trim32 KO mice compared to WT mice in 
response to catabolic and anabolic cytokines, was demonstrated. To investigate whether 
or not Trim32 deficiency affects the phenotype of primary chondrocytes, the expression 
of Col2a1, Acan, Col10a1, and Sox9 mRNA was assessed in comparison to that by 
primary chondrocytes from WT mice, following treatment with no stimulation, catabolic 
(IL1α, TNFα, and OSM), and anabolic (IGF1) cytokines. Col2a1 and Acan encode Col 
II and ACAN, respectively, which are the two major macromolecules in the ECM 
synthesised by healthy mature chondrocytes (432). Col10a1 encodes Col X, which is a 
marker of hypertrophic chondrocytes present in the growth plate and osteoarthritic 
cartilage (433). Sox9 encodes a transcription factor that regulates the chondrocyte 
phenotype and controls the expression of genes encoding important proteins of the 
ECM, including Col II, ACAN, and COMP (434).  
 
4.4.5.1 Gene expression by unstimulated primary chondrocytes from Trim32 
knockout mice 
The expression of Col2a1, Acan, Col10a1, and Sox9 by unstimulated primary 
chondrocytes from WT and Trim32-/- mice was assessed. This permitted analysis of gene 
expression in unstimulated basal conditions, and also provided baseline gene expression 
levels from which changes in gene expression, after cytokine stimulation of primary 
chondrocytes from WT and Trim32-/- mice, could subsequently be compared. Gene 
expression by unstimulated primary chondrocytes from WT and Trim32-/- KO mice is 
shown in Figure 4.9; the expression of Col2a1, Acan, Col10a1, and Sox9 are normalised 
to the expression of GAPDH, a stable reference gene in chondrocyte cultures (435). In 
unstimulated conditions, Col2a1 mRNA expression was significantly lower by 
chondrocytes from Trim32-/- mice compared to the expression by chondrocytes from 
WT mice (Figure 4.9, WT 119 ± 12.69 %, KO 0.98 ± 0.16 %; p = 8.53 x 10-5 WT vs 
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KO). The expression of Acan, Col10a1, and Sox9 mRNA were all significantly greater 
by chondrocytes from Trim32-/- mice compared to their expression by chondrocytes 
from WT mice, as shown in Figure 4.9 (Acan: WT 1.63 ± 0.33 %, KO 5.46 ± 0.84 %, p 
= 0.001 WT vs KO; Col10a1: WT 3.19 ± 0.50 %, KO 28.73 ± 1.87 %, p = 2.18 x 10-5 
WT vs KO; Sox9: WT 42 ± 1.15 %, KO 103.64 ± 2.41 %, p = 2.35 x 10-6 WT vs KO). 
These results indicate that immature primary chondrocytes harvested from femoral head 
epiphyses from Trim32 KO mice may express significantly different levels of Col2a1, 
Acan, Col10a1, and Sox9, compared to those from WT mice (Figure 4.9). 
 
  
Chapter 4 – The role of TRIM32 in human and murine articular tissue ex vivo 
 135 
 Figure 4.9 – Gene expression by unstimulated primary chondrocytes from wild type (WT) and 
Trim32-/- (KO) mice; quantitative reverse transcription-polymerase chain reaction was used to measure 
Col2a1, Acan, Col10a1, and Sox9 mRNA expression by primary chondrocytes from WT and Trim32-/- 
mice following treatment with no stimulation for 48 hours. Col2a1, Acan, Col10a1, and Sox9 mRNA 
expression are displayed relative to GAPDH mRNA expression levels in primary chondrocytes from wild 
type and Trim32-/- mice treated with no stimulation for 48 hours, and were calculated from ∆∆Ct values. 
Values (lines represent mean ± SD) for mRNA expression compared to GAPDH mRNA expression levels 
are shown for each experiment (n = 3 replicates from independent experiments for each group). Ct values 
are shown (mean ± SD). Statistical analysis of mRNA expression of differentiation markers between 
primary chondrocytes from WT and Trim32-/- mice was performed by two-tailed Student’s t-Test: after 
Bonferroni correction for multiple tests, statistical significance was accepted at p < 0.0025, **p = 0.001 
(Acan, WT vs KO), ***p = 8.53 x 10-5 (Col2a1, WT vs KO), ***p = 2.18 x 10-5 (Col10a1, WT vs KO), 
***p = 2.35 x 10-6 (Sox9, WT vs KO). 
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4.4.5.2 Gene expression by primary chondrocytes from Trim32 knockout mice 
following treatment with IL1α 
In the previous section 4.4.5.1, significantly different expression of Col2a1, Acan, 
Col10a1, and Sox9 was demonstrated by primary chondrocytes from Trim32 KO mice, 
compared to those isolated from WT mice. To investigate whether or not Trim32 
deficiency affects the change in chondrocyte phenotype in response to catabolic or 
anabolic cytokines, the change in expression of these genes was measured by qPCR 
following stimulation with IL1α, TNFα, OSM, and IGF1 in primary chondrocytes from 
Trim32 KO mice and WT mice. To control for basal gene expression levels following 
different stimulations, changes in target gene expression, established using the ‘delta-
delta Ct’ method, were normalised to any changes in expression of the stable house-
keeping gene GAPDH following different stimulations (435). 
 
The change in gene expression by primary chondrocytes from WT and Trim32 
KO mice following treatment with IL1α was compared (Figure 4.10). There was no 
significant difference in the change of expression of Col2a1 (Mann-Whitney U test p = 
0.05 (Shapiro-Wilk Tests: WT Col2a1, p = 8.5 x 10-16; KO Col2a1, p = 4.2 x 10-16)), 
Acan (Mann-Whitney U test p = 0.99 (Shapiro-Wilk Tests: WT Acan, p = 8.5 x 10-16; 
KO Acan, p = 8.5 x 10-16)), or Sox9 (Mann-Whitney U test p = 0.08 (Shapiro-Wilk Test: 
KO Sox9, p = 4.2 x 10-16)) mRNA between primary chondrocytes from WT and Trim32-
/- mice following treatment with IL1α (Figure 4.10). However, primary chondrocytes 
from Trim32-/- mice demonstrated a significantly greater expression of Col10a1 
following treatment with IL1α, compared to those from WT mice (Figure 4.10; WT 
5.33 ± 1.53 %, KO 22.33 ± 2.08 %; p = 0.0003 WT vs KO). 
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Figure 4.10 – Gene expression by primary chondrocytes from wild type (WT) and Trim32-/- (KO) 
mice following treatment with IL1α; quantitative reverse transcription-polymerase chain reaction was 
used to measure Col2a1, Acan, Col10a1, and Sox9 mRNA expression by primary chondrocytes from WT 
and Trim32-/- mice following treatment with IL1α (10 ng/ml) for 48 hours. The change in Col2a1, Acan, 
Col10a1, and Sox9 mRNA expression levels following IL1α treatment of primary chondrocytes from WT 
and Trim32-/- mice are displayed relative to unstimulated primary chondrocytes from wild type and 
Trim32-/- mice, normalised against the change in the housekeeping gene GAPDH mRNA expression upon 
IL1α treatment of primary chondrocytes from WT mice and Trim32-/- mice, and were calculated from 
∆∆Ct values. Values (lines represent mean ± SD) for mRNA expression compared to GAPDH mRNA 
expression levels are shown for each experiment (n = 3 replicates from independent experiments for each 
group). Ct values are shown (mean ± SD). Statistical analysis of mRNA expression of differentiation 
markers between primary chondrocytes from WT and Trim32-/- mice was performed by two-tailed 
Student’s t-Test, except for comparisons of groups of data deviating from a normal distribution that were 
analysed by Mann-Whitney U test including mRNA expression of Col2a1 (Shapiro-Wilk Tests: WT p = 
8.5 x 10-16, KO p = 4.2 x 10-16), Acan (Shapiro-Wilk Tests: WT p = 8.5 x 10-16, KO p = 8.5 x 10-16), and 
Sox9 (Shapiro-Wilk Tests: KO p = 4.2 x 10-16): after Bonferroni correction for multiple tests, statistical 
significance was accepted at p < 0.0025, ***p = 0.0003 (Col10a1, WT vs KO). 
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4.4.5.3 Gene expression by primary chondrocytes from Trim32 knockout mice 
following treatment with TNFα 
The change in gene expression by primary chondrocytes from WT and Trim32 KO mice 
following treatment with the catabolic cytokine TNFα was also compared (Figure 4.11). 
There was no significant difference in the change in expression of Acan (Mann-Whitney 
U test p = 0.06 (Shapiro-Wilk Tests: WT Acan, p = 8.5 x 10-16; KO Acan, p = 8.5 x 10-
16)), or Sox9 (Mann-Whitney U test p = 0.08 (Shapiro-Wilk Test: WT Sox9, p = 4.2 x 10-
16)) mRNA between primary chondrocytes from WT and Trim32-/- mice following 
treatment with TNFα (Figure 4.11). There was a near 50-fold increase in Col2a1 mRNA 
expression by primary chondrocytes from Trim32-/- mice following treatment with 
TNFα, but this did not surpass the significance threshold following Bonferroni 
correction (WT 15.33 ± 1.53 %, KO 4982 ± 1796 %; p = 0.009 WT vs KO). In contrast 
to the changes following stimulation with IL1α, another catabolic cytokine, no 
significant difference was demonstrated in the change of expression of Col10a1 by 
primary chondrocytes from Trim32-/- mice following treatment with TNFα compared to 
those from WT mice (Figure 4.11; p = 0.02). 
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Figure 4.11 – Gene expression by primary chondrocytes from wild type (WT) and Trim32-/- (KO) 
mice following treatment with TNFα; quantitative reverse transcription-polymerase chain reaction was 
used to measure Col2a1, Acan, Col10a1, and Sox9 mRNA expression by primary chondrocytes from WT 
and Trim32-/- mice following treatment with TNFα (100 ng/ml) for 48 hours. The change in Col2a1, 
Acan, Col10a1, and Sox9 mRNA expression levels following TNFα treatment of primary chondrocytes 
from WT and Trim32-/- mice are displayed relative to unstimulated primary chondrocytes from WT and 
Trim32-/- mice, normalised against the change in the housekeeping gene GAPDH mRNA expression upon 
TNFα treatment of primary chondrocytes from WT mice and Trim32-/- mice, and were calculated from 
∆∆Ct values. Values (lines represent mean ± SD) for mRNA expression compared to GAPDH mRNA 
expression levels are shown for each experiment (n = 3 replicates from independent experiments for each 
group). Ct values are shown (mean ± SD). Statistical analysis of mRNA expression of differentiation 
markers between primary chondrocytes from WT and Trim32-/- mice was performed by two-tailed 
Student’s t-Test, except for comparisons of groups of data deviating from a normal distribution that were 
analysed by Mann-Whitney U test including mRNA expression of Acan (Shapiro-Wilk Tests: WT p = 8.5 
x 10-16, KO p = 8.5 x 10-16), and Sox9 (Shapiro-Wilk Test: WT p = 4.2 x 10-16); after Bonferroni correction 
for multiple tests, statistical significance was accepted at p < 0.0025. 
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4.4.5.4 Gene expression by primary chondrocytes from Trim32 knockout mice 
following treatment with OSM 
The change in gene expression by primary chondrocytes from WT and Trim32 KO mice 
following treatment with the catabolic cytokine OSM was assessed (Figure 4.12). 
No significant difference was observed in the change in Acan (p = 0.006), 
Col10a1 (Mann-Whitney U test p = 0.99 (Shapiro-Wilk Test: WT Col10a1, p = 8.5 x 
10-16)) or Sox9 (Mann-Whitney U test p = 0.08 (Shapiro-Wilk Test: KO Sox9, p = 4.2 x 
10-16)) mRNA expression by primary chondrocytes from Trim32-/- mice following 
treatment with OSM, compared to the change seen in expression by primary 
chondrocytes from WT mice (Figure 4.12). 
There was a significantly greater change in the expression of Col2a1 mRNA by 
primary chondrocytes from Trim32-/- mice following treatment with OSM, compared to 
that seen in primary chondrocytes from WT mice (Figure 4.12; WT 27.33 ± 4.73 %, KO 
4507 ± 963 %; p = 0.001). 
 
  
Chapter 4 – The role of TRIM32 in human and murine articular tissue ex vivo 
 141 
    
Figure 4.12 – Gene expression by primary chondrocytes from wild type (WT) and Trim32-/- (KO) 
mice following treatment with Oncostatin-M (OSM); quantitative reverse transcription-polymerase 
chain reaction was used to measure Col2a1, Acan, Col10a1, and Sox9 mRNA expression by primary 
chondrocytes from WT and Trim32-/- mice following treatment with OSM (100 ng/ml) for 48 hours. The 
change in Col2a1, Acan, Col10a1, and Sox9 mRNA expression levels following OSM treatment of 
primary chondrocytes from WT and Trim32-/- mice are displayed relative to unstimulated primary 
chondrocytes from WT and Trim32-/- mice, normalised against the change in the housekeeping gene 
GAPDH mRNA expression upon OSM treatment of primary chondrocytes from WT mice and Trim32-/- 
mice, and were calculated from ∆∆Ct values. Values (lines represent mean ± SD) for mRNA expression 
compared to GAPDH mRNA expression levels are shown for each experiment (n = 3 replicates from 
independent experiments for each group). Ct values are shown (mean ± SD). Statistical analysis of mRNA 
expression of differentiation markers between primary chondrocytes from WT and Trim32-/- mice was 
performed by two-tailed Student’s t-Test, except for comparisons of groups of data deviating from a 
normal distribution that were analysed by Mann-Whitney U test including mRNA expression of Col10a1 
(Shapiro-Wilk Test: WT p = 8.5 x 10-16), and Sox9 (Shapiro-Wilk Test: KO p = 4.2 x 10-16); after 
Bonferroni correction for multiple tests, statistical significance was accepted at p < 0.0025, **p = 0.001 
(Col2a1, WT vs KO). 
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4.4.5.5 Gene expression by primary chondrocytes from Trim32 knockout mice 
following treatment with IGF1 
The change in gene expression by primary chondrocytes from WT and Trim32 KO mice 
following treatment with the anabolic cytokine IGF1, was also assessed (Figure 4.13). 
There was also no significant difference in the change in Acan (p = 0.03) or 
Col10a1 (p = 0.01) mRNA expression by primary chondrocytes from Trim32-/- mice 
following treatment with IGF1, compared to the change seen in expression by primary 
chondrocytes from WT mice (Figure 4.13). 
There was a significantly increased expression of Col2a1 mRNA by primary 
chondrocytes from Trim32-/- mice following treatment with IGF1 (approximate 250-fold 
increase), compared to that seen in primary chondrocytes from WT mice (Figure 4.13; 
WT 119.67 ± 13.05 %, KO 25974 ± 3114 %; p = 0.0001). There was also a significantly 
greater decrease in the expression of Sox9 mRNA by primary chondrocytes from 
Trim32-/- mice following treatment with IGF1, compared to that seen in primary 
chondrocytes from WT mice (Figure 4.13; WT 73 ± 3.61 %, KO 47 ± 3 %; p = 0.0007). 
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Figure 4.13 – Gene expression by primary chondrocytes from wild type (WT) and Trim32-/- (KO) 
mice following treatment with IGF1; quantitative reverse transcription-polymerase chain reaction was 
used to measure Col2a1, Acan, Col10a1, and Sox9 mRNA expression by primary chondrocytes from WT 
and Trim32-/- mice following treatment with IGF1 (100 ng/ml) for 48 hours. The change in Col2a1, Acan, 
Col10a1, and Sox9 mRNA expression levels following IGF1 treatment of primary chondrocytes from WT 
and Trim32-/- mice are displayed relative to unstimulated primary chondrocytes from WT and Trim32-/- 
mice, normalised against the change in the housekeeping gene GAPDH mRNA expression upon IGF1 
treatment of primary chondrocytes from WT mice and Trim32-/- mice, and were calculated from ∆∆Ct 
values. Values (lines represent mean ± SD) for mRNA expression compared to GAPDH mRNA 
expression levels are shown for each experiment (n = 3 replicates from independent experiments for each 
group). Ct values are shown (mean ± SD). Statistical analysis of mRNA expression of differentiation 
markers between primary chondrocytes from WT and Trim32-/- mice was performed by two-tailed 
Student’s t-Test; after Bonferroni correction for multiple tests, statistical significance was accepted at p < 
0.0025, **p = 0.0007 (Sox9, WT vs KO), ***p = 0.0001 (Col2a1, WT vs KO). 
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 The results of gene expression studies by primary chondrocytes from WT and 
Trim32 KO mice have identified that Trim32 expression was reduced in WT 
chondrocytes following OSM and IGF stimulation. Murine chondrocytes deficient of 
Trim32 expressed reduced Col2a1 and increased Acan, Col10a1, and Sox9. Finally, in 
Trim32 deficient chondrocytes, treatment with IL1α resulted in increased Col10a1 
expression, treatment with OSM resulted in increased Col2a1 expression, and treatment 
with IGF resulted in increased Col2a1 and reduced Sox9 expression. 
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4.5 Discussion 
The experiments in this chapter aimed to investigate the expression of TRIM32 in 
human and murine articular tissue ex vivo, and to investigate the effect of Trim32 
knockout on both the integrity of murine articular cartilage and the response of primary 
murine chondrocytes to catabolic and anabolic cytokine stimulation. 
Immunostaining for TRIM32 in human articular cartilage from femoral head and 
knee joint tissue demonstrated expression within chondrocytes and predominantly at the 
superficial and mid zones of articular cartilage (Figures 4.1 and 4.3). ASTN2 was not 
detected in cartilage (Figure 4.2). This is consistent with the known expression of 
ASTN2, which is expressed in brain, eye, heart, lung, liver and kidney tissue, but 
minimally expressed in other tissues including connective tissue and musculoskeletal 
tissue (231). Immunostaining intensity in cartilage may often be influenced by 
proteoglycan content of cartilage; it is not likely that proteoglycan content affected 
ASTN2 immunostaining intensity as the same cartilage samples were used for detection 
of TRIM32. PAPPA is a third protein-coding gene at the periphery of the recombination 
hotspot at the 9q33.1 OA susceptibility locus; it was not possible to detect PAPPA by 
immunostaining; the large heterotetrameric glycoprotein product (∼500 kilodaltons 
(kDa)) is only recognised in an unreduced form, which is disrupted by antigen retrieval 
techniques (436).  
The results of immunostaining for TRIM32 provide semi-quantitative evidence 
of the expression of TRIM32 in human articular cartilage, indicating expression by 
chondrocytes in the superficial and middle zones of articular cartilage (Figure 1.2). The 
abundance of chondrocytes is high in these regions, with chondrocytes more elongated 
and parallel to the articular surface in the superficial zone, whereas more typical 
spherical chondrocytes are present in the middle zones. The superficial and middle 
zones also express high levels of Col II and ACAN, respectively. 
TRIM32 was also detected by Western blot analysis of protein extracts from 
cultured femoral head articular chondrocytes from patients with hip OA undergoing 
total hip arthroplasty surgery, and from patients without hip OA (Figure 4.4A and 
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Figure 4.4B). That TRIM32 was detected in cartilage tissue by both immunostaining and 
Western blot analysis supports the finding that TRIM32 is expressed in human articular 
cartilage. Comparison of the expression levels of TRIM32, detected by Western 
blotting, by femoral head articular chondrocytes indicated that TRIM32 expression may 
be reduced in articular chondrocytes from patients with hip OA compared to patients 
without hip OA (p = 0.03; Figure 4.4A and Figure 4.4B). However, the detected 
intensity of β-actin expression appeared stronger in some samples from patients with 
OA compared to control patients (Figure 4.4A). This could confound any detected 
differences in expression of TRIM32 when the results are normalised to β-actin 
expression levels as a control, despite standardising the quantity of protein in each 
sample and controlling for background staining intensities. β-actin protein expression 
levels have previously been reported as stable between cultured human primary 
chondrocytes from normal and OA cartilage (437). Alternative reference proteins that 
may also be expressed at a consistent level by cultured human chondrocytes could 
include beta2-microglobulin (438). Alternatively, a combination of reference control 
proteins could be used (439). Therefore, although the difference in TRIM32 expression, 
as detected by Western blotting, between femoral head chondrocytes from patients with 
and without hip OA was statistically significant, these results should be viewed with 
caution. 
TRIM32 is ubiquitously expressed, and its broad range of substrate specificity 
permits a variety of functions in different tissues (440, 441). TRIM32 has been 
identified in nuclear and cytoplasmic compartments, and extracellular vesicles (442, 
443). Cell types differ in their intracellular distribution of TRIM32 expression, with 
some preferentially expressing TRIM32 in the nucleus or cytoplasm (444, 445). 
TRIM32 is recognised to migrate between intracellular compartments, though the 
nuclear import and export mechanisms for TRIM32 remain largely undetermined. In 
addition to its role as an E3 ubiquitin ligase, TRIM32 can self-associate to form 
cytoplasmic bodies that may act as a reservoir of TRIM32 to maintain appropriate levels 
of soluble free TRIM32 protein (446). TRIM32 may also autoubiquitinate to regulate its 
own intracellular availability (299). TRIM32 can control cell proliferation, motility, and 
apoptosis (447). The identification of TRIM32 expression by cultured human 
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chondrocytes, the level of which may be different between chondrocytes isolated from 
normal and OA cartilage (Figure 4.4), is an interesting finding, and further studies will 
be required to determine the role of TRIM32 in cartilage, and its mechanisms of action. 
Proteolytic cleavage of ACAN within cartilage is a fundamental step in the 
pathogenesis of OA. GAG loss, as an indicator of aggrecanolysis, was measured in 
femoral head explants from WT and Trim32 KO mice following treatment with no 
stimulation, IL1α, or RA (Figure 4.5, Figure 4.6, and Figure 4.7). The concentrations of 
IL1α and RA used were selected for maximal induction of aggrecanolysis (402). GAGs 
comprise 90% of the mass of ACAN, the most abundant of which is chondroitin 
sulphate (448). ACAN is the most abundant proteoglycan in cartilage by weight; in 
consort with Col II it provides cartilage with resistance to mechanical load (448). The 
protein core of ACAN comprises G1 and G2 globular domains at the N terminus, and a 
G3 domain at the C terminus. ACAN is stabilised in the cartilage matrix by binding HA 
through its G1 domain (449). The interval between the G2 and G3 domains contains 
hydrophilic GAGs, providing osmotic swelling pressure that confers cartilage with its 
compressive strength (449). 
 Aggrecanolysis occurs most significantly at the interval between the G1 and G2 
domains of ACAN, termed the interglobular domain (IGD) (448). Aggrecanolysis is 
primarily mediated by neutral proteinases including MMPs such as MMP3 and MMP13, 
and the aggrecanases ADAMTS4 and ADAMTS5. The MMPs and aggrecanases 
preferentially act at distinct sites within the IGD of ACAN. However, the processes that 
activate MMPs and aggrecanases in osteoarthritic cartilage are not fully known. 
 The results of GAG release by femoral head explants from Trim32 KO mice 
indicate greater loss of GAG associated with Trim32 deficiency in unstimulated 
conditions, and following IL1α stimulation, but most marked upon stimulation with RA 
(Figure 4.7).  That the total GAG content of femoral heads from WT and Trim32 KO 
mice was similar in each experiment indicates that GAG synthesis is not affected by 
Trim32 KO (Figure 4.5). Furthermore, that relative GAG release by femoral head 
explants was significantly greater for explants from Trim32 KO mice after each 
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stimulation may indicate that Trim32 deficiency is associated with dysregulation of 
GAG turnover (Figure 4.7). These results complement the findings from the Western 
blot analysis of TRIM32 expression by femoral head chondrocytes from patients with 
hip OA, in which reduced TRIM32 expression was demonstrated in samples from 
patients with OA (Figure 4.4). 
It is interesting that relative GAG release was most marked following RA 
stimulation, as Trim32 has previously been shown to function as a co-activator for 
RARα-mediated transcription (450). TRIM32 physically interacts with RARα and 
enhances RA-dependent RARα-mediated transcriptional activity in a dose-dependent 
manner. Nuclear RARs are both positively and negatively influenced by Wnt/β-catenin 
signalling in a variety of cell types. RA signalling is an established mechanism 
regulating skeletogenesis and cartilage homeostasis ((451-453). During chondrogenesis, 
genes encoding RARs demonstrate specific spatiotemporal expression patterns (454). 
RA may significantly influence cartilage matrix homeostasis by stimulating its synthesis 
or degradation, and also chondrocyte phenotype (452, 455, 456). Dysregulation of RA 
signalling can therefore lead to cartilage degradation. 
RA stimulates Wnt/β-catenin signalling in chondrocytes and thereby increases 
the expression of Wnt proteins and receptors. Wnt/β-catenin signalling is another 
regulator of cartilage matrix synthesis and degradation by chondrocytes (457). 
Stimulation of Wnt/β-catenin signalling downregulates expression of ACAN, Col II and 
Col IX by chondrocytes and increases their production of matrix proteases, resulting in 
matrix loss in cartilage (458), RARγ can differentially regulate Wnt/β-catenin signalling 
in chondrocytes dependent upon RA ligand availability (459, 460). Wnt/β-catenin and 
RA signalling may therefore act together to mediate chondrocyte function and 
phenotype. 
The Wnt/β-catenin signalling pathway is also a key pathway mediated by 
protein-inhibitor of activated STAT3 (Pias3). Mammalian cells contain four members of 
the Pias family. These ligases bring reactants in close proximity and promote increased 
isopeptide bond formation. In mammalian cells, S-nitrosation by nitric oxide promotes 
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Pias3 degradation by facilitating its interaction with TRIM32 (461, 462). Pias3 
degradation is protective against joint destruction in arthritis by reducing activation of 
fibroblast-like synoviocytes and reducing their expression of MMP3, MMP9, and 
MMP13. It is unknown whether similar mechanisms exist in chondrocytes. The results 
described in this chapter, whereby reduced Trim32 expression was associated with 
increased GAG release may support similar mechanisms in chondrocytes and cartilage.  
 There are strengths and limitations of assessing aggrecanolysis in cartilage by 
measuring GAG loss using the DMMB dye-binding assay. GAGs comprise 
approximately 90% of the mass of ACAN, of which chondroitin sulphate is the most 
abundant. ACAN concentration is most commonly estimated by measuring sulphated 
GAG concentration of cartilage and media as surrogate markers of ACAN 
concentration. The DMMB assay has the advantage of measuring the concentration of 
sulphated GAGs and does not detect unsulphated GAGs such as HA, which is also 
relatively abundant in cartilage. One limitation of the DMMB assay is the gradual 
precipitation of dye/GAG complexes; this was avoided by immediate analysis of 
reactions. The DMMB assay is usually normalised to wet weight of the tissue under 
investigation if large tissue volumes are utilised. However, with murine cartilage, very 
small volumes of residual liquid can alter the tissue weight significantly, leading to 
detection errors. Therefore, normalisation of murine cartilage in the experiments in this 
chapter was performed as a proportion of total GAG content; this is more accurate than 
using wet weight as a denominator for tissue such as murine cartilage (402). 
 Aggrecanolysis can also be measured by other methods. The uronic acid assay 
and alcian blue assay may be used to estimate GAG content. However, these assays may 
also detect HA, and are more labour intensive (463). The traditional DMMB assay 
measures the concentration of sulphated GAGs as an indication of the actual ACAN 
concentration. Comparison of the results of the DMMB assay between the conditioned 
media and cartilage explants, therefore, measures relative GAG concentration, and does 
not directly measure aggrecanolysis. A more accurate determination of aggrecanolysis 
in cartilage explant cultures can be achieved by Western blotting to identify ACAN 
fragments following ADAMTS-mediated aggrecanolysis using neoepitope antibodies, 
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which have been validated in murine cartilage (402). Neoepitope antibodies recognise 
the newly generated N-terminus and C-terminus of ACAN fragments following 
proteolysis. To achieve a comprehensive analysis of ADAMTS-mediated activity in 
stimulated femoral head explant cultures, detection of a range of neoepitopes from both 
the chondroitin sulphate and interglobular domains of ACAN can be performed, such as 
VTEGE373, 374ALGSV, SSELE1279, FREEE1467, 1468GLGSV, 1573AGEGP, and 
1673LGHGP (402). The findings described in this chapter of altered GAG release from 
stimulated femoral head explants from Trim32 KO mice compared to WT mice, could 
be examined further in future studies by performing Western blotting for the full length 
ACAN protein, and for a range of ACAN fragments using neoepitope antibodies. This 
could be performed in the media and femoral head explants from WT and Trim32 KO 
mice following treatment with IL1α and RA to examine the effect of Trim32 knockout 
on aggrecanolysis in more detail. The GAG assays using pairs of femoral head explants 
from WT and Trim32 KO mice were only performed in independent replicates of three 
pairs of femoral heads for each genotype group of mice. Although significant 
differences were identified between GAG assay results between WT and Trim32 KO 
mice, an increased number of replicates in each group could lead to more robust 
findings. 
 The effect of Trim32 KO on chondrocyte phenotype was then assessed in 
response to catabolic and anabolic cytokine stimulation. Trim32 mRNA levels were 
found to decrease in chondrocytes from WT mice in response to OSM and IGF1 
stimulation but not IL1α or TNFα stimulation (Figure 4.8). Primary chondrocytes from 
Trim32 KO mice demonstrated reduced Col2a1 expression and increased expression of 
Acan, Col10a1, and Sox9 compared to WT primary murine chondrocytes (Figure 4.9). 
The relative levels of Col2a1 and GAPDH expression were comparable to those 
previously reported for primary murine chondrocytes in vitro (403, 464, 465). These 
results may indicate a significant alteration of the normal phenotype of chondrocytes 
from Trim32 KO mice in vitro compared to WT primary murine chondrocytes, with a 
relatively reduced expression of markers of mature chondrocytes, and an increased 
expression of Col10a1, a marker of hypertrophic chondrocytes, and Sox9, a 
transcriptional regulator of chondrogenesis. 
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 In Trim32 KO murine primary chondrocytes, a greater expression of Col10a was 
detected in response to IL1α; a similar direction of effect was seen following 
stimulation with TNFα, though this was not significant (Figures 4.10 and 4.11). These 
findings are consistent with previous studies demonstrating an increased potency of 
IL1α compared to TNFα in inducing catabolic responses in primary chondrocytes (466). 
This may indicate an increased shift towards a hypertrophic chondrocyte phenotype in 
Trim32 KO primary chondrocytes in response to pro-inflammatory cytokine stimulation 
(467, 468). Upon stimulation with OSM, another catabolic cytokine, and IGF1, an 
anabolic cytokine, there was a significant increase of Col2a1 expression; following 
IGF1 stimulation, a reduced expression of Sox9 by Trim32 KO primary murine 
chondrocytes was also identified (Figure 4.12 and Figure 4.13) (469-473). Col2a1 
expression is significantly increased by activated mature chondrocytes in osteoarthritic 
cartilage (Figures 4.11, 4.12 and 4.13; (474)). It is uncertain whether this increase in 
Col2a1 expression by Trim32-deficient chondrocytes represents an exaggerated shift 
towards a mature chondrocyte phenotype, or also represents a predisposition to an 
activated state typical of osteoarthritic cartilage (475, 476). 
 There are limitations to the gene expression studies performed in immature 
primary murine chondrocytes described in this chapter. The large apparent relative 
increase in Col2a1 expression in chondrocytes from Trim32 KO mice following OSM 
and IGF1 stimulation (Figure 4.12 and Figure 4.13) may be due to the comparison with 
low levels of Col2a1 expression in unstimulated Trim32-deficient chondrocytes (Figure 
4.9; Col2a1 Ct values WT 18.37, Trim32 KO 25.69), though the GAPDH expression 
levels were similar between unstimulated chondrocytes from WT and Trim32 KO mice 
(Figure 4.9; GAPH Ct values WT 25.28, Trim32 KO 25.59). Caution is also required in 
interpreting the gene expression results as each experiment was performed in replicates 
of only three. Furthermore, the findings from in vitro studies of immature primary 
murine chondrocytes cannot be directly extrapolated to pathological mechanisms 
occurring in OA in humans. These experiments utilised immature primary murine 
chondrocytes from femoral head epiphyseal cartilage. Histological analysis or 
phenotyping was not performed to compare the femoral head epiphyses from WT and 
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Trim32 KO mice. Although the murine femoral head epiphyses was cartilaginous at the 
time of harvest in these experiments (3 weeks), the epiphyseal region of the femoral 
head explants contains a heterogeneous population of cells, including resting 
chondrocytes, hypertrophic chondrocytes, chondroclasts, osteoclasts, and osteoblasts 
(477, 478). The changes in gene expression between cells harvested from femoral 
epiphyses of WT and Trim32 KO mice could therefore reflect changes in individual cell 
types or changes in proportion of cell types. This could be investigated further in future 
studies, for example by examining the immunohistochemical localisation of markers 
such as Col II and Col X in epiphyseal cartilage from WT and Trim32 KO mice. Finally, 
although seeded immature chondrocytes were not passaged in these experiments, 
cultured chondrocytes may lose their phenotype upon monolayer culture with change 
from a polygonal to a flattened shape, and reduce Col II, and increased Col X, 
expression (479). 
Measuring gene expression by quantitative reverse transcription-PCR also has 
several advantages and limitations. Chondrocyte phenotype in response to subsequent 
cytokine stimulations was assessed by mRNA expression levels of chondrocyte markers 
of differentiation relative to unstimulated controls and normalised to GAPDH mRNA 
expression within each experiment using the ∆∆Ct method, thereby accounting for 
efficiency and basal expression levels. The interval between stimulation and detection of 
mRNA expression can be important; the interval of 48 hours used in these experiments 
is a reliable time-point at which to assess the response of chondrocytes to stimulation by 
cytokines at the chosen concentrations (480-483). These results represent relative 
changes in expression and not absolute mRNA expression levels. There are also several 
factors that preclude direct translation of results of in vitro mRNA analysis of gene 
expression to the in vivo environment; mRNA may not be translated efficiently, post-
translational modifications may regulate protein activity, and a variety of inhibitors and 
enhancers may ameliorate or potentiate protein activity. 
The results from the analysis of gene expression by immature primary murine 
chondrocytes from WT and Trim32 KO mice indicate that Trim32 deficiency may be 
associated with increased expression of genes associated with chondrocyte hypertrophy 
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following catabolic cytokine stimulation, and dysregulation of Col2a1 and Sox9 
expression upon anabolic cytokine stimulation (Figure 4.9 to Figure 4.13). These results 
may support the findings from analysis of TRIM32 protein expression by human 
primary chondrocytes, in which lower TRIM32 expression was associated with an 
osteoarthritic phenotype, and also the findings from GAG release, as an indicator of 
aggrecanolysis, in murine femoral head explants, in which increased GAG release 
occurred in explants from Trim32 KO mice (Figures 4.4 to 4.7). Further studies are 
required to determine in more detail the role of TRIM32 in immature and mature 
articular cartilage, other joint tissues, and the potential effects of TRIM32 in 
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The role of Trim32 in the development of OA in vivo: 
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knockout mice
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5.1 Summary 
The aim of this chapter was to evaluate the effect of Trim32 knockout on the 
development of OA in vivo in mice following ageing to 10 months or surgically induced 
joint instability (DMM surgery). Following DMM surgery, muscle strength and 
nociception testing were also performed. 
Cartilage degradation was measured histologically using the OARSI score and 
subchondral bone changes were assessed by μCT 8 weeks after DMM surgery in female 
WT (n = 14), Trim32+/- (HET; n = 14), and Trim32-/- (KO; n =13) mice. Muscle strength 
and nociception were assessed using a grip strength meter and von Frey filaments, 
respectively, in WT (n = 7) and Trim32-/- mice (n = 8). Knee joint histomorphometry 
was also analysed in aged female WT (n = 12), Trim32+/- (n = 12), and Trim32-/- mice (n 
= 13). 
Joint OARSI scores and subchondral bone parameters were similar in control 
unoperated contralateral knees from WT, Trim32+/-, and Trim32-/- mice after DMM and 
ageing. After DMM, a greater increase in tibial epiphyseal trabecular volume (p = 5·0 × 
10–5 WT vs KO) and number (p = 8·97 × 10–7 WT vs KO) occurred in Trim32-/- than 
WT mice. In aged mice, tibial medial bone plate thickness (p = 0·004 WT vs KO), and 
femoral epiphyseal trabecular volume (p = 0·032 WT vs KO) and thickness (p = 0·001 
WT vs KO), and medial bone plate thickness (p = 0·001 WT vs KO) were greater in 
Trim32-/- than in WT mice. 
After DMM, total knee joint OARSI scores were more severe in Trim32+/- and 
Trim32-/- mice than in WT mice (p = 0.005 WT vs HET, p = 7.0 x 10-6  WT vs KO). In 
aged mice, knee joint medial compartment OARSI scores were more severe in Trim32 
deficient mice; the trend was approaching statistical significance  (p = 0.06). In aged 
mice, total hip joint OARSI scores were not significantly different between WT, 
Trim32+/-, and Trim32-/- mice. Meta-analysis of knee and hip joint OARSI scores 
showed increased cartilage degradation in Trim32-/- compared to WT mice. Mechanical 
allodynia was more severe (p = 0.0008), and grip strength lower (p = 0.03), in Trim32-/- 
compared to WT mice. 
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These results demonstrate increased cartilage degradation and tibial epiphyseal 
bone changes after DMM, and a trend towards increased cartilage degradation and 
medial knee subchondral bone changes upon ageing in Trim32 KO mice. These findings 
were associated with lower pain thresholds in Trim32 KO mice and indicate a protective 
role for TRIM32 in the maintenance of cartilage integrity in vivo. 
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5.2 Introduction 
In Chapter 4 it was demonstrated that TRIM32 significantly influences the response of 
chondrocytes and cartilage to anabolic and catabolic stimuli in vitro. Interpretation of 
the overall impact of such effects is restricted by the limitations of the cell and tissue 
culture environments. Analysing the effect of deficiency of a gene implicated in the 
development of OA using in vivo models provides an environment that better represents 
the true disease process. Several murine models of OA exist and their appropriate 
application depends upon the experimental objectives. The overall aim of the 
experiments described in this chapter was to investigate the effect of Trim32 knockout 
on the development of OA in vivo following ageing or surgically induced joint 
instability (DMM surgery) murine models of OA. 
 In this chapter, the effect of DMM surgery on the development of OA in WT 
mice, mice with Trim32 haploinsufficiency, and Trim32 KO mice is evaluated through 
analysis of subchondral bone and epiphyseal trabecular bone changes at the distal femur 
and proximal tibia at the knee joint as assessed by µCT, and through analysis of 
histological degenerative changes of the articular cartilage in the medial and lateral 
compartments of the knee joint, and the knee joint as a whole. DMM surgery was 
performed in mice at 8 weeks of age, and joint histomorphometry was analysed 8 weeks 
following the DMM procedure. 
 The effect of natural ageing on the development of spontaneous OA in WT mice, 
mice with Trim32 haploinsufficiency, and Trim32 KO mice is also evaluated through 
analysis of subchondral bone and epiphyseal trabecular bone of both the knee joint and 
proximal femur at the hip joint as assessed by µCT, and through analysis of histological 
changes of the articular cartilage in the medial and lateral compartments of the knee 
joint, the knee joint as a whole, and of the proximal femur of the hip joint. Mice were 
aged to 10 months prior to analysis of joint histomorphometry. 
 The osteoarthritic changes of the articular cartilage following DMM surgery and 
ageing in WT and Trim32 KO mice are assimilated in a meta-analysis to evaluate the 
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overall effect of Trim32 knockout on the development of degenerative osteoarthritic 
changes of the articular cartilage in mice. 
 Finally, in addition to the osteoarticular changes assessed, the effect of the 
development of OA following DMM surgery on pain behaviour and muscle strength 
were also investigated in WT and Trim32 KO mice by evaluating hypersensitivity to 
mechanical stimulation and limb grip strength. 
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5.3 Aims 
The aims of the experiments described in this chapter were to: 
1. Investigate the effect of Trim32 knockout on the development of OA in vivo, 
by assessing knee joint histology and histomorphometry, in response to 
DMM surgery in mice. 
2. Investigate the effect of Trim32 knockout on the development of OA in vivo, 
by assessing knee and hip histology and histomorphometry, in response to 
natural ageing in mice. 
3. Evaluate the effect of Trim32 knockout on the development of pain and 
muscle strength in vivo, by assessing mechanical allodynia and limb grip 
strength, in response to DMM surgery in mice. 
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5.4 Results 
5.4.1 MicroCT analysis of knee joints of Trim32 knockout mice after DMM 
To investigate the effect of Trim32 deficiency on the development of OA in vivo, the 
DMM surgical procedure was performed in WT, Trim32+/-, and Trim32-/- mice at 8 
weeks of age to induce the development of OA. Eight weeks following the DMM 
procedure, mice were culled and operated (right) and unoperated control (left) joints 
were retrieved for analysis of subchondral bone by microCT and cartilage degradation 
by histological scoring. To determine if any alteration in the susceptibility to knee OA 
following DMM surgery in Trim32 KO mice was associated with abnormalities of 
subchondral bone, microCT analysis of both tibial and femoral subchondral bone at the 
knee joint was performed in WT, Trim32+/- (HET), and Trim32-/- (KO) mice. The 
number of cage mates was controlled throughout: there were no significant differences 
in the mean number of cage mates of WT, Trim32+/-, or Trim32-/- mice undergoing 
DMM surgery (WT 1.67, HET 2.0, KO 2.0; p = 0.46 WT vs HET, p = 0.39 WT vs KO). 
There were no significant differences in the weight of WT, Trim32+/-, or Trim32-/- mice 
either at time of surgery aged 8 weeks (WT 18.9 g, HET 18.8 g, KO 19.6 g; p = 0.75 
WT vs HET, p = 0.21 WT vs KO) or at time of analysis aged 16 weeks (WT 22.4 g, 
HET 22.5 g, KO 23.7 g; p = 0.78 WT vs HET, p = 0.09 WT vs KO). 
The absolute values of subchondral bone parameters of the tibia and femur at the 
knee joint are summarised in Table 5.1 and Table 5.2, respectively. There were no 
significant differences in either the tibial or femoral subchondral bone parameters of 
either the operated or unoperated control knee between WT and Trim32+/- mice 
following DMM surgery. Several differences in the absolute values of subchondral bone 
parameters were identified in both the tibial and femoral subchondral bone between WT 
and Trim32-/- mice following DMM surgery. In the tibial subchondral bone of the 
unoperated knee, trabecular thickness was greater (p = 0.015), and trabecular number 
lower (p = 0.02) in the Trim32-/- mice (Table 5.1). In the tibial subchondral bone of the 
operated knee, bone volume (p = 0.003), trabecular thickness (p = 0.02), medial bone 
plate thickness (p = 0.04), and lateral bone plate thickness (p = 0.004) were all greater in 
the Trim32-/- mice compared to WT mice (Table 5.1). In the femoral subchondral bone 
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of the control knee, only trabecular thickness (p = 0.03) was greater in the Trim32-/- 
mice compared to WT mice (Table 5.2). In the femoral subchondral bone of the 
operated knee, bone volume (p = 0.03), trabecular thickness (p = 0.0003), and lateral 
bone plate thickness (p = 0.03) were all greater in the Trim32-/- mice compared to WT 
mice, and medial bone plate thickness was non-significantly increased (Table 5.2; p = 
0.052).  
MicroCT analysis of the subchondral bone of the knee joints of WT, Trim32+/-, 
and Trim32-/- mice following DMM surgery identified increased trabecular thickness of 
the tibia and femur, and reduced trabecular number in control unoperated knee joints 
from Trim32-/- mice compared to WT mice (Table 5.1 and Table 5.2). Further changes 
were identified in the subchondral bone of operated knee joints from Trim32-/- mice 
compared to WT mice following DMM surgery. In addition to increased trabecular 
thickness of the subchondral bone of operated knee joints from Trim32-/- compared to 
WT mice as seen in the control unoperated knee joints, there was a significant increase 
in tibial subchondral bone volume, and medial and lateral bone plate thickness, and 
increased femoral subchondral bone volume and increased lateral bone plate thickness 
in Trim32-/- mice compared to WT mice after DMM surgery. Significant increases in the 
subchondral trabecular bone and subchondral bone plates of knee joints in Trim32-/- 
mice compared to WT mice may signify increased subchondral bone sclerosis following 
DMM surgery in Trim32-/- mice compared to WT mice. 
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Table 5.1 - MicroCT analysis of tibial subchondral bone of DMM-operated and control joints from 
wild-type (WT), Trim32+/- mice (HET), and Trim32-/- mice (KO); WT (n=14), Trim32+/- (n=14), and 
Trim32-/- (n=13) mice underwent the DMM procedure at 8 weeks of age, and operated (right) knee joints 
and unoperated control (left) knee joints were harvested at 16 weeks of age for analysis by microCT of 
subchondral trabecular bone parameters (BV/TV: trabecular volume; Tb.Th: trabecular thickness; Tb.Sp: 
trabecular separation; Tb.N: trabecular number) and subchondral medial and lateral bone plate thickness. 
Values are mean +/- SD. Statistical analysis was performed by one-way ANOVA with post-hoc Tukey 
test, with statistical significance accepted at p < 0.05 and annotated with (*) and presented in bold. 
 
 
Table 5.2 - MicroCT analysis of femoral subchondral bone of DMM-operated and control joints 
from wild-type (WT), Trim32+/- mice (HET), and Trim32-/- mice (KO); WT (n=14), Trim32+/- (n=14), 
and Trim32-/- (n=13) mice underwent the DMM procedure at 8 weeks of age, and operated (right) knee 
joints and unoperated control (left) knee joints were harvested at 16 weeks of age for analysis by microCT 
of subchondral trabecular bone parameters (BV/TV: trabecular volume; Tb.Th: trabecular thickness; 
Tb.Sp: trabecular separation; Tb.N: trabecular number) and subchondral medial and lateral bone plate 
thickness. Values are mean +/- SD. Statistical analysis was performed by one-way ANOVA with post-hoc 
Tukey test, with statistical significance accepted at p < 0.05 and annotated with (*) and presented in bold. 
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To better evaluate the response of the subchondral bone of the knee joint in 
Trim32 KO mice to surgically induced joint instability, the change in absolute values of 
subchondral bone parameters between the operated (DMM) and unoperated (control) 
knees were compared between WT, Trim32+/-, and Trim32-/- mice. There were no 
significant differences in the change in either tibial or femoral subchondral bone 
parameters following DMM surgery in the Trim32+/- mice compared to WT mice 
(Figure 5.1 and Figure 5.2). Several significant changes were identified in the tibial 
subchondral bone parameters following DMM surgery in the Trim32-/- mice compared to 
WT mice. A greater increase in tibial subchondral bone volume (WT +5.89%, KO 
+23.1%; p = 5.0 x 10-5 WT vs KO) was demonstrated in Trim32-/- mice following DMM 
surgery, compared to WT mice (Figure 5.1A). This was associated with a 
correspondingly greater increase in trabecular number in the Trim32-/- mice following 
DMM surgery (WT -3.22%, KO +12.01%; p = 8.97 x 10-7 WT vs KO; Figure 5.1A). A 
non-significant greater increase in lateral tibial subchondral bone plate thickness was 
also demonstrated in Trim32-/- mice following DMM surgery, compared to WT mice 
(WT +8.61%, KO +16.08%; p = 0.268 WT vs KO), though this effect was not as marked 
in the medial tibial subchondral bone plate (Figure 5.1B).  
At the femoral subchondral bone, a greater increase in bone volume was 
observed in Trim32-/- mice following DMM surgery compared to WT mice, which was 
approaching statistical significance (WT +0.07%, KO +10.33%; p = 0.07 WT vs KO; 
Figure 5.2A). This was also associated with a non-significant increase in trabecular 
thickness in the Trim32-/- mice (Figure 5.2A). Similar to the changes identified in the 
tibia, a non-significant greater increase in lateral femoral subchondral bone plate 
thickness was demonstrated in Trim32-/- mice following DMM surgery, compared to 
WT mice (WT +3.78%, KO +10.96%; p = 0.08 WT vs KO (Figure 5.2B)). 
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Figure 5.1 – Percentage change in microCT parameters of tibial subchondral bone of DMM-
operated compared to control joints in wild-type (WT), Trim32+/- mice (HET), and Trim32-/- mice 
(KO); 14 WT, 14 Trim32+/- (HET), and 13 Trim32-/- (KO) mice underwent the DMM procedure at 8 
weeks of age, and operated (right) and unoperated control (left) knee joints were harvested at 16 weeks of 
age for analysis by microCT of subchondral trabecular bone parameters (BV/TV: trabecular volume; 
Tb.Th: trabecular thickness; Tb.Sp: trabecular separation; Tb.N: trabecular number) and subchondral 
medial and lateral bone plate thickness. Values for percentage change (lines represent mean +/- SD) in 
microCT parameters of tibial subchondral bone of DMM operated compared to control joints are shown 
for A) trabecular bone, and B) medial and lateral subchondral bone plates. Statistical analysis was 
performed by one-way ANOVA with post-hoc Tukey test, with statistical significance accepted at p < 
0.05: *p = 5.0 x 10-5; **p = 8.97 x 10-7. 
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Figure 5.2 – Percentage change in microCT parameters of femoral subchondral bone of DMM-
operated compared to control joints in wild-type (WT), Trim32+/- mice (HET), and Trim32-/- mice 
(KO); 14 WT, 14 Trim32+/- (HET), and 13 Trim32-/- (KO) mice underwent the DMM procedure at 8 
weeks of age, and operated (right) and unoperated control (left) knee joints were harvested at 16 weeks of 
age for analysis by microCT of subchondral trabecular bone parameters (BV/TV: trabecular volume; 
Tb.Th: trabecular thickness; Tb.Sp: trabecular separation; Tb.N: trabecular number) and subchondral 
medial and lateral bone plate thickness. Values for percentage change (lines represent mean +/- SD) in 
microCT parameters of femoral subchondral bone of DMM-operated compared to control joints are 
shown for A) trabecular bone, and B) medial and lateral subchondral bone plates. Statistical analysis was 
performed by one-way ANOVA with post-hoc Tukey test, with statistical significance accepted at p < 
0.05. 
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5.4.2 MicroCT analysis of knee joints of Trim32 knockout mice after ageing 
To investigate the effect of Trim32 deficiency on the development of spontaneous OA in 
vivo, WT, Trim32+/-, and Trim32-/- mice were also aged to 10 months, after which  hip 
and knee joints were retrieved for analysis of subchondral bone by microCT and 
cartilage degradation by histological scoring. To investigate any alteration in 
subchondral bone changes representative of knee OA upon ageing of Trim32 KO mice, 
μCT analysis of both tibia and femoral subchondral bone at the knee joint was 
performed in aged WT, Trim32+/-, and Trim32-/- mice. The mean number of cage mates 
was similar throughout the 10 months’ of ageing for WT, Trim32+/-, and Trim32-/- mice 
(WT 4.75, HET 4.5, KO 5.2; p = 0.64 WT vs HET, p = 0.06 WT vs KO). There was no 
significant difference in the mean final weight between WT and Trim32+/- mice, 
although Trim32-/- mice were heavier than WT mice (WT 28.1 g, HET 29.9 g, KO 37.3 
g; p = 0.20 WT vs HET, p = 0.0002 WT vs KO). 
 The absolute values of subchondral bone parameters of the tibia and femur at the 
knee joint of aged mice are shown in Table 5.3. The only significant difference between 
the aged WT and Trim32+/- mice was observed in the trabecular thickness of the femoral 
subchondral bone (WT 54.15 μm, HET 59.32 μm; p = 0.021 WT vs HET); all other 
measured subchondral bone parameters at the knee were similar between aged WT and 
Trim32+/- mice. 
Several significant differences in subchondral bone parameters at the knee were 
identified between aged WT and Trim32-/- mice (Table 5.3). After ageing, Trim32-/- 
mice demonstrated significantly increased medial tibial bone plate thickness compared 
to WT mice (WT 68.55 μm, KO 79.70 μm; p = 0.004 WT vs KO), and increased lateral 
bone plate thickness, which was approaching statistical significance (WT 64.08 μm, KO 
70.07 μm; p = 0.064 WT vs KO; Table 5.3). At the femoral subchondral bone, Trim32-/- 
mice developed increase bone volume (WT 22.46 μm, KO 25.63 μm; p = 0.03 WT vs 
KO), trabecular thickness (WT 54.15 μm, KO 61.34 μm; p = 0.001 WT vs KO), and 
medial bone plate thickness (WT 58.72 μm, KO 67.71 μm; p = 0.001 (Table 5.3)) after 
ageing compared to WT littermates.  
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Table 5.3 - Absolute values of microCT analysis of tibial and femoral subchondral bone of knee 
joints from aged wild-type (WT), Trim32+/- mice (HET), and Trim32-/- mice (KO); WT (n=12), 
Trim32+/- (n=12), and Trim32-/- (n=13) mice were aged to 10 months after which knee joints were 
harvested for analysis by microCT of tibial and femoral subchondral trabecular bone parameters (BV/TV: 
trabecular volume; Tb.Th: trabecular thickness; Tb.Sp: trabecular separation; Tb.N: trabecular number) 
and subchondral medial and lateral bone plate thickness. Values are mean +/- SD. Statistical analysis was 
performed by one-way ANOVA with post-hoc Tukey test, with statistical significance accepted at p < 
0.05; statistically significant results are annotated with (*) and presented in bold. 
 
 In aged mice, microCT analysis of subchondral bone parameters identified a 
significant increase in medial bone plate thickness of the tibial and femoral aspects of 
the knee joints of Trim32-/- compared to WT mice, and also increased trabecular bone 
thickness at the femoral aspect of the knee joint in Trim32 deficient mice, compared to 
WT mice (Table 5.3).  
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5.4.3 MicroCT analysis of hip joints of Trim32 knockout mice after ageing 
To investigate any alteration in subchondral bone changes representative of hip OA 
upon ageing of Trim32 KO mice, μCT of femoral head subchondral bone at the hip joint 
was performed in WT, Trim32+/-, and Trim32-/- mice. Hip joints were harvested from the 
same mice utilised to analyse subchondral bone parameters at the knee joint and thus the 
number of cage mates were similar across genotype groups (see section 5.4.2); Trim32-/- 
mice were heavier than WT mice at age 10 months, but Trim32+/- mice were similar in 
weight to WT mice (see section 5.4.2). The absolute values of subchondral bone 
parameters of the femoral head of the hip joint are summarised in Table 5.4. No 
significant differences were identified between WT, Trim32+/-, and Trim32-/- mice in the 




Table 5.4 - Absolute values of microCT analysis of subchondral bone of the femoral head from aged 
wild-type (WT), Trim32+/- mice (HET), and Trim32-/- mice (KO); WT (n=12), Trim32+/- (n=12), and 
Trim32-/- (n=13) mice were aged to 10 months after which hip joints were harvested for analysis by 
microCT of femoral head subchondral trabecular bone parameters (BV/TV: trabecular volume; Tb.Th: 
trabecular thickness; Tb.Sp: trabecular separation; Tb.N: trabecular number) and subchondral bone plate 
thickness. Values are mean +/- SD. Statistical analysis was performed by one-way ANOVA with post-hoc 
Tukey test, with statistical significance accepted at p < 0.05; statistically significant results are annotated 
with (*) and presented in bold. 
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5.4.4 Histological analysis of knee joints of Trim32 knockout mice after DMM 
In addition to analysis of knee joints from WT, Trim32+/-, and Trim32-/- mice by 
microCT following the DMM procedure, knee joints were also assessed for cartilage 
degradation by histological scoring of sagittal joint sections using the OARSI scoring 
system (383). The reproducibility of the OARSI histological scoring system to assess 
cartilage degradation following joint sectioning and staining with Toluidine Blue was 
evaluated by comparing scores assigned by two observers independently examining 153 
sections from nine randomly selected knee joints. This resulted in an inter-observer 
correlation coefficient (rs) of 0.334 (p = 0.047). This represents a significant positive 
correlation between independent observers scoring OA severity of joint sections and 
supports reproducibility of the histological analysis undertaken. 
 To determine any alteration in susceptibility to knee OA following DMM 
surgery in Trim32 KO mice, grading of OA severity using the OARSI scoring system 
was performed for knee joints harvested from WT, Trim32+/-, and Trim32-/- mice 
following DMM surgery. Knee joints were harvested from the same mice utilised to 
analyse μCT subchondral bone parameters; there were no significant differences in 
number of cage mates or weight of mice across genotype groups (see section 5.4.1). 
 There were no significant differences in the OARSI scores of the medial or 
lateral compartments of unoperated (control) knee joints between WT, Trim32+/-, and 
Trim32-/- mice, as shown in Figure 5.3A (medial compartment p = 0.240 WT vs HET vs 
KO; lateral compartment p = 0.182 WT vs HET vs KO). There were also no significant 
differences on summing medial and lateral compartment scores to compare total knee 
joint OARSI scores of unoperated knee joints between WT, Trim32+/-, and Trim32-/- 
mice, as shown in Figure 5.4 (total knee joint OARSI score p = 0.136 WT vs HET vs 
KO). Representative photomicrographs of histological sections from unoperated knee 
joints of WT, Trim32+/-, and Trim32-/- mice are shown in Figure 5.3 C-E. These results 
indicate that there is no significant difference in OA severity of unoperated knee joints 
of WT, Trim32+/-, and Trim32-/- mice by 16 weeks of age. 
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 The DMM operated knee joints of Trim32-/-, but not Trim32+/- mice 
demonstrated significantly increased OARSI scores of the medial compartment 
compared to WT mice, as shown in Figure 5.3B. Medial compartment OARSI scores 
were (mean ± SD) 3.1 ± 0.9 in WT mice, 4.1 ± 1.3 in Trim32+/- mice, and 5.2 ± 1.1 in 
Trim32-/- mice (Kruskal Wallis p = 0.0003 WT vs HET vs KO; post-hoc Dunn’s tests p 
= 0.157 WT vs HET, p = 5.0 x 10-5 WT vs KO). The DMM operated knee joints of both 
Trim32+/- and Trim32-/- mice demonstrated significantly increased OARSI scores of the 
lateral compartment compared to WT mice, as shown in Figure 5.3B. Lateral 
compartment OARSI scores were 2.3 ± 1.3 in WT mice, 4.1 ± 1.3 in Trim32+/- mice, 
and 4.9 ± 1.4 in Trim32-/- mice (Kruskal Wallis p = 0.0002 WT vs HET vs KO; post-hoc 
Dunn’s tests p = 0.004 WT vs HET, p = 7.0 x 10-5 WT vs KO). The summed total knee 
joint OARSI scores of DMM operated joints were also significantly greater in Trim32+/- 
and Trim32-/- mice compared to WT mice (Figure 5.4). Total knee joint OARSI scores 
were 5.4 ± 1.6 in WT mice, 8.1 ± 2.1 in Trim32+/- mice, and 10.1 ± 2.3 in Trim32-/- mice 
(Kruskal Wallis p = 3.0 x 10-5 WT vs HET vs KO; post-hoc Dunn’s tests p = 0.005 WT 
vs HET, p = 7.0 x 10-6 WT vs KO). Representative photomicrographs of histological 
sections from DMM operated knee joints of WT, Trim32+/-, and Trim32-/- mice 
demonstrating degenerate cartilage lesions are shown in Figure 5.3 F-H. As the mean 
weight of the Trim32-/- mice was non-significantly greater than the WT mice (mean 
weight WT 22.4 g, KO 23.7 g; p = 0.09 WT vs KO), the potential confounding effect of 
weight on the joint cartilage degradation scores was investigated using a generalised 
linear model (GLM). Weight did not have a significant covariate effect on OARSI 
scores when comparing WT and Trim32-/- mice (GLM; p = 0.56).  
These results indicate that cartilage degradation scores were significantly greater 
in Trim32 KO mice compared to WT mice following DMM surgery (Figure 5.3 and 
Figure 5.4). These results also indicate that mice with Trim32 haploinsufficiency may be 
susceptible to increased cartilage degradation after DMM surgery in mice, but the effect 
is greatest in complete Trim32 KO mice. 
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Figure 5.3 – Response to DMM in wild-type (WT), Trim32+/- (HET), and Trim32-/- (KO) mice: 
medial and lateral knee compartment osteoarthritis scores; summed osteoarthritis scores from femoral 
and tibial joint surfaces in medial and lateral compartments of knee joints left unoperated (control; panel 
A), or underwent DMM (panel B) in WT, (n = 14), HET (Trim32+/-, n = 14), and KO (Trim32-/-, n = 13) 
mice. Absolute values are shown (lines represent mean ± SD). Statistical analysis between groups was by 
Kruskal Wallis test with post-hoc Dunn’s tests, with statistical significance accepted at p < 0.05. In panel 
B: medial compartment Kruskal Wallis test p = 0.0003 WT vs HET vs KO (post-hoc Dunn’s test ***p = 
5.0 x 10-5 WT vs KO); lateral compartment Kruskal Wallis test p = 0.0002 WT vs HET vs KO (post-hoc 
Dunn’s tests **p = 0.004 WT vs HET, ***p = 7.0 x 10-5 WT vs KO). Panels C, D, and E show 
representative photomicrographs (sagittal sections) from control knee joints of WT, HET, and KO mice, 
respectively. Panels F, G, and H show representative photomicrographs (sagittal sections) from operated 
knee joints of WT, HET, and KO mice, respectively. Arrows show cartilage lesions. OARSI scores (first 
score for femoral aspect, second score for tibial aspect for the photomicrographs are: (C) 0, 2; (D) 0, 2; 
(E) 1, 2; (F) 2, 0; (G) 0, 3; (H) 2, 4. Scale bars for panels C-H represent 300 μm. 
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Figure 5.4 – Response to DMM in wild-type (WT), Trim32+/- (HET), and Trim32-/- (KO) mice: total 
knee joint osteoarthritis scores; summed osteoarthritis scores from the medial and lateral compartments 
of knee joints that were left unoperated (control), or underwent DMM (operated) in wild type (WT, n = 
14), heterozygous (Trim32+/-, n = 14), and knockout (Trim32-/-, n = 13) mice are shown. In all mice, the 
DMM procedure was performed at 8 weeks of age, and knee joints from mice were harvested for analysis 
at 1 week of age. Histological analysis of cartilage degradation in each knee joint was performed using the 
OARSI histological scoring system to grade severity of cartilage degradation in the medial and lateral 
compartments of both the tibial and femoral aspects of each knee joint. For each knee joint, scores for 
these four compartments were summed to produce a total joint OARSI score. Absolute values for the total 
knee joint OARSI score for each joint are shown (lines represent mean ± SD). Statistical analysis between 
groups was performed by Kruskal Wallis test with post-hoc Dunn’s tests, with statistical significance 
accepted at p < 0.05. For operated groups, Kruskal Wallis test p = 3.0 x 10-5 WT vs HET vs KO (post-hoc 
Dunn’s tests *p = 0.005 WT vs HET, ***p = 7.0 x 10-5 WT vs KO).   
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5.4.5 Histological analysis of knee joints of Trim32 knockout mice after ageing 
To investigate any alteration in the susceptibility to spontaneous primary knee OA, 
grading of OA severity using the OARSI scoring system was performed for knee joints 
harvested from WT, Trim32+/-, and Trim32-/- mice after natural ageing to 10 months. 
Knee joints were harvested from the same mice used to analyse μCT subchondral bone 
parameters in aged WT, Trim32+/-, and Trim32-/- mice (see section 5.4.3). Histological 
analysis demonstrated no significant differences in OARSI scores of the medial 
compartment, lateral compartment, or total knee joint for Trim32+/- mice compared to 
WT mice (Figure 5.5A and Figure 5.6). OARSI scores were more severe in the medial 
compartment, but not the lateral compartment, of the knee in aged Trim32-/- mice 
compared to WT mice, though the difference was only approaching statistical 
significance (Figure 5.5A). Medial compartment OARSI scores were 3.4 ± 1.1 in WT 
mice, 3.3 ± 1.4 in Trim32+/- mice, and 4.7 ± 1.7 in Trim32-/- mice (Kruskal Wallis p = 
0.06 WT vs HET vs KO). Lateral compartment OARSI scores were 4.6 ± 1 in WT mice, 
4.8 ± 1.8 in Trim32+/- mice, and 5.2 ± 1.4 in Trim32-/- mice (Kruskal Wallis p = 0.44 
WT vs HET vs KO). The summed total knee joint OARSI scores upon ageing were 
increased in Trim32-/- mice compared to WT mice, though the difference was not 
statistically significant (Figure 5.6): total knee joint OARSI scores were 8.0 ± 1.7 in WT 
mice, 8.2 ± 1.9 in Trim32+/- mice, and 9.9 ± 2.6 in Trim32-/- mice (Kruskal Wallis p = 
0.09 WT vs HET vs KO). There was, therefore, a trend for more severe cartilage 
degradation OARSI scores in the medial compartment and whole joint in aged Trim32-/- 
mice, compared to WT mice, but these did not reach statistical significance. 
Representative photomicrographs of histological sections from knee joints of WT, 
Trim32+/-, and Trim32-/- mice aged to 10 months are shown in Figure 5.5 B-D. 
 As the mean weight of the Trim32-/- mice was significantly greater than WT 
mice (mean weight WT 28.1 g, KO 37.3 g; p = 2.7 x 10-4), any confounding effect of 
weight on knee joint cartilage degradation scores in aged Trim32 KO mice was 
investigated using a GLM analysis. Weight did not have a significant covariate effect on 
the OARSI score in aged Trim32-/- mice compared to WT mice (GLM; p = 0.05). 
Although the covariate effect of weight using the GLM analysis was approaching 
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significance, the majority of the difference in the joint OARSI score was attributable to 
difference in genotype (GLM corrected model effect 46.2 units; 46.0 units attributable to 
Trim32 genotype). Increased cartilage degradation scores in the medial compartment 
and whole joint of Trim32-/- mice did not reach statistical significance. Although a trend 
for increased cartilage degradation OARSI scores was identified in the medial 
compartment and whole joint of Trim32 KO mice compared to WT mice, these results 
are inconclusive regarding the susceptibility of Trim32 deficient mice to spontaneous 
OA of the knee joint, as the trends were not statistically significant (Figure 5.5 and 
Figure 5.6).  
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Figure 5.5 – Age-related knee osteoarthritis in wild-type (WT), Trim32+/- (HET), and Trim32-/- (KO) 
mice: medial and lateral knee compartment osteoarthritis scores; panel A shows summed 
osteoarthritis scores from the femoral and tibial joint surfaces in the medial and lateral compartments of 
the knee joints from wild type (WT, n = 12), heterozygous (Trim32+/-, n = 12), and knockout (Trim32-/-, n 
= 13) mice aged to 10 months. Histological analysis of cartilage degradation in each compartment was 
performed using the OARSI scoring system. Absolute values are shown (lines represent mean ± SD). 
Statistical analysis between groups was performed by Kruskal Wallis test with post-hoc Dunn’s tests, with 
statistical significance accepted at p < 0.05. For the medial compartment, Kruskal Wallis test p = 0.06 WT 
vs HET vs KO, and for the lateral compartment, Kruskal Wallis p = 0.44 WT vs HET vs KO. Panels B, C, 
and D show representative photomicrographs (sagittal sections) from the knee joints of WT, HET, and 
KO mice aged to 10 months, respectively. Arrows indicate cartilage lesions. OARSI scores (first score for 
femoral aspect, second score for tibial aspect for the photomicrographs are: (B) 0, 2; (C) 2, 2; (D) 3, 4. 
Scale bars for panels C-D represent 300 μm. 
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Figure 5.6 – Age-related knee osteoarthritis in wild-type (WT), Trim32+/- (HET), and Trim32-/- (KO) 
mice: total knee joint osteoarthritis scores; summed osteoarthritis scores from the medial and lateral 
compartments of knee joints from wild type (WT, n = 12), heterozygous (Trim32+/-, n = 12), and knockout 
(Trim32-/-, n = 13) mice aged to 10 months are shown. In all mice, knee joints were harvested for analysis 
at 10 months of age. Histological analysis of cartilage degradation in each knee joint was performed using 
the OARSI histological scoring system to grade severity of cartilage degradation in the medial and lateral 
compartments of both the tibial and femoral aspects of each knee joint. For each knee joint, scores for 
these four compartments were summed to produce a total joint OARSI score. Absolute values for the total 
knee joint OARSI score for each joint are shown (lines represent mean ± SD). Statistical analysis between 
groups was performed by Kruskal Wallis test with post-hoc Dunn’s tests, with statistical significance 
accepted at p < 0.05. For total knee joint OARSI scores in aged mice, Kruskal Wallis test p = 0.09 WT vs 
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5.4.6 Histological analysis of hip joints of Trim32 knockout mice after ageing 
To investigate any alteration in the susceptibility to spontaneous primary hip OA, 
grading of OA severity using the OARSI scoring system was performed for femoral 
head cartilage of hip joints harvested from WT, Trim32+/-, and Trim32-/- mice after 
natural ageing to 10 months. Hip joints were harvested from the same mice used to 
analyse μCT subchondral bone parameters in aged WT, Trim32+/-, and Trim32-/- mice 
(see section 5.4.3). No significant difference was observed in OARSI scores of femoral 
head cartilage between aged Trim32+/- mice and WT mice (Figure 5.7A). A non-
significant increase in femoral head OA severity was observed for the aged Trim32-/-
mice compared to the WT mice (Figure 5.7A). The hip joint OARSI scores upon ageing 
were 0.8 ± 0.5 in WT mice, 0.9 ± 0.5 in Trim32+/- mice, and 1.2 ± 0.6 in Trim32-/- mice 
(Kruskal Wallis p = 0.28 WT vs HET vs KO). Representative photomicrographs of 
histological sections from hip joints of WT, Trim32+/-, and Trim32-/- mice aged to 10 
months are shown in Figure 5.7 B-D. 
 The results of histological analysis of hip joints from aged WT, Trim32+/-, and 
Trim32-/- mice therefore demonstrated no significant difference in hip cartilage 
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Figure 5.7 – Age-related hip osteoarthritis in wild-type (WT), Trim32+/- (HET), and Trim32-/- (KO) 
mice; panel A shows summed osteoarthritis scores from the femoral head of hip joints from wild type 
(WT, n = 12), heterozygous (Trim32+/-, n = 12), and knockout (Trim32-/-, n = 13) mice aged to 10 months. 
Histological analysis of cartilage degradation in each compartment was performed using the OARSI 
scoring system. Absolute values are shown (lines represent mean ± SD). Statistical analysis between 
groups was performed by Kruskal Wallis test with post-hoc Dunn’s tests, with statistical significance 
accepted at p < 0.05. For hip joint OARSI scores in aged mice, Kruskal Wallis test p = 0.28 WT vs HET 
vs KO. Panels B, C, and D show representative photomicrographs (sagittal sections) from the femoral 
head from hip joints of WT, HET, and KO mice aged to 10 months, respectively. Arrows indicate 
cartilage lesions. OARSI scores for femoral head cartilage in photomicrographs are: (B) 0.5; (C) 1; (D) 2. 
Scale bars for panels A and B represent 300 μm; scale bar in panel C represent 200 μm. 
Chapter 5 – The role of Trim32 in the development of OA in vivo 
 179 
5.4.7 Meta-analysis of hip and knee joint histological changes in Trim32 knockout 
mice after DMM and ageing 
A meta-analysis was performed to collate the findings from histological analyses of OA 
severity in Trim32 KO mice compared to WT mice following DMM surgery and ageing. 
This would enable an interpretation of the overall effect of Trim32 deficiency on OA 
severity from the murine disease models. A summary table and forest plot of the results 
of the meta-analysis is shown in Figure 5.8. The overall direction of effect suggests a 
protective role for TRIM32 in maintenance of cartilage integrity, as shown in the forest 
plot. The detected protective effect of TRIM32 in maintenance of cartilage integrity was 
greater in the knee joint compared to the hip joint. This difference is reflected by greater 
mean differences in OARSI scores between WT and Trim32-/- mice of 1.92 [95% CI: 
0.21 – 3.63] for aged knee joints, and 4.72 [95% CI: 3.21 – 6.23] for DMM operated 
knee joints, compared to a mean difference of 0.36 [95% CI: -0.07 – 0.79] for aged hip 
joints (Figure 5.8). 
 
 
Figure 5.8 – Meta-analysis of hip and knee joint osteoarthritis scores in wild-type (WT) and Trim32-
/- (KO) mice; results of histological knee cartilage degradation (OARSI) scores following the DMM 
surgery, and both hip and knee cartilage degradation (OARSI) scores following ageing to 10 months, of 
both WT and Trim32 KO mice were collated in a meta-analysis. Meta-analysis of OARSI scores was 
performed using Review Manager Version 5.3.5 software (The Cochrane Collaboration, Copenhagen). 
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5.4.8  Nociception analysis of Trim32 knockout mice after DMM 
Chronic joint pain is the predominant clinical symptom associated with OA. To 
investigate whether any alteration in the susceptibility to OA in Trim32 KO mice was 
associated with the development of chronic pain as a behavioural sequelae, nociception 
testing was performed in WT and Trim32-/- mice following DMM surgery. Nociception 
was assessed by measuring hind limb withdrawal thresholds following application of 
von Frey filaments of increasing bending strength to the paw of the unoperated and 
operated hind limbs of WT and Trim32-/- mice following DMM surgery.  
 There was no significant difference in the limb withdrawal thresholds in the 
contralateral unoperated (control) limb of Trim32-/- mice and WT mice after DMM 
surgery, as shown in Figure 5.9. The limb withdrawal thresholds in unoperated limbs 
were (mean ± SD) 6.8 ± 1 g for WT mice and 6.9 ± 1 g for Trim32-/- mice (Shapiro-Wilk 
tests p = 0.001 WT, p = 0.001 KO; Mann-Whitney U test p = 0.89 WT vs KO). 
However, the limb withdrawal thresholds in operated (DMM surgery) limbs were 
significantly lower in Trim32-/- mice compared to WT mice (Figure 5.9). The limb 
withdrawal thresholds for operated limbs were 0.8 ± 0.3 g for WT mice, compared to 
0.2 ± 0.1 g for Trim32-/- mice (Shapiro-Wilk tests p = 0.001 WT, p = 0.0003 KO; Mann-
Whitney U test p = 0.0008 WT vs KO).  
The reduced limb withdrawal thresholds in the operated limbs of Trim32-/- mice 
compared to WT mice may indicate the development of increased mechanical allodynia 
in Trim32 KO mice following DMM surgery (Figure 5.9). This is associated with 
increased OARSI scores observed in the knee joints of Trim32 KO mice compared to 
WT mice following DMM surgery and may reflect the development of more severe joint 
degeneration in Trim32 KO mice. 
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Figure 5.9 – Hind limb pain thresholds following DMM surgery in wild-type (WT) and Trim32-/- 
(KO) mice; nociception thresholds were assessed in WT and Trim32-/- mice eight weeks after undergoing 
DMM knee surgery. Nociception thresholds were measured by the application of range of von Frey 
filaments to the hind limbs to assess hind limb hypersensitivity following the DMM surgery. Von Frey 
filaments were applied to both the operated and unoperated hind limb of WT (n = 7) and Trim32-/- (n = 8) 
mice, and limb withdrawal thresholds measured. Absolute values are shown (lines represent mean ± SD). 
Statistical analysis of withdrawal thresholds for each limb between WT and KO mice groups was 
performed by Mann-Whitney U tests, with statistical significance accepted at p < 0.05. For operated 
groups, Mann-Whitney U test p = **0.0008 WT vs KO; for unoperated groups, Mann-Whitney U test p = 
0.89 WT vs KO.  
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5.4.9  Grip strength analysis of Trim32 knockout mice 
Trim32 KO mice have previously been reported to develop a mild skeletal myopathy 
after five months of age (295). In previous experiments to determine any alteration in 
susceptibility to knee OA following DMM surgery in Trim32 KO mice, WT and Trim32 
deficient mice were analysed for changes in subchondral bone parameters by microCT 
and for histological cartilage degradation at 16 weeks of age (see section 5.4.1 and 
section 5.4.4). To investigate any variation in muscle strength that may have also 
contributed to the development of OA in Trim32 deficient mice, forelimb grip strength 
was also measured in both WT and Trim32 KO mice following DMM surgery, at 16 
weeks of age (see section 2.3.8). Forelimb grip strength testing was performed as in 
indication of general skeletal muscle strength. 
 Grip strength was significantly lower in Trim32-/- mice compared to WT mice  
(Figure 5.10). The limiting grip strength (mean ± SD) was 78.9 ± 8 g in WT mice 
compared to 69.1 ± 7 g in Trim32-/- mice, representing a mean 12% reduction in mean 
grip strength in Trim32 KO mice (p = 0.03, WT vs KO). These results indicate the 
development of a mild skeletal myopathy in Trim32 KO mice and that skeletal muscle 
strength is lower in Trim32 KO mice compared to WT mice by 16 weeks of age; this is 
the time point at which microCT and histological assessments were performed in 
previous experiments examining the susceptibility to knee OA following DMM surgery 
in Trim32 KO mice (see section 5.4.1 and section 5.4.4).  
Mild skeletal myopathy in Trim32 KO mice may, therefore, also contribute to 
the development of increased cartilage degradation and subchondral bone changes after 
DMM in the Trim32 KO mice (Figure 5.10). Grip strength testing was not performed in 
mice with Trim32 haploinsufficiency, or in aged mice with Trim32 deficiency. 
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Figure 5.10 – Grip strength testing following DMM surgery in wild-type (WT) and Trim32-/- (KO) 
mice; forelimb grip strength was assessed, as an indicator of skeletal muscle strength, by measuring the 
ability of mice to maintain grip on a grip strength meter. Forelimb grip strength testing was performed to 
investigate whether or not any skeletal myopathy that may develop in Trim32-/- mice could confound any 
changes identified by histological and microCT analysis of knee joint following the DMM procedure. 
DMM surgery was performed in WT (n = 7) and Trim32-/- (n = 8) mice at eight weeks of age, and 
forelimb grip strength testing was measured at eight weeks following DMM surgery (the same time point 
at which histological and microCT assessments of knee joints were performed). Increased resistance 
weight was applied through the grip strength meter and the limiting grip strength at which forelimb 
disengagement from the meter occurred was recorded. Absolute values are shown (lines represent mean ± 
SD). Statistical analysis of forelimb limiting grip strengths between WT and KO mice groups was 
performed by two-tailed Student’s T-test, with statistical significance accepted at p < 0.05: *p = 0.03 
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5.5  Discussion 
The experiments described in this chapter aimed to investigate the effect of Trim32 
knockout on the development of OA in vivo utilising murine models of OA. The models 
studied were the DMM model and ageing model of OA, both performed in WT and 
Trim32 KO mice. 
The DMM model was performed to evaluate the effect of Trim32 knockout on 
the development of accelerated degenerative OA following surgically induced joint 
instability. The results following DMM surgery in WT mice and mice with Trim32 
deficiency have provided several insights into the utilisation of the DMM surgical 
procedure to model OA in mice, in addition to evaluating the effects of Trim32 
deficiency on the development of OA in vivo. 
The DMM procedure was selected as it is the most validated model of surgically 
induced OA in mice. The ACLT model is another commonly used model of surgically 
induced OA in mice, but it is associated with acute severe knee instability that does not 
usually occur in primary human OA (349). There is a risk of inadvertently damaging the 
cruciate ligaments of the knee and other structures during the DMM procedure (484). 
Particular care was taken during the DMM surgical procedures in this study to only 
transect the MMTL and to avoid damaging the cruciate ligaments. By avoiding damage 
to further structures, the procedure induces a localised post-traumatic arthritis rather 
than gross instability in association with an inflammatory arthritis (349). Indeed, the 
cruciate ligaments were intact on subsequent histological sections in this study, and no 
wound complications or further postoperative morbidity occurred in any experimental 
animals. 
 The majority of studies utilising the DMM surgical procedure to induce OA in 
mice have performed sham surgery as a control procedure. The sham surgery can either 
be performed in the hind limb contralateral to that in which the DMM surgery is 
performed (485-487), or can be performed in a further control group of mice (465, 488, 
489). Recent studies have demonstrated that no significant histological changes occur in 
the contralateral unoperated knee in response to the DMM procedure in mice (484, 490). 
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Sham surgery was therefore not performed for DMM experiments, and the contralateral 
knee was used as a control based on the absence of significant differences demonstrated 
in previous studies, and to safeguard animal welfare. 
The majority of studies assessing the effects of DMM surgery in KO mice have 
also used male mice. It has previously been reported that the development of OA is 
more severe in male than female mice following DMM surgery (376). This gender effect 
was particularly marked in mice of the 129SvEv strain, which are also particularly 
susceptible to cartilage degradation following surgically induced instability. The 
severity of histological changes of knee joint cartilage following DMM surgery has been 
evaluated further in different strains of experimental mice; C57Bl/6 mice demonstrate a 
moderate response to DMM surgery (349). Furthermore, several studies, including those 
examining transgenic mice on C57Bl/6 background, have demonstrated no significant 
difference between male and female mice in response to DMM surgery (489, 491). 
Therefore, as the 9q33.1 locus at which TRIM32 resides was identified as associated 
with OA specifically in female patients in the arcOGEN study, the effect of knockout of 
Trim32 was examined in female mice only. The relatively moderate response of 
performing DMM surgery on mice of C57Bl/6 background strain permitted the 
identification of either a decrease or increase in OA severity in Trim32 deficient mice, in 
whom the direction of effect of TRIM32 deficiency on the development of OA was not 
previously known. The number of mice included in the WT, Trim32+/-, and Trim32-/- 
groups in the DMM experiments provided reasonable power (80%) to detect a 
significant difference in the histological total knee joint cartilage degradation scores (see 
section 2.3.3). 
The femoral aspect of the knee joint is less commonly assessed in murine studies 
utilising the DMM procedure, and descriptions of subchondral bone changes of the 
distal femur following DMM surgery are particularly limited. Analysis of subchondral 
bone changes following DMM surgery in the WT and Trim32 KO mice demonstrated 
that subchondral bone changes may occur throughout both the proximal tibia and distal 
femur at the knee joint, indicating that changes may occur throughout the knee joint 
following the DMM procedure in which the surgical lesion is induced on the medial 
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meniscus overlying the medial tibial plateau (Table 5.1 and Table 5.2; Figure 5.1 and 
Figure 5.2).  
To assess the development of chronic pain following DMM surgery in the 
Trim32 KO mice, von Frey filament testing was performed to measure hypersensitivity 
to mechanical stimulation of the hind limbs. The demonstration of similar limb 
withdrawal thresholds in the unoperated limbs, despite the development of cartilage 
lesions in the operated limb, further supports the use of the contralateral limb as an 
internal control in experiments using the DMM procedure (Figure 5.9). Few studies 
have examined nociception and pain behaviour following DMM surgery in mice. The 
von Frey testing is particularly suitable for assessing the development of chronic pain 
following DMM surgery as mechanical allodynia can be detected as soon as eight weeks 
after DMM, which correlates with the interval required to reliably detect histological 
and histomorphometric changes following DMM surgery (489). Other measures of 
chronic pain such as gait pattern and activity level require greater intervals 
postoperatively for changes to become reliably detectable between operated and 
unoperated hind limbs (492). These studies in mice with targeted deletion of Trim32 
demonstrate that increased cartilage degradation may be associated with an increase in 
chronic pain in the affected limb on assessing mechanical allodynia (Figure 5.9). It is 
possible that a sensory or neurological deficit may also contribute to the development of 
OA, though this cannot be determined from these results as the significant difference 
was only demonstrated after DMM surgery and was not observed in the unoperated 
contralateral hind limb between WT and Trim32 KO mice. No gross alterations in gait 
or activity level were observed; these usually develop later following DMM surgery, 
and would require formal assessment to be addressed accurately (492). That 
significantly different levels of chronic pain may be detected using von Frey filament 
testing after DMM surgery provides some validation for this modality for the evaluation 
of potential novel disease modifying therapies for OA. 
 Grip strength in Trim32 KO mice has previously been reported as reduced by 
17% by age 5-9 months compared to WT littermates, but mice with Trim32 
haploinsufficiency exhibit preserved skeletal muscle strength (295). In previous studies, 
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Trim32 deficient mice also developed increased weight after several months of age 
compared to WT littermates, but no further developmental abnormalities have been 
reported (295). The developmental phenotype of Trim32 deficient mice was not assessed 
in the experiments in this thesis, although the weight and grip strength of WT and 
Trim32 deficient mice were measured during the DMM experiments, and the weight of 
mice was measured during the ageing experiments, to assess for any confounding effects 
on joint histological changes, bone histomorphometry, and nociception results. In the 
experiments described in this chapter, forelimb grip strength was reduced by 12% in the 
Trim32 KO mice compared to WT mice when measured following the DMM procedure 
at age 16 weeks, indicating development of a mild skeletal myopathy (Figure 5.10). In 
the experiments investigating the development of OA in WT and Trim32 deficient mice 
in this chapter, grip strength was only evaluated in mice following the DMM procedure, 
and not upon ageing. The differences in the identified severity of mild skeletal 
myopathy in these experiments and previous studies reflects the relative ages at which 
skeletal muscle strength was measured in previous studies and in these experiments 
(295). The mild skeletal myopathy in Trim32 KO mice may have a confounding effect 
on the development of increased cartilage degradation and subchondral bone changes 
after DMM in the Trim32 KO mice. However, Trim32+/- mice, which have preserved 
skeletal muscle strength, also demonstrated significantly increased total knee joint OA 
scores in response to DMM surgery, suggesting that increased cartilage degeneration 
may occur in Trim32 deficient mice following the DMM procedure, independent of any 
alteration in skeletal muscle strength (Figure 5.4). To better understand whether or not 
development of mild skeletal myopathy significantly contributed to the development of 
subchondral bone and cartilage changes in the Trim32 KO mice after the DMM 
procedure would require performing grip strength testing, microCT analysis of 
subchondral bone, and histological analysis of cartilage in WT and Trim32 KO mice at 
multiple time points following the DMM procedure and upon ageing, and could be 
addressed in future studies. It is a limitation of the experiments investigating the 
development of OA in Trim32 deficient mice following the DMM procedure described 
in this chapter that further time points for analysis of subchondral bone, cartilage, 
nociception, and grip strength were not performed following the DMM procedure. 
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Analysis of WT and Trim32 deficient mice at only one time point following 
DMM surgery also limits interpretation of the histological changes occurring in the joint 
after DMM surgery. Analysis of several time points may permit more detailed analysis 
of whether changes occur first in the cartilage, subchondral bone or synovium, and the 
subsequent sequence of involvement, and progression of, degenerative or inflammatory 
changes in other joint tissues (374, 493).  Nociception testing was also performed at 
only a single time point (eight weeks) following DMM surgery in female WT and 
Trim32 KO mice. Assessment of mechanical allodynia at multiple time points following 
DMM surgery may better inform the understanding of pathways involved in generation 
of mechanical allodynia during lesion development (489). Mechanical allodynia was 
also only measured in female WT and Trim32 KO C57Bl/6 mice. Caution is required in 
interpreting the findings of increased mechanical allodynia in the operated hind limb of 
female Trim32 KO mice compared to WT mice following DMM surgery, as there is 
limited published data regarding the time course of development of mechanical 
allodynia in female mice following DMM surgery, different mouse strains display 
variability between the development of mechanical allodynia in the ipsilateral operated 
hind limb and the contralateral unoperated hind limb, and because variability exists 
between male and female mice in the development of pain-relevant parameters, 
including mechanical allodynia (Figure 5.9) (489, 494, 495). Further pain-relevant 
parameters that could be assessed to provide a more comprehensive analysis of the 
development of pain in mice following DMM include thermal allodynia, locomotor 
activity, gait analysis, and response to analgesia (489, 496, 497).  
Another potential confounding factor on the development of OA in Trim32 KO 
mice is their increased weight after several months of age compared to WT littermates 
(295). At the time of analysis of joint histology and histomorphometry following DMM 
surgery (aged 16 weeks), Trim32 KO mice were non-significantly heavier than WT 
littermates in this study. Further evaluation by GLM analysis supported an absence of a 
confounding effect of weight on histological grade of OA following DMM surgery in 
Trim32 KO mice (see section 5.4.4). The aged mice were significantly heavier but there 
was no significant covariate effect on GLM analysis (see section 5.4.5). This suggests 
that increased cartilage degradation in Trim32 KO mice was not dependent on their 
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increased weight. Previous studies have also demonstrated that obesity itself is not 
directly correlated with increased susceptibility to OA in mice (498). Leptin-deficient 
and leptin-receptor deficient mice both develop extreme obesity without an increased 
incidence of knee OA (364). Furthermore, increased joint loading is not sufficient to 
cause increased incidence of knee OA with obesity in C57Bl/6 mice (363). However, 
adipose tissue is a significant source of pro-inflammatory and anti-inflammatory 
cytokines, which may promote catabolic processes to predispose to OA in the presence 
of obesity (499-501). Mice that develop obesity induced by a very high-fat diet do 
develop OA and systemic inflammation in proportion to body fat, further supporting a 
predominant mechanism by which obesity induced by exposure to a high fat diet and a 
pro-inflammatory state predisposes to OA, rather than by increased mechanical loading 
(363). Furthermore, following surgically induced knee OA, C57Bl/6 mice fed a short-
term high fat diet develop increased OA in the absence of weight gain, compared to 
mice fed a lean diet (502). Diet was consistent for the Trim32 KO and WT mice 
throughout this study. Circulating adipokines levels were not assayed in Trim32 KO 
mice in this study, but this could be insightful if further studies indicate the involvement 
of related molecular pathways. 
Following DMM surgery in Trim32 KO mice, increased tibial subchondral bone 
density and trabecular number were observed, compared to WT mice (Figure 5.1). 
Similar, non-significant, changes were identified in the femoral subchondral bone in the 
Trim32 KO mice. Subchondral bone sclerosis was associated with increased cartilage 
degeneration in both the medial and lateral aspects of the operated knee joint in Trim32 
KO mice compared to WT mice (Figure 5.3). This pattern of cartilage degeneration and 
subchondral bone changes, with the more severe cartilage degeneration in the medial 
than lateral compartment, and the tibial subchondral bone altered to a greater extent than 
the femoral subchondral bone, is consistent with findings from studies of other KO mice 
predisposed to OA following DMM surgery (484, 503, 504). The increased severity of 
cartilage degeneration was exaggerated in Trim32-/- mice compared to Trim32+/- mice 
(Figure 5.4). The development of increased cartilage degeneration in both Trim32-/- and 
Trim32+/- mice, but significantly altered subchondral bone changes only in Trim32-/- 
mice may indicate that cartilage lesions were the primary event following the DMM 
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surgery, with subchondral bone changes occurring secondarily. To definitively establish 
the temporality of changes in cartilage and subchondral bone in Trim32 KO mice would, 
however, require evaluation of subchondral bone changes and histological changes at 
several time intervals following DMM surgery. 
There are limitations to the animal models of OA used in these experiments. In 
evaluating the in vivo effect of targeted gene deletion on the development of OA using 
animal disease models, it is beneficial to assess more than one model as no single model 
can fully replicate the pathological processes leading to OA in humans. The DMM and 
the ageing models of OA in mice were selected to investigate the effect of Trim32 
deficiency on the development of OA in vivo. Findings from variant screening of 
TRIM32 in patients with hip OA implicated genetic variation in TRIM32 as associated 
with the development of hip OA in humans (see section 3.5), and TRIM32 is the most 
biologically plausible candidate gene for OA risk at the 9q33.1 locus (see section 
1.3.2.2). The DMM model induces the accelerated development of knee OA and 
represents a secondary post-traumatic type of OA. Performing DMM surgery in mice 
aged 8 weeks with subsequent knee joint analysis at age 16 weeks also permitted 
assessment of severity of OA before the development of other significant phenotypes 
that occur upon ageing in Trim32 deficient mice, such as increased weight and skeletal 
myopathy (295). However, caution needs to be applied in translating results from the 
DMM model of knee OA in the study of genetic association with hip OA in humans. 
The DMM model of knee OA was selected, as it is the most validated model of 
accelerated OA in mice. Accelerated models of hip OA have been reported in larger 
animals such as dogs, rabbits, rats, and sheep, including intra-articular injection of MIA, 
NGF, papain, and sodium urate, and surgical models including debridement of femoral 
head cartilage, femoral neck osteotomy, gluteal muscle excision, and induction of 
developmental dislocation of the hip or femoroacetabular impingement (505-514). 
However, surgically- and chemically-induced models of hip OA have not been reported 
in mice, likely due to the high reproducibility of the DMM procedure, and because 
surgical and intra-articular injection procedure of the hip joint in mice are technically 
challenging with significant risk of complications (505). 
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The expression, or effect, of genetic variants on the development of OA may be 
specific for certain anatomical sites (198). However, genes implicated in the 
development of either hip or knee OA in humans, have subsequently been demonstrated 
to predispose to both hip and knee OA in studies of KO mice (515, 516). This indicates 
that there may be some redundancy and common aetiopathological mechanisms through 
which genetic variants predispose to hip and knee OA, in keeping with shared risk 
factors associated with their development (18). A combination of examining the 
development of hip and knee OA in aged Trim32 deficient mice, and the development of 
knee OA following DMM surgery can therefore provide initial investigation of the 
effect of Trim32 on the development of OA in vivo. Ageing of Trim32 KO mice 
demonstrated a more subtle phenotype than findings from the DMM studies of Trim32 
KO mice. Aged Trim32 KO mice showed significantly increased knee cartilage 
degradation, and non-significantly increased hip cartilage degradation, compared to WT 
littermates. These more subtle findings in aged Trim32 KO are consistent with the 
results following DMM surgery, but may represent the mechanism of action and overall 
effect in humans more closely than results from the DMM model. 
Ageing-related OA and destabilisation-mediated OA develop by different 
mechanisms. Destabilisation-mediated OA may represent a form of post-traumatic OA. 
Pro-inflammatory cytokines are elevated following joint injury. In particular, intra-
articular IL1, rather than TNFα, is an important mediator of cartilage degeneration and 
synovitis following acute joint injury (517). MMPs, including MMP1, MMP3, and 
MMP13, play a key role in IL1-driven cartilage degeneration and cartilage GAG loss, 
and ADAMTS4 is a key mediator of aggrecanolysis in human articular cartilage (518). 
In contrast, in ageing-related OA, several cytokines are upregulated including IL1, IL6, 
and monocyte chemoattractant protein-1 (519). These cytokines are also associated with 
a senescence phenotype, and chondrocytes in ageing-related OA exhibit several features 
that are characteristic of senescent cells, including increased p16INK4A expression and 
reduced expression of the microRNA miR-24, which may predispose aged chondrocytes 
to undergo senescence during subsequent proliferation after injury (520-522). 
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Examining the development of OA after ageing of Trim32 KO mice was 
performed to model spontaneous primary OA in humans. Experimental mice were aged 
to 10 months, as this is the youngest age at which mice of C57Bl/6 background develop 
spontaneous degenerative changes in the knee joint that may be detected by histology 
and histomorphometry. The degenerative changes that develop by 10 months in these 
mice is mild, and may explain the lack of significance of the increased knee joint 
OARSI scores in the aged Trim32 deficient mice compared to WT mice (Figure 5.6). 
The non-significant increased severity of OARSI scores in Trim32-/- mice was 
associated with significantly increased sclerosis of the medial subchondral bone plates 
and femoral epiphyseal trabecular bone (Table 5.3). The number of mice included in the 
aged WT, Trim32+/-, and Trim32-/- groups provided 70% power to detect a significant 
difference in the histological total knee joint cartilage degradation scores (see section 
2.3.4). It is therefore possible that with increased numbers of mice in each group, the 
trends in cartilage degradation scores, like the subchondral bone changes, might become 
statistically significant. The trends of increased severity of cartilage degradation and 
subchondral bone sclerosis of the knee joint in aged Trim32 KO mice are similar to the 
results following the DMM surgery. However, the trends of increased knee cartilage 
degradation scores in the aged Trim32 KO mice compared to WT mice are not 
conclusive regarding the susceptibility of Trim32 deficient mice to spontaneous OA of 
the knee joint, as the trends in the aged mice were not statistically significant.  
The medial trabecular thickness of the subchondral bone was also significantly 
increased in the control knees of Trim32 KO mice assessed in the DMM experiments 
(Table 5.1 and Table 5.2). The combination of altered medial subchondral bone and 
medial cartilage changes may indicate spontaneous abnormality of the osteochondral 
unit. Elevated subchondral bone remodelling is associated with progression of OA 
(523). These findings may, therefore, also represent a distinct subchondral bone 
phenotype. Subchondral bone is initially reduced in thickness in early OA due to 
attenuation of late phase tissue mineralisation coupled with increased bone turnover 
(524). In advanced OA, bone remodelling is reduced and bone deposition is increased, 
leading to increased density and thickness of the subchondral bone plate and the 
subchondral trabecular bone (525). Subchondral bone is composed of osteocytes, 
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osteoblasts, and osteoclasts, whose function is abnormal in OA. Osteoblasts in particular 
develop an abnormal phenotype in advanced OA with increased secretion of IL6, IL8, 
leptin, PGE2, and Col I (526). As the medial subchondral bone was significantly 
increased in thickness in control knees of Trim32 KO mice in the DMM experiments, 
and in knees from aged Trim32 KO mice, these findings may imply an abnormality of 
osteoblast, osteoclast or osteocyte function. This could be primary in nature or in 
response to the associated increased weight or skeletal myopathy of Trim32 deficient 
mice, or develop with cartilage changes.  Although Trim32 KO mice develop 
phenotypically indistinguishable from their wild type littermates, weight was not a 
significant confounding factor in the GLM analysis, and no gross skeletal abnormality 
was evident (appendix 7.3.3), it is a limitation of the experiments described in this thesis 
that the bone and synovium were not examined in more detail in the Trim32 deficient 
mice (295). It is especially important to determine if a primary bone phenotype exists in 
Trim32 KO mice as subchondral bone changes can precede the development of articular 
cartilage degeneration in OA (527). It is also a limitation that further time points were 
not examined in the DMM or ageing studies of Trim32 KO mice, which would help 
determine the chronology of changes in the subchondral bone and cartilage. Further 
studies are required to examine the effect of Trim32 deficiency on osteoblast, osteoclast, 
and osteocyte function, and also any effect in the synovium, and whether these, or 
effects in the cartilage or muscle, are the predominant mechanisms leading to an 
increased susceptibility to OA in Trim32 KO mice. 
The hip joint was also analysed in aged Trim32 KO mice, as the 9q33.1 locus at 
which TRIM32 resides was associated with hip OA in the arcOGEN study (229). The 
hip joint is infrequently studied in murine studies of OA, and no validated surgical 
model exists for hip OA, likely due to the high reproducibility of the DMM procedure 
and because the hip joint is more technically challenging to access surgically without 
complications, especially in small rodents. The hip joint was only analysed in aged WT 
and Trim32 deficient mice, and was not examined following the DMM surgical 
procedure; analysis of the hip joint by histology and bone histomorphometry following 
the DMM surgical procedure has not been previously reported or validated, and analysis 
of the hip joint after ageing most likely represented the pathology in human hip OA 
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more closely. Significant alterations of subchondral bone were not identified on analysis 
of the femoral head of the hip joint in aged Trim32 KO mice (Table 5.4). Altered 
subchondral bone parameters of the femoral head in aged Trim32 KO mice may not 
have been detected due to the variable development and ossification of the femoral head 
in mice up to an advanced age (528). This should not preclude the hip joint in evaluation 
of OA in murine studies, but does indicate that more extensive ageing may be required 
to detect more consistent alterations of subchondral bone. A non-significant increase in 
hip OARSI scores was observed in the Trim32-/- mice compared to WT mice (Figure 
5.7). This suggests that the effect of TRIM32 on the development of OA may not be 
limited to the knee joint and is consistent with the findings from DMM and ageing 
studies examining the knee joint in Trim32 KO mice. 
In summary, the results of surgically induced and ageing induced OA in Trim32 
KO mice indicate that TRIM32 has a protective role against the development of OA in 
vivo. An increased susceptibility to OA in mice with Trim32 deficiency also provides 
support that TRIM32 might be the candidate gene at the 9q33.1 locus conferring 
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6.1 Discussion 
Primary OA is a late-onset degenerative condition of synovial joints and is the major 
cause of pain and disability in older persons. OA represents a significant disease burden, 
its management has significant economic implications, and it is therefore a focus of 
research. Current treatments are inadequate; no disease-modifying therapies exist to 
manage the condition, which is therefore treated by analgesic medications until severe 
OA necessitates total joint replacement. OA has an established hereditary component, 
though the exact genetic variation and molecular mechanisms predisposing to the 
disease are incompletely understood. The arcOGEN study, the most powerful genome-
wide association study yet to investigate OA, identified the 9q33.1 locus to be 
significantly associated with hip OA in females (229). TRIM32 lies within the 9q33.1 
susceptibility locus and may have biological relevance to OA; it encodes a protein with 
E3 ubiquitin ligase activity. This thesis therefore had several aims: to investigate the 
genetic variation of TRIM32 to identify novel or rare variants in TRIM32 that are 
associated with OA of the hip in females; to examine the expression of TRIM32 in 
articular tissue and to determine whether TRIM32 expression is altered in female 
patients with OA of the hip; to investigate whether Trim32 affects the response of 
chondrocytes to anabolic and catabolic stimuli, and whether or not Trim32 affects the 
integrity of articular cartilage in vitro; and to examine the effect of Trim32 knockout on 
the development of OA in vivo in response to surgically induced joint instability and 
upon ageing. 
In chapter 3, Sanger sequencing of the proximal promoter, 5’UTR, both exons, 
and 3’UTR of TRIM32 in the youngest 500 female patients with hip OA from the 
arcOGEN cohort detected nine variants (Figure 3.1). Two of these variants, rs811457 
and rs3019, were detected in female patients with hip OA at disproportionate frequency 
compared to the control population, and may affect the expression of Trim32 (Table 
3.1). Indeed, it is now established that most variants that affect complex polygenic traits, 
such as OA, do so by regulating nearby gene expression (529, 530). The rs811457 and 
rs3019 variants were not in direct significant LD with the top hit SNP rs4836732 at this 
locus that was associated with female hip OA in the arcOGEN study (229). However, 
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further analysis of these two variants in larger cohorts of patients with OA, by 
imputation with population genome databases, by comparison with confirmed disease-
free matched controls, and by conditional analysis with the rs4836732 and its 
immediately adjacent polymorphisms could further validate these findings. Investigating 
further forms of genetic variation at this locus could also be informative; DNA 
methylation analysis of TRIM32 and the 9q33.1 locus in DNA isolated from peripheral 
blood cells and articular cartilage of the hip in both female patients with primary hip OA 
and controls matched for both age and gender could further inform the understanding of 
the genetic variation predisposing to hip OA at this locus. The cohort examined in these 
experiments (n = 500) was relatively low compared to the arcOGEN study that 
identified the 9q33.1 locus as associated with hip OA in female patients (229). The 
cohort examined in these experiments also only represented patients from European 
Caucasian populations. However, the youngest 500 female patients with primary hip OA 
from the arcOGEN study were selected for sequencing of TRIM32 as disease-associated 
variants are most likely enriched in the youngest individuals affected by primary hip 
OA. 
 The rs811457 variant was under-represented in female patients with hip OA, 
while the rs3019 variant was over-represented in patients with hip OA, conferring 
increased risk for hip OA (Table 3.1). Correlation of the rs811457 and rs3019 variants 
with relevant endophenotypes including radiographic parameters of hip morphology 
could also indicate whether these variants confer altered risk for hip OA through altered 
development or geometry of the hip joint (254). Furthermore, analysis of the effect of 
these variants on chondrocyte function may inform understanding of associated 
pathological molecular mechanisms. The rs811457 variant may affect TRIM32 
expression and lies adjacent to the TFAP2A/TFAP2C transcription factor binding site 
(Figure 3.2); TRIM32 expression in chondrocytes expressing this variant could be 
measured as could the ability of TFAP2A1/TFAP2C to bind the altered sequence in the 
proximal promoter of TRIM32 be analysed by ChIP. The rs3019 variant in the 3’UTR 
may affect TRIM32 expression by disrupting a binding site of miR-511, which targets 
TRIM32 and is associated with joint inflammation (420, 423). It could be insightful to 
measure the expression of TRIM32 and miR-511 in chondrocytes expressing the rs3019 
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variant. Examining the effect of these two variants on the expression of TRIM32 and 
associated regulatory factors in chondrocytes may implicate a direct role in abnormal 
chondrocyte function and the OA disease process. 
 The 9q33.1 locus examined in the experiments described in this thesis was 
identified as an OA susceptibility locus in the arcOGEN study (229). GWAS have 
enabled the investigation of variability across the whole human genome in association 
with specific diseases and without prior hypothesis. The power of GWAS depends upon 
the sample size, significance threshold, the effect size of the causal SNPs, and the 
frequency of their alleles. GWAS and GWAS meta-analyses have identified several OA 
susceptibility genes, though the number of susceptibility loci identified for OA is 
relatively low compared to other complex trait diseases (Table 1.1 and Table 1.2). 
Heterogeneity of OA phenotypes and insufficient sample sizes have contributed to these 
limited results in GWAS in OA. The number of disease-associated susceptibility loci 
identified by a GWAS is a function of sample size. In GWAS investigating OA 
susceptibility, the sample sizes have been insufficient to identify as many susceptibility 
loci as generated from larger studies in disease such as myocardial infarction, Crohn’s 
disease, breast cancer, and type 2 diabetes (531). The detection power of new variants 
by GWAS investigating OA could be enhanced by focusing on endophenotypes most 
relevant to particular types of OA (254). The detection power of causal variants is also 
enhanced by using control populations selected on the same criteria used to select 
disease cases (262). The identification of disease-associated variants by GWAS is also 
enhanced by reducing heterogeneity in the population of cases and controls. Another 
limitation of previous GWAS has been incomplete coverage provided by genotyping 
arrays, with limited coverage most relevant for rare genetic variants, some complex 
CNVs, and microsatellites (532).  
The number of identified OA susceptibility loci is relatively low compared with 
other complex trait diseases. Strategies to improve the investigation of the genetic 
predisposition to OA include increasing the sample size of GWAS studies of OA, 
standardising the patient phenotypes, completing the genetic variation coverage using 
information from studies such as the 1000 genomes project, and examining genetic 
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variation more comprehensively through exome sequencing, epigenome-wide 
association studies, studying microsatellites and complex CNVs not previously 
examined by GWAS, and by gene-base analysis (255). 
In chapter 4, altered expression of TRIM32 was identified in femoral head 
articular chondrocytes from female patients with primary OA of the hip, compared to 
age and gender-matched control patients without hip OA (Figure 4.4). These results are 
consistent with those from experiments, examining GAG release, as a marker of 
aggrecanolysis, in femoral head explants from Trim32 KO mice; increased GAG release 
occurred in cartilage explants from Trim32 KO mice compared to explants from WT 
mice (Figure 4.7). These results also support an association in which reduced Trim32 
expression may correlate with an OA phenotype. Although TRIM32 staining was 
identified in human hip and knee cartilage (Figure 4.1 and Figure 4.3) and significantly 
reduced expression of TRIM32 was identified by articular chondrocytes from patients 
with hip OA compared to control patients, these results should be reviewed with caution 
due to the low sample sizes (Figure 4.4A). In experiments assessing proteoglycan 
depletion in WT and Trim32 deficient mice, GAG loss was measured using the DMMB 
dye-binding assay as a surrogate marker of aggrecanolysis. More detailed investigation 
of aggrecanolysis in cartilage explant cultures from WT and Trim32 deficient mice 
could be achieved by Western blotting to identify ACAN fragments following 
ADAMTS-mediated aggrecanolysis using neoepitopes antibodies (402).  
It was also demonstrated that chondrocytes deficient in Trim32 expressed 
increased Col10a1 following IL1α, increased Col2a1 following OSM, and IGF1 
stimulation, and reduced Sox9 following IGF1 stimulation (Figures 4.10 to 4.13). 
Changes in expression of these genes have previously been associated with the 
associated with the development of OA (533, 534). Caution is required in the 
interpretation of the gene expression results as each experiment was performed in 
replicates of only three. The gene expression studies were performed in cells harvested 
from femoral head epiphyseal cartilage, which may comprise a heterogeneous 
population of cells including predominantly chondrocytes, but also osteoclasts and 
osteoblasts. It would also be interesting to further evaluate the effect of Trim32 
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deficiency on chondrocyte phenotype by examining the expression of chondrocyte 
phenotypic markers in Trim32 deficient chondrocytes and cartilage explants in response 
to both physiological and pathological mechanical stimulation in vitro, particularly as 
TRIM32 has been reported to concentrate in the retracting basal process that acts as a 
template for the formation of microtubules and primary cilia, which are important 
mechanosensors in articular chondrocytes (281, 302, 535). Although these results 
indicate altered chondrocyte phenotype and increased degradation of articular cartilage 
with deficiency of Trim32, the exact molecular pathways in which TRIM32 is involved 
in chondrocyte and cartilage homeostasis are not known. TRIM32, similar to other E3 
ubiquitin ligases, is implicated in a variety of molecular pathways and pathological 
processes due to its broad substrate specificity. Affinity purification mass spectrometry 
to identify interactors with TRIM32 in chondrocytes and articular cartilage could 
provide insights into the relevant molecular pathways in which TRIM32 is involved in 
articular cartilage (440). Nevertheless, the results of these in vitro experiments of 
TRIM32 expression in human and murine articular tissues may indicate a role for 
TRIM32 in chondrocyte and cartilage homeostasis, warranting correlation of these 
findings with studies of the role of TRIM32 on the development of OA in vivo. 
The role of Trim32 on the development of OA in mice following surgically 
induced knee joint instability (DMM procedure) or ageing was investigated in chapter 5. 
Following DMM, increased tibial epiphyseal trabecular volume and number developed 
in Trim32 KO mice compared to WT mice (Figure 5.1). This was associated with more 
severe cartilage degeneration scores in the knee joints of Trim32 deficient mice, 
compared to WT mice, after DMM (Figure 5.3 and Figure 5.4). This also correlated with 
more severe mechanical allodynia developing in Trim32 KO mice compared to WT 
mice after the DMM procedure, though the Trim32 deficient mice did also develop 
reduced muscle strength (Figure 5.9 and Figure 5.10). Upon ageing, Trim32 deficient 
mice also developed increased subchondral bone changes, especially in the medial 
aspect of the knee joint, and not significantly changed degeneration of the cartilage of 
the knee joint (Table 5.3, Figure 5.5, and Figure 5.6). Meta-analysis of hip and knee 
joint cartilage degradation scores demonstrated increased cartilage degradation in 
Trim32 KO mice compared to WT mice (Figure 5.8). The results of these in vivo studies 
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of the effect of Trim32 on the development of OA support the findings from sequencing 
studies in chapter 3 and in vitro studies in chapter 4 that reduced Trim32 expression may 
be associated with the development of OA. 
There are limitations to the experiments investigating the development of OA in 
Trim32 deficient mice. Following the DMM procedure only a single time point, rather 
than multiple time points, was used for the analysis of subchondral bone, cartilage, 
nociception, and grip strength following the DMM procedure. Analysis of several time 
points may permit more detailed analysis of whether changes occur first in the cartilage, 
subchondral bone, or synovium of the knee joint following the DMM procedure, and the 
subsequent sequence of progression of degenerative or inflammatory changes in other 
joint tissues (374, 493). Nociception following the DMM procedure was assessed by the 
development of mechanical allodynia, but other pain-relevant parameters could also be 
assessed such as thermal allodynia, locomotor activity, gait analysis, and response to 
analgesia (489, 496, 497). Grip strength testing to assess skeletal muscle strength was 
also only evaluated in WT and Trim32 deficient mice following the DMM procedure, 
and not following ageing. Furthermore, examining the development of degenerative 
changes in the knee joints of aged WT and Trim32 deficient mice may have produced 
more significant findings if increased numbers of mice were included in each group, as 
the number of mice in the ageing studies described in chapter 5 provided only 70% 
power to detect significant degenerative changes in the knee joint of experimental mice. 
The mice examined in the surgically induced and ageing induced OA 
experiments had global deficiency of Trim32. After 5-9 months of age, Trim32 KO mice 
have been shown in previous published studies, to develop a 17% reduction in skeletal 
muscle strength and increased weight compared to WT littermates (295). However, mice 
with Trim32 haploinsufficiency have been reported in a previous study to have 
preserved skeletal muscle strength and similar weight, compared to WT littermates 
(295). In the experiments in this thesis, Trim32 KO mice develop a mild proximal 
skeletal myopathy (12% reduction in grip strength; p = 0.03 WT vs KO; Figure 5.10) 
and non-significantly increased weight at 16 weeks of age, compared to WT littermates 
(WT 22.4 g, KO 23.7 g; p = 0.09 WT vs KO). The mild skeletal myopathy and increased 
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weight could potentially have confounded the results of the development of OA in 
Trim32 deficient mice compared to WT mice. Although Trim32 KO mice developed a 
non-significant increase in weight over the duration of the experiments investigating 
development of OA after DMM surgery in the experiments described in chapter 5, the 
increase in weight was shown by GLM analysis not to significantly contribute to the 
development of OA (p = 0.56). Furthermore, Trim32+/- mice, which have preserved 
skeletal muscle strength, also demonstrated significantly increased total knee joint OA 
scores in response to DMM surgery, suggesting that increased cartilage degradation may 
occur in Trim32 deficient mice following the DMM procedure, independent of any 
alteration in skeletal muscle strength (Figure 5.4).  
To validate these findings and overcome any confounding extra-articular effects 
of global Trim32 deficiency, the surgically induced and ageing induced models of OA 
could be performed in mice with cartilage-specific knockout of Trim32, which could be 
generated using the LoxP Cre system specific for Col2a1 (536, 537). In the experiments 
assessing histological and histomorphometric changes in the knee joint following DMM 
surgery in WT and Trim32 deficient mice, the medial trabecular subchondral bone 
thickness was significantly increased in the control knee joints of Trim32 KO mice 
compared to those from WT mice (Table 5.1 and Table 5.2). This may indicate a distinct 
subchondral bone phenotype in addition to effects on cartilage integrity, in the joints of 
Trim32 deficient mice. Subchondral bone comprises osteocytes, osteoblasts, and 
osteoclasts, whose function is abnormal in advanced OA. In particular, osteoblasts 
develop an abnormal phenotype in advanced OA, with increased secretion of IL6, IL8, 
leptin, PGE2, and Col I (526). The effect of Trim32 on joint development and epiphyseal 
cell types could also be evaluated by examining the immunohistochemical localisation 
of Col II, Col X, VEGF, and tartrate-resistant acid phosphatase (TRAP) in growth plate 
and epiphyseal cartilage from immature WT mice and mice with cartilage-specific 
deletion of Trim32 (477). Assessing the development of OA by histology and 
histomorphometry at several time points in surgically induced and ageing induced OA 
models in mice with cartilage-specific KO of Trim32 generated using the LoxP Cre 
system specific for Col2a1 may help to determine if a primary cartilage or subchondral 
bone phenotype exists in Trim32 deficient mice. This could also then permit additional 
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studies to investigate whether the protective effects of Trim32 for the integrity of 
articular cartilage can be rescued with administration of exogenous TRIM32; following 
induction of OA through DMM surgery, injection of Trim32-expressing adenovirus into 
operated knee joints of mice with cartilage-specific deletion of Trim32 could be 
performed to investigate if the OA phenotype can be prevented (465, 538). In addition to 
assessing mechanical allodynia as a surrogate marker of chronic pain following 
surgically induced OA in mice with cartilage-specific knockout of Trim32, it could also 
be useful to examine the development of chronic pain more directly by measuring levels 
of the nociceptor TRPV1 (transient receptor potential cation channel subfamily V 
member 1) in the dorsal root ganglia (539). Such studies could further validate the 
potential of investigating and targeting pathways involving TRIM32 for the 
development of novel therapeutics to treat OA. 
The mechanism of action of TRIM32 in the development of OA could be 
investigated further, expanding on the results described in this thesis and previous 
studies. Sequencing of TRIM32 in female patients with hip OA identified two variants 
associated with risk of developing hip OA (Table 3.1). The rs811457 variant lies 
adjacent to the TFAP2A/TFAP2C transcription factor binding site, and the rs3019 
variant may disrupt a binding site for miR-511. The binding of TFAP2A/TFAP2C 
transcription factors to the variant sequence in the proximal promoter of TRIM32 could 
be assessed by ChIP analysis, and the expression of TRIM32 and miR-511 in 
chondrocytes and synoviocytes expressing the rs3019 variant could be evaluated. 
Immunostaining and Western blot analysis demonstrated that TRIM32 is expressed in 
human articular cartilage, and that TRIM32 expression may be reduced in articular 
chondrocytes from patients with hip OA compared to patients without hip OA (Figure 
4.1, Figure 4.3, and Figure 4.4). In experiments evaluating GAG turnover, GAG release 
was increased by femoral head explants from Trim32 KO mice compared to WT mice, 
and most marked following RA stimulation. TRIM32 interacts with RARα and enhances 
RA-dependent RARα-mediated transcriptional activity, and dysregulation of RA 
signalling can lead to accelerated cartilage degradation (450, 459). A more accurate 
evaluation of aggrecanolysis in cartilage explants cultures from Trim32 deficient mice 
could be achieved by Western blotting to identify ACAN fragments following 
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ADAMTS-mediated aggrecanolysis using neoepitopes antibodies (402). Through 
interactions with RARs and Pias family members, TRIM32 may mediate Wnt/β-Catenin 
signalling, which regulates chondrocyte phenotype and cartilage matrix homeostasis 
(457). Trim32 deficiency was associated with increased expression of genes associated 
with chondrocyte hypertrophy following catabolic cytokine stimulation, and 
dysregulation of Col2a1 and Sox9 expression upon anabolic cytokine stimulation 
(Figure 4.10, Figure 4.11, Figure 4.12, and Figure 4.13). Affinity purification mass 
spectrometry could be performed to identify interactors with TRIM32 in chondrocytes 
and articular tissue to help determine the most relevant of the potential mechanisms 
through which TRIM32 may be involved in protection against OA (Figure 6.1).  
The potential protective role for TRIM32 in the maintenance of cartilage 
integrity is supported by the findings of increased cartilage degradation and tibial 
epiphyseal bone changes, and a trend towards increased cartilage degradation and 
medial knee subchondral bone changes upon ageing in Trim32 deficient mice (Figure 
5.1, Figure 5.4, Table 5.3, and Figure 5.6). The results of this thesis indicate that Trim32 
may have a protective role in maintaining the integrity of articular cartilage, though the 
mechanisms underlying reduced TRIM32 expression in OA cartilage, or through which 
TRIM32 contributes to maintenance of healthy articular cartilage remain incompletely 
understood. In addition to examining the development of OA in joint tissues of mice 
with cartilage-specific deletion of Trim32, further studies are required to determine the 
most important molecular pathways through which TRIM32 may provide protection 
against the development of OA (Figure 6.1). 
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Figure 6.1 – Potential mechanisms for protective role of TRIM32 in osteoarthritis; a schematic is 
shown demonstrating mechanisms in which TRIM32 may be involved in joint tissues to confer protection 
from OA; i) TRIM32 is targeted by miR-511, which mediates TLR4-dependent cytokine production in 
synovial joints, and genetic variants in the TRIM32 binding site of miR-511 may predispose to hip OA in 
females (421, 422)(Table 3.1); ii) deficiency of Trim32 is associated with subchondral bone changes in 
murine models of OA (Figure 5.1, Table 5.3); iii) TRIM32 regulates proliferation of skeletal muscle stem 
cells after muscle injury by ubiquitination of c-myc (298, 301); iv) TRIM32 ubiquitinates muscular 
substrates, such as desmin, actin, and dysbindin, to regulate muscle homeostasis and atrophy (442); v) loss 
of TRIM32 leads to increased levels of Piasy and accumulation of SUMOylated proteins in myoblasts 
(299). Disruption of these mechanisms by reduced TRIM32 activity may contribute to skeletal muscle 
weakness, pathological joint loading, and development of OA. TRIM32 may regulate Pias3 degradation; 
Pias3 protects against cartilage degradation by reducing expression of MMPs by synoviocytes (461, 462). 
vi) TRIM32 enhances RA-dependent RARα-mediated transcriptional activity, and both RA and Piasy 
mediate Wnt/β-catenin signalling in chondrocytes (459); vii) TRIM32 sensitises cells to TNFα-induced 
apoptosis by ubiquitinating XIAP, and viii) TRIM32 concentrates in the basal process required for 
microtubule and cilia formation (281, 300, 302). These mechanisms may contribute to regulation of 
chondrocyte phenotype and cartilage ECM homeostasis by TRIM32 and its role in protection against the 
development of OA. 
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By investigating the 9q33.1 locus associated with hip OA in females, the 
experiments and results described in this thesis have demonstrated variants in the 
proximal promoter and 3’UTR of TRIM32 within this locus that are disproportionately 
represented in females with hip OA, reduced expression of TRIM32 in femoral head 
chondrocytes from patients with hip OA, increased GAG release from Trim32 deficient 
murine femoral head explants, increased expression of markers of hypertrophic 
chondrocytes upon catabolic cytokine stimulation of Trim32 deficient murine 
chondrocytes, increased subchondral bone changes upon ageing of Trim32 KO mice, 
and both increased subchondral bone changes and cartilage degradation after surgically 
induced knee joint instability in Trim32 KO mice. These results demonstrate that genetic 
variation in TRIM32 may be associated with hip OA in females, and that TRIM32 might 
be protective both in the maintenance of cartilage integrity and against the joint 
degeneration evident in OA. The results of this thesis support the further focused study 
of TRIM32 in the pathophysiology of OA and the development of novel therapeutic 
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Table 7.1 – Oligonucleotide primer sequences for DNA sequencing of TRIM32 
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7.1.2 PCR reagents 
Reagent Volume (μl) 
Taq Reaction Buffer 2.5 
dNTPs 2 
Forward Primer 1.25 
Reverse Primer 1.25 
Distilled H2O 10.875 
Q solution 5 
DNA 2 
Q-Taq Polymerase 0.125 
Total 25 
 
Table 7.2 – PCR reagents for DNA sequencing of TRIM32 
 
 






1. Denature template 94 3 minutes 
2. Denature template 94 45 seconds (30 cycles of steps 2-4) 
3. Anneal primers Variable 30 seconds 
4. Extend primers 72 90 seconds 
5. Extend primers 72 10 minutes 
6. Completion 4 Incubate 
 
Table 7.3 – PCR cycling conditions for DNA sequencing of TRIM32 
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7.2 The role of TRIM32 in human and murine articular tissue ex vivo 
7.2.1 Primers for qPCR reactions 
 
Gene Primer Primer sequence (5’-3’) 
Universal probe 


























Table 7.4 – Oligonucleotide primer sequences for qPCR reactions 
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7.3 The role of Trim32 in the development of OA in vivo: surgically induced and 
ageing induced OA in Trim32 knockout mice 
7.3.1 Regions of interest at the hip and knee joint for analysis of subchondral 
bone by microCT 
 
A      B 
  
Figure 7.1 – Representative regions of interest (ROI) at the hip and knee joint for analysis of tibial 
and femoral subchondral bone by microCT in control, DMM-operated and aged wild-type (WT), 
Trim32+/- mice (HET), and Trim32-/- mice (KO); panel A shows a mid-coronal 2D-reconstruction of 
murine knee joint with representative regions of interest (ROI) selected for analysis of bone parameters of 
the epiphyseal trabecular bone, medial bone plate, and lateral bone plate of the femur and tibia following 
destabilisation of the medial meniscus surgery or ageing for 10 months. Panel B: mid-coronal 2D-
reconstruction of murine hip joint with representative regions of interest (ROI) selected for analysis of 
bone parameters of the femoral head subchondral bone plate and trabecular bone following ageing for 10 
months. Scale bar in panel A represents 1000 μm, and scale bar in panel B represents 200 μm. 
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7.3.2 3D reconstruction of microCT images of subchondral bone 
 
A    B    C 
     
D    E    F 
     
G    H 
  
Figure 7.2 – Representative 3D reconstructions of microCT images of subchondral bone for analysis 
of hip and knee joint parameters in control, DMM-operated and aged wild-type (WT), Trim32+/- 
mice (HET), and Trim32-/- mice (KO); representative 3D-reconstructions used for analysis of 
subchondral bone parameters are shown for regions of interest selected for tibial trabecular bone (panel A; 
anterior view), tibial medial bone plate (panel B; sagittal view), tibial lateral bone plate (panel C; sagittal 
view), femoral trabecular bone (panel D; anterior view), femoral medial bone plate (panel E; sagittal 
view), and femoral lateral bone plate (panel F; sagittal view) from murine knee joints. Representative 
regions of interest for similar analyses are shown for femoral head trabecular bone (panel G; anterior 
view), and femoral head subchondral bone plate (panel H; sagittal view) from murine hip joints. Scale 
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7.3.3 MicroCT images of whole skeleton of Trim32 knockout mice 
 
A   B   C   D 
      
Figure 7.3 – MicroCT images of whole skeleton of adult wild-type (WT), and Trim32-/- mice (KO); 
representative microCT images of whole skeletons of adult wild-type (WT) mice (coronal view in Panel 
A; sagittal view in Panel B) and Trim32-/- (KO) mice (coronal view in Panel C; sagittal view in Panel D) 
at age 10 months. Scale bars in panels A-D represent 3 cm. 
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7.4 Reagents and solutions 
7.4.1 Orange-G loading Dye 
7.4.1.1 10X Orange-G (stock) 
0.2 g Orange-G (Sigma®) + 7 ml distilled water + 3 ml 100% glycerol (BDH) 
7.4.1.2 1X Orange-G 
2 ml 10X Orange-G stock in 30% glycerol (BDH). 
7.4.2 5X loading buffer 
5.2 ml of 1 M tris-hydrogen chloride (HCl; pH 6.8, Sigma®) + 1 g DL-DDT (Sigma®) + 
1.3 g sodium dodecyl sulphate (SDS; Sigma®) + 6.5 ml glycerol (BDH) and 130 µl of 
10% (w/v) bromophenol blue (Sigma®). 
7.4.3 1X transfer buffer 
25 mM tris-base (Sigma®) + 192 mM glycine (Sigma®) + 20% (v/v) methanol (Sigma®) 
+ 0.037% (w/v) SDS (Sigma®) in distilled H2O. 
7.4.4 TBS 
7.4.4.1 20X TBS (stock) 
1 M of tris-base (Sigma®) + 1M tris-HCl (pH 7.9; Sigma®) + 3 M sodium chloride 
(NaCl; Sigma®). 
7.4.4.2 1X TBS 
50 ml of 20X TBS (stock) + 950 ml distilled H2O. 
7.4.5 TBS-T 
0.1% (v/v) Tween 20 (Sigma®) in 1X TBS. 
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7.4.6 DMMB stock 
16 mg of 1,9-Dimethylmethylene blue chloride (Sigma®) + 5 ml ETOH + 2 g sodium 
formate + 2 ml formic acid + 993 ml distilled H2O. 
7.4.7 Papain buffer 
0.1 M sodium acetate (pH 5.5) + 5 mM EDTA + 5mM L-cysteine-HCl + papain 
(Sigma® P3125; 0.05 M sodium acetate suspension;) for final papain buffer 
concentration of 125 µg/ml papain. 
7.4.8 Formic acid (10%) 
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